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Welcome to Cochrane
Methods
Welcome to the 2015 issue of Cochrane Methods, the ofﬁcial annual publication that reports on methodological developments and
related issues within Cochrane.
Cochrane is a global independent network of researchers, professionals, patients, carers, and people interested in health. This
not-for-proﬁt organization hasmore than 35,000 contributors fromover 130 countries, dedicated tomaking accessible up-to-date and
credible information about the effects of healthcare free from commercial sponsorship and other conﬂicts of interest. The Cochrane
Reviews produced and published online in the Cochrane Database of Systematic Reviews as part of the Cochrane Library include
evaluations of healthcare interventions, diagnostic tests and methodology. Our reviews help providers, practitioners, patients and
the publicmake informed decisions. Therefore, the reliance on themethods underpinning these reviews is important to the credibility
of each review. The sixteen Cochrane Methods Groups provide methodological policy advice to improve review validity, precision
and applicability. In addition, these Methods Groups provide training, peer review and specialist advice, contribute to software
developments, and conduct methodological research. You can read more on the current activities of the individual Methods Groups
and their achievements on pages 52–68.
Cochrane continues to transform with an expanded Central Executive Team to take forward Cochrane’s organizational Strategy to
2020. Two key components of this strategy this year have been the rebrand project and the structure and function reviews of Cochrane
Groups. The rebrand has provided all Groups with individual logos, and we have a distinct logo for Cochrane Methods, see page 3 for
further information. We are in the process of conducting a structure and function review on the Cochrane Methods infrastructure, see
page 2.
In this year’s Cochrane Methods, David Tovey the Editor-in-Chief sends a personal message to the Cochrane Methods community. We
also report on a ‘state of the art’ series of papers on individual participant data meta-analysis, the Cochrane Methods Innovation
Fund, with further funding for seven new projects, progress on the development of reviews prognostic studies, and this year’s annual
ColloquiumMethods Symposium on the concept of ‘Evidence-based Methods’, see page 7.
We have a series of interesting short articles covering the best available methods to calculate the uncertainty around the summary
intervention effect and the heterogeneity variance in random-effects meta-analysis, a tool to access the conﬁdence within qualitative
evidence synthesis ﬁndings, methodological implications from an audit of published Cochrane Reviews, a report of a randomized
controlled trial to evaluate an alternative format for a ‘Summary of ﬁndings’ table, and two articles covering prioritisation in research.
We have an article addressing the challenges of the causal effect of treatment assignment, and one investigating the impact on search
strategy precision and sensitivitywhen focusing Emtree terms to improve searching in Embase. Finally, James Thomas and colleagues
contribute a substantive article that introduces text mining and crowdsourcing as combined activities to create review efﬁciencies.
‘Project Transform’ is a Cochrane funded project.
We continue our series of published article abstracts with commentaries, covering a broad range of methodological topics, such
as small study effects and evaluating methods for random-effects meta-analysis, outcome completeness, a checklist for prediction
modelling studies, and a ‘one-stage’ logistic regressionmodel for meta-analysis. Other topics include evaluating overviews, reporting
in protocols for the planned extraction of data from ﬁgures and tables, handling abstracted data, development of a search strategy,
intervention synthesis and ﬁnally articles addressing research prioritisation, ethics, equity and sex or gender analysis in reviews.
We are interested in providing a platform for discussions on topical or highly debated topics. If you have any ideas for
contribution, or would like to consider reporting the ﬁndings from your study in a future issue of Cochrane Methods, please contact
jchandler@cochrane.org. You can also visit methods.cochrane.org for updates on Cochrane Methods.
We are, as ever, very grateful to the many people who have contributed news items, commentaries, and articles, to this publication.
We wish also to thank, Jane Burch, Editor (CEU) for completing the structured abstracts, Louisa Dunn, Methods Support, for her work
on the design and population of the template and ﬁnally Elizabeth Royle for the copy edit.
Jackie Chandler, Jo McKenzie, Isabelle Boutron, and Vivian Welch (Editors of Cochrane Methods)
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Methods News
Reviewing the Structure and Function
of Methods
Personal message from David Tovey,
Editor-in-Chief, Cochrane Library
Correspondence to: dtovey@cochrane.org
Cochrane Editorial Unit, London, UK.
The Methods Structure and Function project provides a timely
opportunity for us to reﬂect on the role and contribution of
our Methods community. Methods and their development have
always been, and will remain, essential to the Cochrane mis-
sion, and this is reﬂected in our Strategy to 2020. Alongside the
reviews, the Cochrane Handbooks and the empirical work that
underpins them are important building blocks of the credibility
we have within the ‘evidence community’ and elsewhere. Recent
landmark developments, such as the Cochrane ‘Risk of bias’
tool, the MECIR (Methodological Expectations of Cochrane In-
tervention Reviews) standards and the contribution of Cochrane
methodologistswithin the GRADE (Grading of Recommendations
Assessment, Development and Evaluation) working group exem-
plify this. Equally, the work on the Cochrane-funded Methods
Innovation Projects will help shape future directions. Systematic
reviews andevidence are changing: becomingmore complex and
sophisticated in order to meet the changing needs of decision
makers. At recent meetings with non-governmental organisa-
tions working within the non-communicable disease area, I was
struck by how their research priorities were all dominated by
health systems and implementation questions rather than those
addressed by conventional drug intervention reviews. The re-
views of the future will be broader, enhanced by additional
content such as qualitative data, and will investigate different
forms of questions, such as risk and prognosis. To achieve this
they will need to incorporate new methods. We want Cochrane
to represent the leading edge in methods development. The
question underpinning this review is how we will achieve this.
Unlike Review Groups or Centres, Cochrane Methods Groups and
Fields are rarely funded from national infrastructure funding.
This naturally creates tensions and challenges. Furthermore, the
pressure on researchers within academic institutions to generate
income to fund their work, and to publish high impact articles
creates additional tensions. It is crucial to ensure that we can
attract and retain methodology researchers within our Cochrane
community. Key to ensuring this is personal and professional
progression through engaging in Cochrane activities, whether
this is in providing methodological support for review activities,
undertaking important methodological research, taking part in
training or through work aimed at the implementation and diffu-
sion of newmethods within the Cochrane Reviewmodel.
Thesuccessof theStructureandFunction reviewrequires that the
Cochrane Methods community owns it, that it energises current
members, and engages new people to meet Cochrane’s mission.
I hope that the Cochrane Methods community will consider this
question –whatwouldhave to change tomakemevaluemywork
in Cochrane more, and to encourage colleagues to do likewise?
If Cochrane is to succeed, we need to adopt both ‘top down’ and
‘bottomup’ initiatives and tounderstandhowwecanbest deliver
on our aims together. I look forward to engaging more with you
as the process continues and to understanding your perspectives
better.
Methods Structure and Function
project
Jackie Chandler
Correspondence to: jchandler@cochrane.org
Cochrane Editorial Unit, London, UK
Cochrane’s Strategy to 2020 objectives to build a sustainable
organisation include a target ‘‘to conduct a review of Cochrane’s
governance structure and processes’’. A governance review of
the Cochrane Steering Group and a structure and function re-
view of the Cochrane Review Groups (CRGs) have already been
undertaken. Cochrane wants to ensure current structures are
ﬁt for purpose as we move forward. Discussions between the
Methods Executive, other Methods Group representatives, David
Tovey the Editor-in-Chief and independent consultant Ray Flux,
have sought to frame the review and devise a plan that engages
colleagues to ensure the review is representative of the Methods
community.
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Some key points of debate or questions raised in these discussions were:.
The Structure and Function Review
Methods are ‘fundamental’ to the review production process, in particular the quality assurance of reviews.
We need to address increasing complexity of methods within the Cochrane model and therefore increased resources and input
are required.
Should we, therefore, conduct fewer, but higher quality reviews retaining the goal of Cochrane setting the gold standard?
Instead of focusing on the function of Methods Groups, could we instead focus on the roles of convenors?
How do we bring methods work to the attention of policy makers, so that this work has a greater impact?
What are the methodological drivers for publishing outside Cochrane?
Systems, resources and processes need to be managed to ensure that we are getting the right methods input where it is needed,
particularly specialist methods input so that Methods Groups are not ‘ﬁreﬁghting’ near the end of the process.
The issue of responsibilities and roles of CRGs to ensure liaison with the Methods community for methodological input should be
considered. This would involve formal roles, responsibilities and a requirement for the CRG to work with methods people.
Is there an external market or demand for the Methods Groups’ work?
What opportunities exist for Methods Groups’ output to be knownmore widely outside Cochrane and for their contribution to be
used and valued?
What does Cochrane need from the methods function in the next ﬁve years?
What priority methods activity requires investment?
What infrastructure components and central support components require investment?
What qualities characterise supportive and productive Methods Groups?
How domembers beneﬁt frommembership of a Cochrane Methods Group?
The Structure and Function Review process
The review should be inclusive and engage people, and be less about structure, and more about people and processes.
Volunteerism and enthusiasm are crucial and fundamental characteristics of the organisation.
We should speak to people who have held formal roles who are now less involved.
Questionnaires are a vital way of collecting data and Interviews will allowmore detail about improvements required.
Methods Groups have played a pivotal role in the scientiﬁc devel-
opment of systematic reviews, and as new review types emerge
and current review types are enhanced, the Methods community
will need to continue to develop and evaluate new methods. A
primary objective for Methods Groups is to support the provision
of timely methods input into Cochrane Reviews and contribute
to methods research. The changing academic environment, with
increasing accountability for researchers, means that Cochrane’s
reliance on in-kind support for methods input and research may
not be sustainable. Furthermore, Cochrane’s scope is likely to
broaden, as other types of questions are addressed. This broad-
ening of scope challenges current structures. Consideration also
needs to be given to other factors such as advances in review
methods undertaken outside Cochrane. We need to consider
how Cochrane Methods works effectively together to meet these
developments and challenges, recognising Cochrane’s desire to
continue to be a leader in evidence-based methods and the
publication of systematic reviews.
This review will link in with other reviews undertaken (CRGs) and
those planned (Centres and Fields).
Approach undertaken
• Conduct a self-assessment exercise.
• Gather external stakeholder perspectives.
• Gather internal perspectives.
• Synthesize ﬁndings.
Methods
• Conduct a Cochrane wide survey with Methods Groups
convenors and members, CRG, Field and Centre repre-
sentatives.
• Identify key informants for in-depth interviews.
• Conduct an external survey seeking to obtain review
stakeholder perspectives.
• Conduct a review with the Methods Board at the 2015
Vienna Colloquium.
• Collate, synthesize, and disseminate ﬁndings for discus-
sion and decision-making.
Rebranding of Cochrane and its Groups
Jackie Chandler
Correspondence to: jchandler@cochrane.org
Cochrane Editorial Unit, London, UK
Cochrane has undergone a rebrand. We are now ‘Cochrane’
not ‘The Cochrane Collaboration’, although, of course, we still
collaborate, and this remains central to our brief. The look is
updated and simpliﬁed –clean and fresh. However, this is not just
an ‘interior design’ exercise. Cochrane needs to move on in
a changing research synthesis environment to continue to meet
its mission and objectives. No-
tably, the rebrand has had
quite an impact on Cochrane
Groups, some more than others, in providing them with an
opportunity to consider their individual Group identity. Many
discussions have occurred because the rebrand exercise allowed
us to consider how we present ‘methods’ to a wider audience
beyond Cochrane. Each Methods Group has its own logo and is
a sub-group of the collective logo for Cochrane Methods. There-
fore, the individual Group logos include Cochrane Methods in
their logo. This ensures clarity to the wider world that, for exam-
ple, bias and patient reported outcomes relate to methods. The
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Applicability and Recommendations Methods Group is consider-
ingchanging its registerednameto theGRADEingMethodsGroup.
Some Groups will retain their registered names but will shorten
their titles in their logos. For example, Agenda and Priority
Setting will change to Priority Setting, and the Non-Randomised
Studies Methods Group clariﬁes their title in the logo to ‘NRS
for interventions’ to discriminate from prognostic and diagnos-
tic studies. Some changes are very subtle, for example, the
Statistical Methods Group use Statistics in their logo. Colour is
used to classify Groups. The generic Cochrane Methods logo is
cyan, and most Methods Groups’ logos adopt this colour. The
partnership between the Cochrane and Campbell Collaboration
Methods Groups, ‘Economics’ and ‘Equity’, are identiﬁed by the
Campbell colour of mustard in their logo. The GRADEing logo
is red for a similar reason, since the Applicability and Recom-
mendations Methods Group is aligned closely with the GRADE
Working Group, whose logo is red. Individual Methods Groups’
logos are presented in the reports on pages 52–68. The rebrand
will provide a revamped Cochrane Methods website.
The Cochrane Methods Innovation
Fund (MIF) Report
Jackie Chandler
Correspondence to: jchandler@cochrane.org
Cochrane Editorial Unit, London, UK
Cochrane has provided funding for methodological research
through this speciﬁc fund since 2012. The evaluation of research
methods is a ﬁeld that struggles to obtain and justify funding.
This year’s Methods symposium will spotlight the importance of
knowing the uncertainties within, and limits of the methods we
use to ensure we appreciate their impact on review ﬁndings. By
2018 Cochrane will have spent over GBP 700,000 on methods
development and implementation projects. Due to generous
indirect support provided by ourmembers, an estimate suggests
the true monetary value of this work nearly doubles Cochrane’s
contribution, making it extraordinary value for money. This
work contributes to the wider body of knowledge on research
synthesis methods. It also ensures that Cochrane methodology
is up to date as methods advance. All projects are expected to
provide implementation and dissemination plans. Many projects
provide guidance as core output and involve review authors in
the development of that guidance
MIF 1 –Completed projects
(see last year’s publication for details - www.cochranelibrary.
com/dotAsset/8df3b5a2-217a-41fd-ac77-9d8d05487970.pdf)
1. Searching for unpublished trials using trials registers
and trials web sites and obtaining unpublished trial
data and corresponding trial protocols from regulatory
agencies: See MIF 2 project on the inclusion of clinical
study reports and other regulatory data that takes this
work forward.
2. Enhancingtheacceptanceand implementationof ‘Sum-
mary of ﬁndings’ tables in Cochrane Reviews: This
project has now completed. Extensive user testing and
an international randomized controlled trial (RCT) with
290 participants showed an alternative format of the
‘Summary of ﬁndings’ (SoF) table has advantages over
the current format used in Cochrane Reviews (see pages
41–45). A new format of SoF table for therapeutic inter-
ventionsandtestaccuracy reviewshasbeendeveloped in
collaboration with the Grading of Recommendations As-
sessment,DevelopmentandEvaluation (GRADE)Working
Group. SeeMIF 2 project on the development of guidance
for GRADE assessments to incorporate non-randomized
studies alongside randomized studies in SoF tables.
3. Methodological Investigation of Cochrane Reviews of
Complex Interventions (MICCI): This project has now
completed additional outputs and includes two papers
submitted to journals on the work comparing the rel-
ative contribution of qualitative sibling (studies related
to randomized trials) and unrelated qualitative studies
to understanding a phenomenon of interest, and the
iCAT SR (Intervention Complexity Assessment Tool for
Systematic Reviews) and its guidance.
MIF 1 –Projects near completion
1. Extending the Cochrane ‘Risk of bias’ tool to assess risk
of bias in randomized trialswith non-parallel-group de-
signs, and non-randomized studies: A version of the tool
for non-randomized studies (NRS) has been developed
with deﬁnedbias domains and strategies for their assess-
ment (signalling questions). They are also completing
work on a similar tool for nonstandard designs. Due to
complete October 2015.
2. Addressing missing trial participant data in Cochrane
Reviews: Four journal articles are in progress to dis-
seminate project work, which includes a protocol for a
comparison of different methods for dealing with miss-
ing participant data on pooled effect estimates. Due to
complete September 2015
3. Methods for comparing multiple interventions in inter-
vention reviews and overviews of reviews: A one-day
workshop at the 2015 Vienna Colloquium will dissemi-
nate guidance developed in the project. The workshop
will introduce the concepts andmethods of indirect com-
parison and network meta-analysis in the context of a
Cochrane Review. Convenors of the Comparing Multiple
Interventions Methods Group (CMIMG) have drafted the
new Cochrane Handbook for Systematic Reviews of Inter-
ventions Chapter on ‘Comparing multiple interventions’
targeting both authors and editors. Due to complete
October 2015.
MIF 2 –Projects starting this year
Development of guidance for inclusion of adverse effects in
systematic reviews
Lead investigator: Yoon Loke
Co-convenor Adverse Effects MG endorsed by the Non-
Randomised Studies MG and the Information Retrieval MG
Duration 12 months
This project aims to appraise the evolvingwork intomore reliable
or useful ways of identifying and summing up the whole body
of evidence on harmful effects. From this, they will provide
clear and concise guidance to researchers on the best methods
for assessing harm through systematic reviews. To achieve this
they will search scientiﬁc databases for articles that describe
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methods of searching for data on harms, aswell as assessing bias
in datasets of studies that report adverse effects. This includes
noting any signalling questions speciﬁc to adverse events and
risk of bias not currently covered in ACROBAT-NRSI (A Cochrane
Risk Of Bias Assessment Tool: for Non-Randomized Studies of
Interventions). In addition, they will determine situations where
such signalling questions are of particular importance. A team
of experts will read these articles, evaluate evidence, and decide
how best to implement the methods that have been described.
Engagement with review authors will identify barriers in assess-
ing harms and address ways of overcoming these challenges to
produce guidance material and training.
Interim guidance on the inclusion of clinical study reports and
other regulatory documents in Cochrane Reviews
Lead investigator: Tom Jefferson
Supported by the Information Retrieval MG, Bias MG, Adverse
Effects MG, and Individual Participant Data Meta-analysis MG
Duration 18 months
Systematic reviews aim to provide complete and unbiased sum-
maries of research evidence. Most SRs rely on data from journal
publications. However, there is compelling evidence that not all
studies are published, and those that are published, at times,
misreport beneﬁts and harms. In consequence, the reliability
of systematic reviews based only on published data may be
undermined and give misleading results. Detailed documents
produced for pharmaceutical licensing and regulation include
more information about clinical trials than is reported in journal
articles, but are not usuallymade public. This project will initially
develop guidance on how to decidewhether to incorporate clini-
cal study reports and other regulatory documents into Cochrane
Reviews. The team will draw on their experience with neu-
raminidase inhibitors, the ﬁrst Cochrane Review based entirely
on regulatory documents, and others’ similar experiences.
Methods for systematic review andmeta-analysis of prognostic
factors and prediction modelling studies
Lead investigator: Carl Moons
Co-convenor Prognosis MG
Duration 36 months
Prognostic information is essential to educate or inform man-
agement and decision making for patients. Systematic and
transparent syntheses are necessary to evaluate a massive
proliferation of prognostic factors and models available. This
project will support the completion of prognostic exemplar
reviews and develop new related training materials. The team
will further develop necessary methods for this novel type
of Cochrane Review. This will include testing the use of the
QUIPS (Quality in Prognostic Studies) and CHARMS (CHecklist
for critical Appraisal and data extraction for systematic Reviews
of prediction Modelling Studies) tools for critical appraisal of
prognostic factors andmodelling studies, respectively (see pages
19–20). They will test methods of prognostic factor systematic
review literature searching, develop and illustrate meta-analysis
methods for summarizing resultsofprognosticmodellingstudies.
Assessing the quality of evidence using GRADE and presenting
results from non-randomized studies in Cochrane Systematic
Reviews
Lead investigator: Holger Schu¨nemann
Co-convenor Applicability and Recommendations MG
Duration 26 months
This project builds on previous work from the Applicability and
Recommendations Methods Group, and results of work from the
MIF 1 project. It will assist Cochrane authors to decide how and
when to include, assess, and present evidence obtained from
non-randomized studies (NRS) in a systematic review, and to
facilitate the GRADE assessment in the ‘Summary of ﬁndings’
(SoF) table on a body of evidence from both randomized studies
(RS) andNRS.With the launch of the ACROBAT-NRSI tool, authors
need guidance speciﬁc to the use of GRADE and creating SoF
tables. Speciﬁcally, the project will address solutions for:
• when to include NRS in a systematic review and in SoF
tables;
• how to incorporate the risk of bias for NRS (ACROBAT-
NRSI) into the GRADE assessments, and how to GRADE
evidence fromNRS (includingmore details about criteria
to upgrade evidence);
• how to draw conclusions based on a consideration of
effect and levels of evidence from both RS and NRS com-
bined (e.g. when conﬂicting results from RS and NRS are
present, but they have the same level of evidence); and
• how to present both RS and NRS combined data in a SoF
table.
Developing plain language summaries for DTA reviews
Lead investigator: Penny Whiting
Supported by the Screening and Diagnostic Tests MG
Duration 18 months
A plain language summary (PLS) is a stand-alone summary of
the systematic review, which should provide rapid access to the
content of Cochrane Reviews. PLS clarity is essential to ensure
that systematic reviews are useful to users who are not familiar
with themore technical content of the review. This is particularly
the case for systematic reviews of diagnostic tests. These reviews
include results thataremorecomplexand less familiar than those
from reviews of interventions. However, there is no guidance on
how to write a PLS for reviews of diagnostic tests. This project
will investigate what information potential users of diagnostic
reviews would like to have included in PLS and how they would
prefer this information to bepresented. Users include the science
andhealth-interested public, health professionals, policymakers
and journalists. They will also explore how this information can
be best described using plain language. A combination of focus
groups, user testing, and a web-based survey methods will be
used to develop guidance for authors of reviews of diagnostic
tests about the information needed to write an informative PLS
for potential users of these reviews.
Statistical methods for updatingmeta-analyses
Lead investigator:Mark Simmonds
Supported by the Statistical MG
Duration 24 months
Reviews in the Cochrane Database of Systematic Reviews (CDSR)
should be updated as new studies emerge. Often this requires
updatingmeta-analyses; usually achievedby repeating themeta-
analysis on the larger collection of studies. This process is known
to have statistical problems: the chance of ﬁnding a statistically
signiﬁcantﬁndingofbeneﬁt (orharm)of the intervention,when in
fact the intervention has no effect (i.e. a type I error), increases as
the meta-analysis is repeated. So updating a meta-analysis may
producemisleading results if care is not taken to account for this
multiplicity. Formal statistical methods are available, adapted
from analyses of clinical trials, to compensate for this possibility
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of error when repeating meta-analyses. It has been argued that
these produce a more appropriate conclusion. However, this
is a controversial area, since the context of a meta-analysis is
different from that of a clinical trial. This project will identify
all the proposed statistical methods for updating or repeating
meta-analyses and compare their properties by applying them to
existing Cochrane Reviews and using simulated meta-analyses.
The results will be used to recommend which methods are
most appropriate when updating a meta-analysis, and to inform
discussions within Cochrane about when an update is needed.
The CERQual approach for assessing howmuch conﬁdence to
place in ﬁndings from qualitative evidence syntheses –Devel-
opmentofcomponent1: CochranequalitativeMethodological
Limitations Tool (CAMELOT)
Lead investigator: Claire Glenton
Supported by the Qualitative and Implementation MG
Duration 18 months
Qualitative evidence synthesis is a growing areawithin Cochrane.
However, using these syntheses to inform decisions is chal-
lenging because methods to indicate how much conﬁdence to
place in synthesis ﬁndings are lacking. The CERQual (Assessing
Conﬁdence in the Evidence fromReviews of Qualitative research)
approach aims to assess how much conﬁdence to place in
evidence from reviews of qualitative research and is designed to
be used alongside GRADE tools for assessing evidence on effec-
tiveness. Assessing the methodological limitations of individual
studies contributing toa reviewﬁnding is oneof four components
of the CERQual approach. There is no agreement, however, on
how best to assess such limitations. This project aims to map
existing critical appraisal tools for primary qualitative studies
as the ﬁrst step in creating a qualitative risk of bias or method-
ological limitations tool. This project will be the ﬁrst phase of
several phases required. This phase will review existing critical
appraisal tools for qualitative research and identify common
elements across tools. This work and the following phases
will result in a Cochrane qualitative Methodological Limitations
Tool (CAMELOT) for incorporation in CERQual. The output will
be publication of an overview of existing tools and common
elements across these tools.
New series of papers on systematic
reviews andmeta-analyses based on
individual participant data (IPD)
Jayne Tierney, Larysa Rydzewska, Lesley Stewart,
Maroeska Rovers, Mike Clarke, Paula Williamson, Claire
Vale, Catrin Tudur-Smith, Richard Riley and Sarah Burdett
on behalf of the IPD Meta-analysis Methods Group
Correspondence to: ipd.mrcctu@ucl.ac.uk
MRC Clinical Trials Unit, University College London, London, UK
Members of the IPD Meta-analysis Methods Group have been
collaborating to develop a state of the art series of papers on
individual participant data (IPD).
Figure 1. IPD workshop (London, 2012).
These open-access papers will be a key information source for
multiple stakeholders, in an era when IPD are becoming more
accessible andmore common in meta-analyses.
With support from the UK Medical Research Council (MRC) Net-
workofHubsforTrialsMethodologyResearch(HTMR),webrought
together international experts todiscusskey topics, andestablish
working groups to develop papers on the impact, understanding
anduseof systematic reviewsandmeta-analysesof IPDatawork-
shop in 2012 (Figure 1) that are now bearing fruit summarized
here.
Undoubtedly, many IPD meta-analyses of treatments have
changedclinicalpractice, but itwasnotclearwhether thiswas the
result of their impact on clinical guidelines. Based on a sample of
‘highquality’ IPDmeta-analysesof randomized trials,matched to
a sample of clinical guidelines, we found that IPD meta-analyses
are under-utilized, with guideline developers commonly carrying
out their own new systematic review instead.1 Where guideline
developersdiduse themoredetailed resultsof IPDmeta-analyses
in preference to those from aggregate data systematic reviews,
they were able to provide more nuanced recommendations.1
Evidence that systematic reviews of aggregate data are being
used to inform the design of clinical trials is limited. However, by
providing more detailed and reliable results, IPD meta-analyses
offer greater potential to impact on trial design, conduct and
reporting. It was not clear if and how they have been used for
this purpose. We have identiﬁed examples of IPD meta-analyses
having a direct impact on trials, sometimes in ways that would
not have been possible with aggregate data, but the richness of
the results, and the collaborative advantages of the IPDapproach
do not seem to have been exploited fully.2
As the process of collecting, checking and analysing IPD is more
complex than that for aggregate data, and not all are done to
the same standard, it may be difﬁcult for trialists, practition-
ers and guideline developers, as well funders and publishers,
to understand why IPD meta-analyses are important and how
to use them. We have developed step-by-step guidance, illus-
trated by examples, to help such stakeholders judge and use IPD
meta-analyses of efﬁcacy better3 and so help ensure that policy,
practice and research is informed by the most robust evidence
about the effects of interventions.
In recent years, IPDmeta-analysis hasbecome increasinglypopu-
lar for improvingthedevelopment, validationandgeneralisability
of predictionmodels. The associated issues are different to those
for assessing efﬁcacy, the methodology is less well established
andguidance is lacking. Therefore,wehavedevelopedapractical
introduction to using IPD for the development or validation of
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diagnostic andprognosticmodels and interpreting their ﬁndings,
illustrated with recently published examples. We highlight the
key advantages and the challenges for their design and conduct.4
Even with such guidance, proper understanding, appraisal and
appropriate use of systematic reviews and meta-analyses based
on IPD, cannot be achieved without good reporting of the meth-
ods, results and conclusions. The Preferred Reporting Items for
Systematic reviews and Meta-Analyses (PRISMA) Statement was
developed principally for standard systematic reviews based on
aggregate data. In a separate project that included hosting an
international workshop funded through a National Institute for
Health Research (NIHR) Senior Investigator award, we developed
PRISMA-IPD, a stand-alone extension to PRISMA, covering the
speciﬁc requirements for the IPD approach.5
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2015 Cochrane Methods Symposium:
Why do we need evidence-based
methods for use in systematic reviews?
2nd October 2015, Palais Niedero¨sterreich, Vienna, Austria
Jo McKenzie
Correspondence to: joanne.mckenzie@monash.edu
School of Public Health & Preventive Medicine, Monash Univer-
sity, Melbourne, Victoria, Australia
This year’s Methods Symposiumwill be on the topic of evidence-
based methods. As systematic reviewers, we devote long hours
to scrutinising the evidence underpinning clinical practice. Nev-
ertheless, how often do we question whether there is good
evidence for the methods we use in reviews? Our conﬁdence in
the ﬁndings of more than 30,000 systematic reviews that exist
rests on the evidence base underpinning methods. Just as there
are consequences arising from our healthcare choices, so too are
there consequences to the choice of methods we use in system-
atic reviews. Methods research can allow us to make informed
decisions about the best methods to use in reviews through the
provision of information that allows us to understand trade-offs
in terms of bias, efﬁciency, usability, and resource use.
In this symposium, case studies will be presented to illustrate
the identiﬁcation and development of methods; approaches to
evaluating methods (with their strengths and weaknesses); con-
sideration of the quality of evidence required to changemethods;
and how we bring about change in the methods that review
authors use. In addition, we will discuss how best to determine
where methods development is required and how to prioritize
that development. The symposium will conclude with a debate
on how we determine a method is valid, and therefore, whether
it should be implemented within the Cochrane model.
Methods underpin systematic reviews, and their evaluation and
development is necessary to ensure that the results from system-
atic reviews do not mislead. As such, methods research plays a
critical role in ‘‘increasing the value and reducing the waste’’ in
research. Please look out for planned Cochrane Database of Sys-
tematic Reviews (CDSR) editorials to disseminate the discussions.
More information is available at methods.cochrane.org.
Systematic reviews of prognostic
studies
Karel GMMoons, on behalf of the convenors of the
Prognosis Methods Group
Correspondence to: k.g.m.moons@umcutrecht.nl
Julius Center for Health Sciences and Primary care, UMCUtrecht,
Utrecht, Netherlands
TraditionallyCochranehas focusedonsystematic reviewsof ther-
apeutic intervention studies. In the past decade, we broadened
the scope to include reviews of diagnostic test accuracy studies.
We also include other types of study designs and analyses in our
reviews, such as network meta-analysis, individual participant
data, and non-randomized studies. More recently, Cochrane has
invested in an evaluation of the feasibility of including prognostic
studies in its review portfolio.
Prognostic studies address the (future) outcomes and the pre-
diction of these outcomes in individuals with a certain health
condition. There is no health condition or disease where progno-
sis does not play a role. Prognostic information is important to
inform patients and relatives about their prognosis and to make
treatment or other management decisions including the with-
holding of treatment. Indeed, it forms the basis of personalized
or risk-based medicine. Primary prognostic studies abound in
themedical literature. Thousandsof prognostic factor andmodel
studies are published each year; indeed, published prognostic
factors or (bio)markers for a particular disease, outcome, or tar-
get populationareoftennumerous and sometimesnumber in the
hundreds. In addition, there are oftenmultiple - sometimes even
more than 200 –so-called prognostic models developed for the
same outcome or target population. Healthcare professionals
andguidelinedevelopersoftencannot see the ‘wood for the trees’
and simply do not know which prognostic factor or model to use
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or appraise in which context. Hence, the development of system-
atic reviews of prognostic studies to enhance evidence-based
practice is essential, as the number of such studies increases
every day. Fortunately, in the last decade we have seen a sharp
increase in the number of systematic reviews of prognostic factor
andmodel studies.
The Cochrane Prognosis Methods Group (PMG), established
in 2005, has an international membership with approximately
170 researchers listed on the Archie database. PMG promotes
systematic reviews of prognostic studies within Cochrane. De-
velopment of clear guidance and methods for such reviews
(www.prognosismethods.cochrane.org/en/index.html) are un-
derway. Over the last few years we have successfully completed:
• a protocol template for Cochrane Reviews of prognostic
studies;
• search strategies for retrieving both prognostic factor
andmodelling studies;1
• the QUIPS (Quality in Prognostic Studies) tool to assess
risk of bias in prognostic factor studies;2,3
• the CHARMS (CHecklist for critical Appraisal and data
extraction for systematic Reviews of prediction Mod-
elling Studies) checklist to frame the review question,
develop a reviewprotocol, and guide data extraction and
critical appraisal of prognostic studies;4
• A series of 4papers in theBMJandPLOSMedicine journals
on the conduct of prognosis studies 5−8;
• the TRIPOD (Transparent Reporting of a multivariable
prediction model for Individual Prognosis Or Diagnosis)
reporting guideline for prediction modelling studies;9,10
• the PROBAST (Prediction study Risk of Bias ASsessment
Tool) tool to assess risk of bias in prediction modelling
studies (Abstracts Cochrane Colloquium 2015, 2014,
2013)
• statistical methods to combine evidence quantitatively
from prognostic studies;11−14 and
• GRADE (Grading of Recommendations Assessment, De-
velopment and Evaluation) recommendation for system-
atic reviews on overall prognosis.15
Seven distinctive workshops that incorporate these develop-
ments will be held at the upcoming 2015 Vienna Colloquium.
Currently there are three exemplar reviews of prognostic studies
underway with published protocols in the CDSR. These include
reviews on the overall prognosis of autism spectrum disorder,
prognostic factors in patients with low back pain, and exist-
ing prognostic models for the risk of postoperative nausea and
vomiting.
Finally, Cochrane recently agreed to extend the current exemplar
reviews of prognostic studies. If there is a relevant topic with
substantial published primary studies, such as, prognostic fac-
tors or models for a speciﬁc outcome or disorder, and there is
capacity to retrieve and review these primary studies, please do
not hesitate to contact us. The conveners of the PMG can provide
the necessary tools, which include a protocol template, search
strategies, and critical appraisal andmeta- analytical guidance.
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Published Methodological
Research: structured
abstracts and commentaries
Innovations in data collection,
management and archiving for
systematic reviews
Li T, Vedula SS, Hadar N, Parkin C, Lau J, Dickersin K.
Annals of Internal Medicine 2015;162(4):287-94.
Background: In order to provide a complete and accurate pic-
ture of an intervention or disease, accurate and complete data
extraction from relevant studies is essential. The Institute of
Medicine recommend standard, piloted, data extraction forms
developed speciﬁcally for a systematic review, and independent
data extraction of quantitative and other critical data by two or
more researchers.
Objective: To produce a step-by-step tutorial for collecting,
managing, and archiving data for systematic reviews, and to
suggest steps for developing rigorous data collection forms in the
Systematic Review Data Repository (SRDR).
Main content: The key to successful data collection is easy-to-
use forms, and complete and unambiguous data extracted in a
structured and organized manner. A good data abstraction form
should minimize the need to go back to the source documents.
Eight stepswere suggested for setting up data collection forms in
the SRDR; these can be applied to any method of data collection
for systematic reviews.
1. Develop outlines of tables and ﬁgures. Ensures the correct
data are extracted, not too much (avoids wasted effort)
or too little (avoids going back to source documents).
2. Assemble and group data elements (general information,
study characteristics, participant characteristics, inter-
vention/exposure, setting, outcomes/results). Datamust
be collected on important characteristics that maymod-
ify the treatment effect or associations of interest.
3. Optimize framing of the data abstraction item. Ask closed-
ended questions as often as possible, with an option to
expand where necessary (‘other, specify’). Open-ended
questions are useful when potential responses are im-
possible to anticipate, or where abstractors may be led
by having speciﬁc options, but provide little control over
data quality. Each question should deal with a single
point. Avoid blank ﬁelds as these lead to ambiguity
over whether no response means a negative response,
or that data were missing (use: not available, not ap-
plicable, cannot tell, unclear, not reported). Avoid data
manipulation during the data extraction process.
4. Develop data abstraction forms. These forms serve as
a permanent reference that can be distributed. The
study name, form name, version number, and version
date should be documented. Every data item should be
numbered. Brief deﬁnitions/instructions helpful for an-
swering aquestion shouldbe included to improvequality
and consistency across abstractors.
5. Set up and pilot-testing. Develop a user manual with in-
structions, coding conventions, and deﬁnitions speciﬁc
to the project and test for consistency.
6. Train data abstractors. Familiarize the abstractors with
the data system and form, clarify ambiguous questions
and improve consistency.
7. Qualityassurance/controlplan/monitoringprogress.Com-
pare duplicate data extraction, discuss differences, and
adjudicate disagreements. The Data Comparison Tool
in the SRDR displays responses from two abstractors
underneath each question.
8. Export and clean all, or a subset, of the data for analysis.
Conclusions: If done well, data collection for systematic reviews
only needs to be done by one team and placed into a publicly
accessible database for future use.
Commentary
Prepared by Karen A Robinson
Correspondence to: krobin@jhmi.edu
CochraneMethodology ReviewGroup, Johns Hopkins University,
Baltimore, MD, USA
Li and colleagues provide guidance for the abstraction of data for
systematic reviews. The paper also moves beyond data abstrac-
tion to describe the Systematic Review Data Repository (SRDR)
–an online tool for the abstraction of data, aswell as aweb-based
archive of systematic review data.
As with guidance provided in the Cochrane Handbook for Sys-
tematic Reviews of Interventions and the Institute of Medicine
(IOM) standards for systematic reviews, there is little evidence to
inform the guidanceprovidedby Li and colleagues. As such, there
are a few places where transparency about the rationale behind
the guidance would be helpful. For instance, the authors state
that spreadsheets should not be used to collect data, but do not
providea reason. Given thepopularity of using spreadsheets, and
that sophisticated ﬁles with input masks and drop down items
may be created,more detail aboutwhy this is badwould bemore
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persuasive. Likewise, a statement is made about the need to
number every question and response option on an abstraction
form. Thismakes sense when paper forms are used and numbers
are needed for data entry, but the necessity for numbering when
using online entry is unclear.
A personal concern with repositories is that the data contained
therein may not be accurate. Unfortunately, this article does not
help address this concern. While it is noted that data may be
exported for cleaning, the step of uploading the cleaned data
back into the repository is not explicit –and is not listed as a step
(Table 1). Do freely accessible but inaccurate systematic review
data still promote reliability in the systematic review process?
The availability of abstracted data increases the transparency of
the systematic review process. The efﬁcient use of such data
also adheres to the Cochrane principle of avoiding duplication of
effort, to theextent that systematic reviewersmayno longerneed
to re-abstract data from a study for each new review. However,
the full use of a repository requires a cultural shift in how data
abstracted for reviews are viewed, shared and used.
Validation of a search strategy to
identify nutrition trials in PubMed
using the relative recall method
Durao S, Kredoa T, Volmink J. Journal of Clinical
Epidemiology 2015;68(6):610-6.
Background: Acritical stepwhenconductinga systematic review
is identifying as many relevant trial reports as possible through
a comprehensive search. The availability of a comprehensive,
up-to-date trials register could help to achieve this. In order for
such a register to be established, a suitable, validated, search
strategy needs to be developed.
Objective: To develop, assess, and maximize the sensitivity of a
search strategy to identify diet and nutrition trials in PubMed.
Design and analysis: PubMed was searched for controlled vo-
cabulary terms (Medical SubjectHeadingsorMeSH terms) related
to diet and nutrition. Suitable keywords were used in PubMed to
identify further associated terms. Once the list ofMeSH termsand
keywords was decided, they were combined with the Boolean
operator ‘OR’ and repeated searches were run in PubMed; the
search results were used to delete search terms that retrieved
irrelevant results, and add additional relevant terms identiﬁed.
Once the search strategy was optimized, it was combined with
the Cochrane highly sensitive search strategy for identifying ran-
domized trials inPubMed toﬁlter for randomizedcontrolled trials
(RCTs).
All Cochrane Reviews that evaluated the effectiveness of nutri-
tional interventions in RCTs, quasi-RCTs or controlled clinical
trials published between January 2012 and March 2013 were
selected from a search of the Cochrane Database of Systematic
Reviews (‘nutrition’ or ‘diet’ or any MeSH descriptor with quali-
ﬁers). A list of all primary studies included in the reviews was
produced, and PubMed was searched to ensure these were in-
dexed on the database. The ﬁnal list was used as a gold standard
set of primary studies against which to validate the new search
strategy.
Main results: The gold standard list comprised 298 trials, derived
from16 systematic reviews. Thenewlydeveloped search strategy
identiﬁed 242 of the 298 gold standard references (relative recall
81.2%, 95% conﬁdence interval (CI) 76.3 to 85.5). After analysis
of the titles and abstracts of the 56missed references, additional
termswere added to the search strategy; the relative recall of the
modiﬁed search strategy was 88.6% (95% CI 84.4 to 91.9).
Conclusions: A sensitive search strategy was developed to iden-
tify diet and nutrition trials in PubMed that could be useful for
establishing a nutrition trials register to support the conduct of
future systematic reviews.
Commentary
Prepared by Rehana A Salam, Zulﬁqar A Bhutta and Vivian Welch
Correspondence to: rehana.salam@aku.edu
Division of Women & Child Health, The Aga Khan University,
Karachi, Pakistan
Background: Rigorous and transparent systematic reviews are
recognized internationally as a credible source for evidence of
effectiveness. However, in the ﬁeld of nutrition, there is a need
to develop consensus on standardized methodologies for con-
sistency and possibly facilitating development and collation of
the evidence in this subject area.1 In terms of development of
guidelines for action, the World Health Organization (WHO) has
led the ﬁeld with a series of activities geared towards develop-
ment of nutrition policy guidelines based on the best evidence.
The US Agency for Healthcare Research and Quality (AHRQ) also
publishes a description of systematic review methodology with
particular regard to the steps for performing systematic reviews
and areas unique to the discipline of nutrition.2 However, there
is still a lack of coordination among various academic groups
and development agencies working in parallel silos. To stan-
dardize the critical step of identifying the relevant trial reports in
conducting a systematic review, there is a need for a comprehen-
sive, up-to-date trials register, and validated search strategies to
identify nutrition trials. There is emerging interest in develop-
ing a trials register for diet and nutrition for Cochrane authors,
along with developing nutrition-speciﬁc guidance and central-
ized editorial review within both Cochrane and the Campbell
Collaboration for nutrition-related reviews.
What did the authors say? The article by Durao and colleagues3
aimed to develop and validate a search strategy to identify
diet and nutrition trials in PubMed. To date, no other study
has assessed the validity of a ﬁlter for diet and nutrition tri-
als. The authors have used the relative recall method proposed
by Sampson and colleagues4 to develop a search strategy and
validate it using a set of 298 randomized trials identiﬁed from
16 Cochrane Reviews on diet and nutrition (published between
January and March 2013). Their search strategy showed good
sensitivity, with a relative recall of 88.6%. The strength of this
study is the use of a large set of trials –derived from high quality
Cochrane Reviews –as the gold standard (n = 296), however,
the precision was low. A limitation was that none of the source
reviews focused on non-health system interventions that aim
to improve nutrition through sectors other than health, such
as agriculture, social welfare, trade (such as conditional cash
transfers or agricultural interventions). Furthermore, studies
were included from reviews publishedbetween January toMarch
2013, whichmight have limited the topics covered andmay have
inﬂuenced the relative recall. The authors propose the need to
assess further the precision of the search strategy to address low
precision.
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Importance of the research for practice:
• For Cochrane authors, this search strategy provides a
useful starting point for structured and validated search-
ing for nutrition and diet interventions; this may also
be useful for searching for nutrition related systematic
reviews.
• For future methodological research, this could guide the
establishment of a nutrition trials register to support col-
lation of the nutrition related evidence and the conduct
of future systematic reviews.
• For future research, itwould be imperative to expand this
search strategy to include non-health sector, nutrition
interventions.
• In future, it will be important to include databases other
than PubMed to identify all nutrition-relevant trials.
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The contribution of different
information sources to identify
adverse effects of a medical device: a
case study using a systematic review of
spinal fusion
Golder S, Wright K, Rodgers M. International Journal of
Health Technology Assessment in Health Care
2014;30(4):1-7.
Background: Comprehensive evaluations of evidence on the
safety of medical devices are an important priority for patients,
healthcare professionals and policy makers. To produce an un-
biased evaluation, systematic reviews need to identify as many
relevant studies as possible. Authors of systematic reviews of
adverse effects have tended to focus on searching MEDLINE and
reference lists; it is unclear whether such a limited search would
identify all relevant articles with adverse effects data.
Objective:To identify the most effective sources to search in
order to identify adverse effects data for medical devices.
Design: A case study systematic review of the safety of recombi-
nant human bone morphogenetic protein-2 (rhBMP-2) for spinal
fusion was selected to evaluate the impact of searching different
information sources for adverse effects. This case study review
searched ten on-line databases; checked bibliographies; con-
tacted authors of key papers; published calls for evidence in the
Spine Journal, The Black Letter newsletter and on the internet;
and used automated ‘current awareness’ searches in Zetoc Alert
fromtheBritishLibraryandinMEDLINE.Foreachsourcesearched,
a record was made regarding whether each relevant publication
(randomized controlled trials and observational studies) was re-
trieved by the search strategy, or was available in the database
but not retrieved. The sensitivity, precision, and number needed
to read were calculated, as well as the minimum combination of
sources to identify all the publications and studies.
Main results: Eighty-two publications (49 studies) were included
in the systematic review. Only one article was available in a
database searched, but not retrieved by the search strategy. Sci-
ence Citation Index (SCI) and Embase both achieved the highest
sensitivity (62%), followed closely by MEDLINE/PubMed (56%).
The minimum combination of sources needed to identify all the
publications was Science Citation Index (SCI), Embase, Cochrane
Central Register of Controlled Trials (CENTRAL), and either MED-
LINE or PubMed, in addition to reference checking, contacting
authors and an automated current awareness service. To identify
all the relevant studies, the minimum combination of sources
was similar with the exclusion of CENTRAL.
Conclusions: In order to identify all the relevant publications
or studies included in the case study systematic review, several
different sources needed to be searched.
Commentary
Prepared by Andrew Booth
Correspondence to: A.Booth@shefﬁeld.ac.uk
Information Resources, School of Health and Related Research,
University of Shefﬁeld, Shefﬁeld, UK
Identiﬁcation of adverse effects data is a key and challenging
task within the context of systematic reviews of effects. This
recent offering originates from a University of York team that
has contributed signiﬁcantly to the safety domain of information
retrieval. As the authors observe, much analysis to date focuses
on adverse effects of pharmaceutical interventions. This study
extends the consideration to medical devices. Essentially the
authors report a case study of a speciﬁc intervention examined
within the framework of a large and well-conducted systematic
review. To the uninitiated reader ‘‘recombinant human bone
morphogenetic protein-2 (rhBMP-2) for spinal fusion’’ does not
readily evoke a ‘medical device’. Closer examination reveals that
this protein is delivered via a collagen sponge carrier within a
titanium cage, which manifestly falls within such a deﬁnition.
However, the relevance of this study to others involved in tech-
nology assessment would be less likely to be overlooked had the
case examined a more familiar device such as a breast implant
or a hip prosthesis. Unfunded information retrieval method-
ological research is typically constrained by dependence on the
opportunistic individual case study, as in this instance. Further
development of the evidence base is then achieved by subse-
quent replication across additional topic areas, either by the
innovators themselves or by those who have been inﬂuenced by
their methodology. Practically, such methodological studies are
feasible because they carry a relatively light evaluation overhead
by enhancing the documentation required for reporting the re-
viewandharnessing goodpractice in referencemanagement and
coding.
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This study almost eliminates the potential confounding by in-
adequate within-database retrieval strategies (i.e. searched but
not retrieved) that complicates many practical observations on
information retrieval. It ﬁnds that the need formultiple database
searching is not simply dictated by the need to be risk averse
when working within the context of safety. Multiple database
searching is further informed by the incomplete coverage of ad-
verse effects in any one single database source. In comparison
with other topics, where MEDLINE coverage may approach 70%
to 80% of included studies, adverse effects of medical devices, in
this case, occasions barely more than 50%. This has particular
implications in resource-constrained contexts given that access
to the SCI or Embase, as required by this topic, may require
a prohibitively expensive subscription. Use of a reader-friendly
‘number needed to read’ metric helps to emphasize associated
efﬁciency and cost effectiveness considerations.
The facility to draw generalizable conclusions for the context of
medical devices is, as the authors openly acknowledge, limited
by this research being a single case study and, wemight add, pos-
sibly by the characteristics of this particular device. Nevertheless,
this study remindsusof amoregeneralizable takehomemessage
–namely the need to identify the deﬁning characteristics of each
particular review when planning appropriate search strategies.
A minimum generic conﬁguration of MEDLINE, Embase and CEN-
TRAL would overlook the value of SCI in this particular case.
Within the discipline of surgery, there is considerable ongoing
debate regarding the optimal relationship of volume to outcome.
To what extent are information specialists, and review teams
generally, similarly required to specialise in a particular type of
review in order to deliver to an acceptable quality and what is
the appropriate level of specialization? Are rapid reviews the
synthesis equivalent of keyhole surgery? At a time when the con-
cept of comprehensive searching is challenged by exhaustive (i.e.
resource-dependent) searching and funders, review teams and
information specialists grapple with the question of how many
databases is enough; it is timely that studies such as this remind
us that there is no substitute for a detailed knowledge of the
tailored requirements for each sub-type of review. Sharing this
specialist knowledge through workshops, or through published
studies such as this one, at least ensures a platform for evidence
based information practice.
Using text mining for study
identiﬁcation in systematic reviews: a
systematic review of current
approaches
O’Mara-Eves A, Thomas J, McNaught J, Miwa M,
Ananiadou S. Systematic Reviews 2015;4:5
Background:Highlysensitivesearchesmayhavepoorspeciﬁcity,
resulting in large numbers of irrelevant citations for screening,
whichmay not be feasiblewithin the time constraints of a review.
Text mining may assist with the screening of titles and abstracts,
and identiﬁcation of articles for retrieval andmanual screening.
Objective: To present the evidence on existing text mining
methods related to the title and abstract screening stage in a
systematic review.
Design and analysis: A systematic review of text mining applica-
tions forassisting the identiﬁcationofpotentially relevant studies
for a systematic review was conducted. Databases and websites
weresearchedfrom2005(earliestuseof textmining forscreening)
to December 2013. There were ﬁve review sections: state of the
evidence-base; workload reduction; purpose and effectiveness
of semi-automation; overcoming contextual problems; and chal-
lenges to implementation. Categorical data (gathered by noting
the presence or absence of certain characteristics) were used to
produce frequency tables and cross tabulations for describing
the state of the evidence base, and direct quotations (through
line-by-line codingof thepapers)wereused to evaluate emerging
themes.
Main results: The evidence base is active, diverse and rapidly
evolving. There was almost no replication between studies, or
collaboration between research teams. The approaches used
were: reducing the number of citations that need to be screened
manually; reducing the number of people needed to screen (text
mining as second screener); increasing rate/speed of screening;
and improvingworkﬂowefﬁciency. Most studies suggestedapos-
sible 30% to 70% saving in workload; this saving was sometimes
accompanied by a 5% loss of relevant studies (95% recall).
High recall (sensitivity) was highlighted as critical for the ac-
ceptability and uptake of text mining techniques. Attempts
to maximize recall included: voting or committee approaches;
specialist algorithms; and human input (active learning). Hasty
generalization (bias introduced when features of the training
document set are not representative of the documents required
by the review) was identiﬁed as a potential problem for active
learningmethods. Class imbalance was another challenge, given
the far greater number of excluded/irrelevant studies than in-
cluded/relevant ones; giving greater weight to included/relevant
studies and under-sampling (using fewer non-relevant studies in
the training set) may mitigate class imbalance.
Conclusions: It is difﬁcult to identify the best approach, but
efﬁciencies and reductions in workload are potentially achiev-
able. Four of the six systems available, are speciﬁcally designed
for selection of studies in a systematic review: Abstrackr, EPPI-
Reviewer, GAPScreener and Revis. Using text mining to prioritize
the order in which items are screened should be considered safe
and ready for use. Textmining as a ‘second screener’maybeused
with caution. Text mining to eliminate studies automatically is
not yet fully proven.
Commentary
Prepared by Byron C Wallace and Iain J Marshall
Correspondence to: byron.wallace@utexas.edu
School of Information, University of Texas at Austin, Austin,
Texas, USA
In the ﬁrst three months of 2015, Cochrane published more
than 200 new or updated systematic reviews.1 If estimates from
a Cochrane updating pilot are generalized (1436 screened at
an average rate of 2.6 minutes per abstract),2 then reviewers
have spent over 1500 person-hours screening abstracts for these
reviews alone. With the aim of reducing this burden, several
research groups have developed machine-learning methods to
partially automate abstract screening.3 The review by O’Mara-
Eves and colleagues provides a valuable synthesis of this work.
The semi-automated approaches described in the review aim to
identify all relevant abstracts for human review while discarding
enough irrelevant ones to reduce reviewer workload substan-
tially. The technology is alreadymature: the authors reviewed 67
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studies, most of which retrospectively compared the decisions
made by an algorithm to those made by humans in published
systematic reviews. Automation reduced workload by 30% to
70%. In some instances, this came at the cost of overlooking
approximately 5% of the relevant studies, but in many cases
semi-automation achieved perfect, or near-perfect, sensitivity.
O’Mara-Eves and colleagues conclude that semi-automation
technology is ready for use, either as a means of prioritizing
the order in which citations are to be screened or (cautiously)
as a replacement for one of two reviewers. Cochrane has an
opportunity to lead the adoption of this technology. Concretely,
Cochrane should train and continuously evaluate an automated
system against human double-assessed decisions as part of their
routine workﬂow (with the algorithm being used in the back-
ground, and not affecting the methods). Once the automation
is sufﬁciently reliable, automated decisions could replace one
reviewer (and eventually both). If the vast amount of data rou-
tinely collected by Cochrane were harnessed to its full potential,
a robust evaluation could be performed quickly, and with little
additional effort.
Looking forward, other steps in the systematic review pipeline
may similarly be semi-automated, further reducing manual ef-
fort. Extracting data from full-texts is a natural next target for
semi-automation, given that well-established methods already
exist for information extraction generally.5 Indeed, work on au-
tomated extraction for systematic reviews has already begun.6−8
Thus while O’Mara-Eves, and colleagues, have demonstrated
that reliable semi-automation of abstract screening appears to
be within reach, the overarching goal of modernizing evidence
synthesis using computational tools andmethods remains. Real-
izing this goal will allow reviewers to spend less time on tedious
work andmore time thoughtfully synthesizing evidence.
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Association between analytic strategy
and estimates of treatment outcomes
in meta-analyses
Dechartres A, Altman DG, Trinquart L, Boutron I, Ravaud
P. JAMA 2014;312(6):623-30.
Background: Meta-analysis of all available randomized con-
trolled trials (RCTs) may produce a precise pooled result (narrow
conﬁdence intervals (CI)), however, the pooled estimate may be
adversely affected by trials at a high risk of bias or those with
small sample sizes. Several strategies are available to reduce
these biases, but these may lead to imprecise estimates.
Objective: To compare treatment outcomes estimated bymeta-
analysis of all trials with four alternative strategies.
Design: Meta-analyses of RCTs from the Cochrane Database of
SystematicReviews that hadbeen identiﬁed in three independent
searches for prior studieswereused; 48meta-analyses (421RCTs)
published between 2008 and 2009, 45 (314 RCTs) published in
2011, and 70 (505 RCTs) published between 2012 and 2013.
Data collection and analysis: Data were extracted from the
component RCTs (ﬁrst collection of reviews) or the Cochrane
Reviews (latter two collections). RCTs were assessed using the
Cochrane ‘Risk of bias’ tool; where RCTs were not retrieved,
the assessment of the review authors was used. Overall risk
of bias was classiﬁed as low if sequence generation, allocation
concealment, blinding, and incomplete outcome data were all at
low risk. Outcomes were classiﬁed as objective or subjective and
analyzed separately. The DerSimonian and Laird random-effects
model was used to evaluate ﬁve strategies: 1) all trials; 2) single
most precise trial (narrowest CI); 3) 25% largest trials only; 4)
‘limit meta-analysis’ (predicts outcome for a trial of inﬁnite size);
5) trials at low risk of bias only. The ratio of odds ratio (ROR)
was estimated for each alternative strategy compared with the
meta-analysis of all trials. The difference between the alternative
strategyandmeta-analysisofall trialswasconsideredsubstantial
if the ROR was less than 0.77 or more than 1.30.
Main results: Treatment outcomes were larger in the meta-
analysis of all trials than in the singlemost precise trial; combined
ROR 1.13 (95% CI 1.07 to 1.19) for subjective outcomes, and 1.03
(95% CI 1.01 to 1.05) for objective outcomes. The difference in
treatment outcomes between these strategies was substantial
in 47 of the 92 (51%) meta-analyses of subjective outcomes (40
had larger outcomes with all trials) and in 28 of the 71 (39%)
meta-analyses of objective outcomes (21 had larger outcomes
with all trials). The combined ROR was: 1.08 (95% CI 1.04 to
1.13) for subjective and 1.03 (95% CI 1.00 to 1.06) for objective
outcomes when the meta-analyses of all trials were compared
with the 25% largest trials; 1.17 (95%CI 1.11 to 1.22) for subjective
and 1.13 (95% CI 0.82 to 1.55) for objective outcomes when com-
pared to ‘limit meta-analysis’; and 0.94 (95% CI 0.86 to 1.04) for
subjective and 1.03 (95% CI 1.00 to 1.06) for objective outcomes
when compared to meta-analysis of low risk of bias trials only.
Conclusions: Estimation of treatment outcomes in meta-
analyses differ depending on the analysis strategy used. Sys-
tematic assessment of the robustness of meta-analysis results
should be undertaken using sensitivity analyses. Disagreement
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between the result of a meta-analysis and either the single most
precise trial or meta-analysis of the largest trials should lead to
careful interpretation of the meta-analysis result. If ten or more
trials are included, a ‘limit meta-analysis’ may be useful.
Commentary
Prepared by Kerry Dwan
Correspondence to: kdwan@cochrane.org
Cochrane Editorial Unit, London, UK
Systematic reviews and meta-analyses are considered to be the
gold standard inproviding reliable evidence formedical interven-
tions. However, over the years, research has demonstrated that
small studies can have an impact on meta-analysis estimates,
which arises from small trials tending to show larger treatment
effects than large trials.
Although this study appears to be well conducted, it included
three separate cohorts of reviews published between 2008 and
2013, and thereforedoesnot represent themost recent literature.
After considering163meta-analysesofbothobjectiveandsubjec-
tiveoutcomes, theauthors foundthat theestimationof treatment
outcomes in meta-analyses differed depending on the strategy
used, that is, depending on which studies were included in
the meta-analysis (25% largest trials, single most precise trial,
‘limit meta-analysis’, low overall risk of bias), and therefore the
conclusions of the review were not robust.
This paper has important implications for practice for all review-
ers, showing the importance of conducting sensitivity analyses to
assess the robustness of meta-analysis results. Users of reviews
should pay careful attention to these sensitivity analyses and not
just rely on the results of meta-analyses of all eligible trials.
An investigation of how many Cochrane Reviews implement
sensitivity analyses, the type of sensitivity analyses used, and
whether they are pre-speciﬁed would be of interest.
The Hartung-Knapp-Sidik-Jonkman
method for random-effects
meta-analysis is straightforward and
considerably outperforms the
standard DerSimonian-Laird method
IntHout J, Ioannidis J, Borm G. BMCMedical Research
Methodology. 2014;14(1):25.
Background: The DerSimonian and Laird (DL) random-effects
meta-analysis can give too many statistically signiﬁcant results
(inﬂated type I error rate) when the number of studies is small
and/or heterogeneity is moderate or substantial. The Hartung,
Knapp, Sidik and Jonkman (HKSJ) method performs better than
DLwhen trialsof similar sizearecombined; however, it isnot clear
how it compareswhen trial sizes are unequal. Themethods differ
in the calculation of the conﬁdence interval and the statistical
test. For DL, these are based on the normal distribution, while
for HKSJ these are based on the t-distribution (with the degrees
of freedom equal to ‘n trials-1’), and a weighted version of the DL
standard error.
Objective: To evaluate the relative performance of DL and HKSJ
methods when studies of different sizes are combined, and to
develop a simple method to convert DL results to HKSJ results.
Design and analysis: Simulated meta-analyses containing be-
tween two and 20 trials, with varying sample sizes and between-
study heterogeneity were generated and used to evaluate the
performance of HKSJ and DL methods. For each sample
size/heterogeneity scenario, 10,000 meta-analyses were simu-
lated. The type I error rate (percentage of statistically signiﬁcant
meta-analyses when the overall mean treatment difference was
zero) was calculated for each simulation scenario. The number
of statistically signiﬁcant (P value< 0.05) ﬁndings produced by
DL and HKSJ methods was also compared using empirical data
frommeta-analyseswith threeormore studies fromtheCochrane
Database of Systematic Reviews (2012 issues).
Main results:Bothmethodsperformed relativelywellwhen trials
wereof equal size andheterogeneitywasabsent (error rates 2.1%
to 6.9% for HKSJ and 0.9% to 4.6% for DL). Simulations showed
that the HKSJ method consistently resulted in more adequate
error rates than the DL method for a range of scenarios (small
number of equally sized but heterogeneous studies; one trial
1/10th the size of the others; 50:50 small and large trials (ratio
1:10); one trial 10 times larger than the other trials). When the
signiﬁcance level was 5%, HKSJ error rateswere 11%or less, with
the higher rates in meta-analysis with few trials of unequal sizes.
The error rates for DL were higher, generally ranging from 10% to
34% in analyses with few trials of unequal sizes. The empirical
data from 689 meta-analyses showed that 25% of signiﬁcant
ﬁndings with DL were non-signiﬁcant with HKSJ. The authors
provided instructions for conversionof DL results toHKSJ results.
Conclusions: HKSJ consistently resulted in more adequate type
I error rates than the DL method, especially when the number of
studies was small. Even with HKSJ, extra caution is neededwhen
there are ﬁve or fewer studies of very unequal sizes. DL results
can easily be converted into HKSJ results.
Commentary
Prepared by: Wolfgang Viechtbauer
Correspondenceto:wolfgang.viechtbauer@maastrichtuniversity
.nl
Department of Psychiatry and Neuropsychology, School for
Mental Health and Neuroscience, Maastricht University, The
Netherlands
The Hartung and Knapp method,1,2 independently derived by
Sidik and Jonkman3 (HKSJ) method), is a method for making
inferences about the size of the overall treatment effect in meta-
analysesbasedonarandom-effectsmodel. Numeroussimulation
studies have demonstrated that themethod provides hypothesis
tests and conﬁdence intervals (CIs) with essentially nominal type
I error rate and coverage, while the standard Wald-type (Wt)
method, often referred to as the DerSimonian and Laird (DL)
approach, typically leads to tests with inﬂated type I error rate
and CIs that are too narrow.
Building on this earlier work, IntHout and colleagues describe
similar ﬁndings based on an additional simulation study, with
focus on the performance of the methods when the sample sizes
of the trials are simulated under various scenarios (e.g. equally
sized trials, all small trials except one large one or vice-versa). In
a collection of 689 meta-analyses from the Cochrane Database
of Systematic Reviews, the authors also demonstrate that about
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25% of the signiﬁcant ﬁndings based on the Wt test would turn
out to be non-signiﬁcant if the (HKSJ) method was applied.
The implications for practice of the present, and prior, compar-
isons between themethods are extremely important: In essence,
the ﬁndings indicate that the standard Wt/DL approach that has
been applied in most meta-analyses to date (including Cochrane
Reviews) is considerably more likely to lead to incorrect con-
clusions (especially type I errors) than could ever be considered
acceptable –in some scenarios, the actual chances of rejecting
the null hypothesis that the overall treatment effect is zero, when
in fact it is true, was not 5% (i.e. the nominal signiﬁcance level)
but could run as high as 30%.
Of course, in practice, and in any particular case, when methods
disagree, one cannot knowwhichmethod (Wt/DL or HKSJ, or any
other) provides the correct inference. Moreover, in rare cases, it
is possible that the HKSJmethod leads to the rejection of the null
hypothesis, while theWt/DLmethoddoes not, and even theHKSJ
method does not always provide perfect control of the type I er-
ror rate, especially whenmeta-analyzing a small number of trials
that vary greatly in size. However, when in doubt, conclusions
based on the HKSJ method should be given more credibility and
the evidence so far even suggests that the Wt/DL method should
be abandoned altogether and replaced by the HKSJ method as
the standard approach.
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A general framework for the use of
logistic regression models in
meta-analysis
Simmonds MC, Higgins JP. Statistical Methods in Medical
Research. 2014. PMID: 24823642. Epub 2014/05/16.
Background:Where individual participant data are available for
every randomized trial in a meta-analysis of dichotomous event
outcomes, ‘one-stage’ random-effects logistic regressionmodels
have been proposed as a way to analyse them. Such models
can also be used even when individual participant data are not
available and we have only summary contingency table data.
One beneﬁt of the one-stage regression model is that it avoids
some of assumptions of conventional meta-analysis methods. A
second beneﬁt is that, with only minor modiﬁcations, the one-
stage regression model can be used in a range of meta-analysis
areas.
Objectives: To describe the general framework for the one-stage
logistic regression approach formeta-analysis with dichotomous
outcomes.
To describe the minimal changes to the model structure that al-
low for modelling of sparse data, meta-regression and subgroup
analysis, networkmeta-analysis andmeta-analyses of diagnostic
test accuracy studies.
Main content: The general framework for the one-stage logistic
regression model is provided. Each section of the paper then
describes how the model can be modiﬁed to address a different
meta-analysis area (sparse data, meta-regression and subgroup
analysis, networkmeta-analysis andmeta-analyses of diagnostic
test accuracy studies). Examples are used to illustrate the appli-
cation of the one-stage logistic regressionmodel, and the results
are comparedwithothermeta-analysismethods. Computer code
to conduct the analyses is provided.
Conclusions: The one-stage random-effects logistic regression
model offers advantages in that it avoids many of the assump-
tions common to meta-analysis, and may be particularly useful
where studies are small and events are rare. The one-stage ap-
proach also uniﬁes meta-analysis, because the same model can
beused in a rangeof contexts andmaybeﬁtted inmost statistical
software packages. This could avoid the need to perform a range
of different, and often complex, statistical techniques speciﬁc to
the type of analysis.
Commentary
Prepared by Adriani Nikolakopoulou
Correspondence to: nikolakopoulou.adriani@gmail.com
School of Medicine, University of Ioannina, Ioannina, Greece
Background: Since there has been recognition of the need
for sound evidence to inform clinical research, the impact of
meta-analysis has grown, andmethodology has been developed
to address several issues beyond the relative effectiveness of
just two interventions. Methodological developments in meta-
analysis include meta-regression, to examine the inﬂuence of
several covariates on the summary effect estimates, and network
meta-analysis, to examine the relative effectiveness of several
treatment options for a healthcare condition. Moreover, meta-
analytic techniques have been developed to synthesize evidence
from diagnostic test accuracy (DTA) tests or prognostic studies.
When individual patient data (IPD) are meta-analyzed, usually a
‘one-stage’ logisticmodel is used. The term ‘one-stage’ is used to
differentiate themodel from the conventional ‘two-stage’ proce-
dure ofmeta-analysis, where the two stages involve ﬁrst deriving
all the study effect estimates, and secondly, combining these
study effects into a summary effect.
What did the authors say? Simmonds and Higgins explain
why and how the ‘one-stage’ model, usually adopted in the use
of IPD meta-analysis, can also be applied in the conventional
pairwise meta-analysis that uses aggregated data, as well as in
a range of meta-analytic scenarios (meta-regression, network
meta-analysis, meta-analysis of DTA, sparse data). A particularly
useful application of the ‘one-stage’ model is in the analysis
of sparse data; meta-analyses of studies with rare events are
subject to several challenges, and as such, numerous methods
have been proposed to handle them. While the conventional
approach involves the use of a continuity correction, simulation
studies have shown that logistic regression is amongst the best
approaches to deal with rare events.1,2 The authors propose a
general framework for the ‘one-stage’ logistic regression model
in meta-analysis. The importance of this framework rests on
the uniﬁcation of different meta-analytic models in a general
approach, which require only slight modiﬁcations in order to
address a wide range of contexts. Strengths of the proposed
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general framework include the avoidance of assumptions com-
monly made in meta-analysis, and that the model can ﬁt in most
statistical software packages.
Importance of the research for practice: The importance of
the paper is its potential to assist authors, reviewers and editors
to comprehend the broad picture of the meta-analytic method-
ology in parallel to each context-speciﬁc situation. Moreover,
the proposed general framework provides the basis for useful
extensions to address several challenging issues such as incon-
sistency in network meta-analysis and consideration of multiple
diagnostic test thresholds in DTA studies.
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Outcomes in Cochrane Systematic
Reviews addressing four common eye
conditions: an evaluation of
completeness and comparability
Saldanha IJ, Dickersin K, Wang X, Li T. PLOS ONE
2014;9(10):e109400.
Background: Studies that address a reviewquestionoften report
differentoutcomes, both toeachotherand to thosechosenby the
systematic reviewer. Systematic reviewers must decide whether
to choose outcomes they believe to be important (systematic
review author judgment), or those outcomes reported in the
clinical trials (clinical trialist judgment). It is unclear how system-
atic reviewers choose and pre-specify outcomes for systematic
reviews.
Objective: To assess the completeness of pre-speciﬁcation and
comparability of outcomes in Cochrane Reviews addressing four
common eye conditions.
Designandanalysis:Protocols forallCochraneReviewsaddress-
ingglaucoma, cataract, age-relatedmaculardegeneration (AMD),
and diabetic retinopathy (DR) to June 2013were examined. Com-
pleteness and comparability for outcomes speciﬁed in at least
25%of protocolswere assessed. A completely-speciﬁedoutcome
included information on domain/outcome title (e.g. anxiety,
visual acuity); speciﬁc measurement/instrument/scale; speciﬁc
metric (e.g. change from baseline); method of aggregation (e.g.
mean, median, proportion); and time-points. Comparability was
assessed by examining how individual elements were speciﬁed
across protocols for each domain.
Main results: Fifty-seven systematic reviews (22 glaucoma, 16
cataract, 15 age-related macular degeneration, 4 diabetic
retinopathy) were identiﬁed, for which there were protocols
for 54; the methods sections were used for the remaining three.
Completeness and comparability for ﬁve domains which ap-
peared in 145 instances (quality-of-life (83% of protocols), visual
acuity (83%), intraocular pressure (37%), disease progression
(26%), and contrast sensitivity (26%)) were evaluated.
Only 15/145 instances (10.3%) were completely speciﬁed (me-
dian three elements per outcome); speciﬁcation was better in
protocols published after 2006. Primary outcomes were more
completely speciﬁed than non-primary (median four versus two
elements, respectively). Intra-ocular pressure was themost com-
pletely speciﬁed outcome (median four elements), although only
24%of theprotocols assessing this outcome reported the speciﬁc
measurement to be used; quality of life was the least completely
speciﬁed (medianoneelement). Across theprotocols, thespeciﬁc
metric used was unclear for 15% to 100% of outcomes, and the
method of aggregation unclear for 40% to 100% (quality of life
being the worst for both elements).
Conclusions:Outcomepre-speciﬁcationwas largely incomplete;
systematic reviewers should consider all ﬁve elements, indicat-
ing the importance of complete speciﬁcation to clinical trialists,
on whose work systematic reviewers depend. Complete pre-
speciﬁcation could improve efﬁciency and reduce bias in data
abstraction and analysis, and make systematic reviews more
useful to decision-makers.
Commentary
Prepared by Augusto Azuara-Blanco and Mike Clarke
Correspondence to: m.clarke@qub.ac.uk
Queen’s University of Belfast, Northern Ireland, UK.
Background: AlthoughCOMET (CoreOutcomeMeasures in Effec-
tiveness Trials) has now identiﬁed approximately 200 core out-
come sets in many areas of health (www.comet-initiative.org),
core outcomemeasures are still to bedeﬁned for eyediseases. An
additional challenge for trialists andsystematic reviewers (partic-
ularly those hoping to dometa-analyses) is the lack of consensus
in the speciﬁcation of ﬁve different elements that should be used
to describe each outcome, that is, domain (e.g. visual acuity),
speciﬁc measurement or scale (e.g. Snellen chart at 6 meters),
speciﬁc metric (e.g. change from baseline), method of aggre-
gation (e.g. mean), and time-point. Saldanha and colleagues
evaluated the completeness and variability of outcomes used in
CochraneReviews in fourmajoreyediseases: glaucoma, cataract,
age-related macular degeneration, and diabetic retinopathy.
What did the authors say? The authors assessed ﬁve out-
comes used in the protocols for 57 Cochrane Reviews. These
were quality-of-life, visual acuity, intraocular pressure, disease
progression, and contrast sensitivity. They considered an out-
come to be completely reported if the protocol described the ﬁve
elements noted above.
Only a small proportion of the outcomes (15/145, 10.3%) spec-
iﬁed all ﬁve elements (median: three elements per outcome).
Primary outcomes were more completely speciﬁed than non-
primary (median= four versus two elements). Quality of life was
the least completely speciﬁed (median= one element).
Importance of the research for practice: Saldanha and col-
leagues’ research highlights that reviewers need to describe the
domain, speciﬁcmeasurement, speciﬁcmetric,methodof aggre-
gation, and time-points of each outcome more fully. Reviewers
should discuss their proposed choices with their editorial team
at an early stage of the review. Editors need to provide guidance
regarding each of the ﬁve elements that fully characterize each
outcome for each condition, and it might be helpful to seek
consensus on this.
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Implications for Cochrane
The current version of the Cochrane Handbook of Systematic Re-
views of Interventions requires that the domain, measurement,
and time point should be described, but there is no explicit re-
quest to pre-specify the metric or method of aggregation. This
should be considered for future revisions of this Handbook.
Implications for trialists
The COMET initiative is primarily focused on core outcomes for
use in effectiveness trials, with a focus on ‘what’ tomeasure. Less
attention has been given to the speciﬁcation of the ﬁve different
elements that fully characterise each outcome, including the
‘how’ and ‘when’ of outcome measurement; and consideration
of the reliability, validity, responsiveness and interpretability is
also important in the selection and evaluation of core outcomes
and their elements.
Survey of Cochrane protocols found
methods for data extraction from
ﬁgures not mentioned or unclear
Vucic K, Jelicic Kadic A, Puljak L Journal of Clinical
Epidemiology 2014:S0895-4356(14)00473-9. [Epub ahead
of print]
Background: Data needed for a systematic review may be
presented only in ﬁgures. The Cochrane Handbook of System-
atic Reviews of Interventions contains no methodological advice
about extraction of such data. Cochrane Reviews rarely mention
data extraction from ﬁgures; if they do, there is no description of
the method used.
Objective: Toexaminewhethermethods fordataextraction from
trial ﬁgures are reported in Cochrane Review protocols.
Design and analysis: Two independent authors screened proto-
cols of Cochrane Reviews for data extraction published between
May 2013 and May 2014 for descriptions and methods from
trial ﬁgures. Data collected included date of protocol publica-
tion, country of authors’ origin, number of authors, number of
afﬁliated institutions, Cochrane Review Group, whether the pro-
tocol contained a description about data extraction from ﬁgures,
method of data extraction, and reference to the method of data
extraction.
Main results: Among 589 protocols, 33 (5.6%) mentioned data
extraction fromﬁgures in themethods section. Only oneprotocol
speciﬁed that computer software would be used. One protocol
speciﬁcally stated that data from ﬁgures would not be used.
Most protocols (18 of the 33) stated that data from ﬁgures would
be included only if two reviewers independently extracted the
same result. Seven protocols stated that data from ﬁgures was
not preferred and would be included only if speciﬁc numerical
values were not discernible, or if data were not available in any
other form. One protocol stated that data from ﬁgures would be
estimated by three authors independently, with a fourth author
acting as arbiter if necessary. Three protocols stated that data
from ﬁgures would be approximated, with no further details
given. Two protocols just mentioned in the methods that ﬁgures
might be a source of data.
Conclusions: Very few protocols of Cochrane Systematic Re-
views mention data extraction from ﬁgures, and even when
mentioned, methods for data extraction are unclear. Methodol-
ogy for data extraction from ﬁgures should be incorporated into
the Cochrane Handbook for Systematic Reviews of Interventions
and newmethodological standards for Cochrane Reviews.
Commentary
Prepared by Alain Mayhew
Correspondence to: almayhew@ohri.ca
Bias Methods Group. Knowledge Synthesis Group, OttawaHospi-
tal Research Institute, Ottawa, Canada
Background: Vucic and colleagues undertook a well-designed
study to assess the reporting of the planned use of data from
ﬁgures or graphs in Cochrane protocols. This is an impor-
tant issue which is not currently included in the Cochrane
Handbook for Systematic Reviews of Interventions1 or The
Methodological Expectations of Cochrane Intervention Reviews
(MECIR).2
What did the authors say? The authors reported that only 50
of 589 protocols reported the intention of extracting data from
ﬁgures if necessary. This included 17 protocols that mentioned
accessing data from ﬁgures in the appendix of the protocol.
Of the remaining 33 protocols, only one speciﬁed the use of
a computer program. The study authors describe the difﬁcul-
ties with obtaining data directly from trialists, but unfortunately
do not report whether protocol authors intended to contact
the trialists for the numeric data that was presented in graph
formats.
Importance of the research for practice:
• Choice of method of extracting data presented only in
graphs and reporting of the methods in protocols are
important, but separate, issues. It would be very in-
teresting to explore whether the different methods of
extraction actually bias review results. Trialists should
be encouraged to provide access to numeric data that
are presented in graphs in a paper; the availability of the
data in anonline appendixmay lead tomore precise data
being available for systematic reviews. A further evalu-
ation of published reviews to assess the actual methods
used to extract data from graphs would also be useful.
• Currently, reviewprotocols lackacleardescriptionofhow
the data in graphs will be extracted; both the Cochrane
Handbook for Systematic Reviews of Interventions and
Methodological Expectations for Cochrane Intervention
Reviews (MECIR) Standards should consider adding this
requirement.
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Intervention synthesis: a missing link
between a systematic review and
practical treatment(s)
Glasziou PP, Chalmers I, Green S, Michie S. PLOS Medicine
2014;11(8): e1001690.
Background: Current methods to guide the translation of ev-
idence in systematic reviews to the selection and prescription
of a speciﬁc intervention are poorly developed and absent from
most instructions on systematic review methods. If a systematic
review ﬁnds that a class of interventions is effective, users of the
review will want to know which version of the intervention they
should use.
Objective: To identify methods for translating evidence from
systematic reviews to selection and prescription of a speciﬁc
intervention.
Main content: Databases and bibliographies of papers were
searched to identify methods for proceeding from evidence in
systematic reviews to choosing a speciﬁc intervention; a forward
citation search from relevant articles was also conducted. Three
approaches were identiﬁed: single-trial-based choice; common
components hybrid; and model-guided synthesis.
1. Single-trial-based choice: Criteria such as feasibility, size
and certainty of the estimates of the effect, suspected
or deﬁnite harms of the interventions, applicability in
particular settings, costs, acceptability, practicality, or
familiarity, are used to choose which trial’s treatment
to adopt. This is the simplest approach, requiring little
additionalwork, andavoids assumptions about untested
effects of composite interventions. Since no single inter-
vention may be rated best on all criteria, choices should
be tabulated (similar to the ‘buyer’s guides’ in consumer
magazines) including a ‘no intervention’ option.
2. Common components hybrid: Extracted components
based on frequency and importance, allowing ‘the best’
fromall interventions to be used, if ‘the best’ can be iden-
tiﬁed. Components may include mode of delivery, mate-
rials, intensity/dose, sequencing/scheduling; checklists
to assist with deconstruction are available. More com-
monly used components may or may not be the most
important; the minimal set of active components nec-
essary to achieve beneﬁcial effects may be appropriate.
There isconsiderableadditionalwork involved indescrib-
ing, comparing, and analyzing the included trials, and
identifying potentially active components, which may
be poorly described. After deconstruction, the method
used to recombine components will depend on how in-
dependent or dependent they are, and the quality and
quantity of evidenceof their effectiveness. Heterogeneity
will mean there will rarely be sufﬁcient statistical power
to detect whether or not the components contributed to
the observed effects.
3. Model-guided synthesis: Models the mechanisms of ef-
fect, coding and assessing the importance of compo-
nents; requires a theoretical understanding that may
not have guided the review, or may not be accepted
by practitioners. This method requires multiple trials
with well-described interventions that provide sufﬁcient
variation and statistical power for subgroup analyses
or meta-regression. Also, meta-regression can be con-
founded by variables such as the population studied,
context, or methods used; individual patient data would
be desirable, but would increase workload.
Conclusions: If cliniciansandpolicymakersare tobase theirprac-
tices on the results of systematic reviews, these approaches will
need to be more widely adopted. Whichever approach is used,
review authors should provide an ‘intervention options table’,
which describes the ‘pros and cons’ of intervention alternatives.
Commentary
Prepared by Agnes Dechartres
Correspondence to: agnes.dechartres@htd.aphp.fr
Research Centre Epidemiology and Biostatistics, Inserm U1153,
Paris, France
The goal of systematic reviews and meta-analyses is to help in-
formdecisionmakingby synthesizing thebest available evidence
to determine which interventions are most effective for a given
clinical topic. If readers cannotapply the results to theirpractice,1
the meta-analysis has not fully achieved its goal and therefore
can be considered a waste of effort and resources.2 In 2008,
Glasziou and colleagues showed that interventions were insufﬁ-
ciently described from reports of trials and systematic reviews,3
which hampers the applicability of results in practice. In this
study, Glasziou and colleagues outline another important gap
between evidence synthesis and practice related to the variation
in interventions among trials, within a systematic review. Al-
though interventions should be closely related, there are always
variations, particularly for complex interventions. Therefore, the
choice of the intervention to apply in practice may be unclear.
Glasziou and colleagues discuss the ‘pros and cons’ of three
methods to improve the transposition of evidence from system-
atic reviews to practice. The ﬁrst method, the simplest one, is to
choose one intervention among those evaluated in trials. Criteria
are needed to deﬁne how to choose this ‘best’ intervention. The
two other methods involve deconstruction of the intervention to
identify all relevant components and identify the most relevant
ones. In one of these methods, the intervention to apply in
practice is a composite based on the ‘best’ components of inter-
ventions across trials. In the other, subgroup or meta-regression
analyses are performed to help identify which elements of the in-
tervention are important. Eachmethod raises speciﬁc issues. For
the ﬁrst method, how to choose the intervention (whether based
on the largest trial, the largest treatment effect etc.)? The second
involves an importantworkload toobtain anew intervention that
was not evaluated. The low number of trials limits the third.
Although thesemethods are not perfect, it is crucial to have such
reﬂection, and at a minimum, a table summarizing the different
interventions evaluated across trials must be provided to help
readers judge which interventions are the most appropriate for
their practice.
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Mediating policy-relevant evidence at
speed: are systematic reviews of
systematic reviews a useful approach?
Caird J, Sutcliffe K, Kwan I, Dickson K, Thomas J. Evidence
and Policy 2015;11(17):81-97
Background: Policy-makers require swift and accurate ap-
praisals of evidence within time and budget constraints. Reviews
of systematic reviews (RoRs; i.e. umbrella reviews, overviews of
reviews, meta-reviews) can be useful when addressing a broad
research question where limited time and resources preclude a
full systematic review. However, they do have methodological
challenges, and there are questions about whether they are ﬁt
for purpose.
Objective: To consider the impact of RoRmethods on timeliness
and utility of evidence, and to present strategies to address the
challenges inherent in RoRmethodology.
Design: The authors drew on their own experience of conducting
RoRs todiscussﬁvekey factors that support the timely translation
of evidence into policy, and potential strategies to address the
challenges encountered.
Main results: Quality/reliability: Quality assessment for RoRs
requires assessment of each included review and of the primary
research containedwithin them; limited reportingwithin reviews
may hamper the latter. Reviews where detailed reporting of the
quality of primary studies was not provided, or reviews of low
methodological quality could be excluded from a RoR, but this
could lead to extensive data loss, limited scope, and an incom-
plete picture of the interventions being evaluated, and therefore
adversely affect the utility of the evidence-base.
Consistency: Similarity of reviewquestions/scopesandcomplete-
ness of the primary research within each review, will impact on
the similarity of ﬁndings, and consequently, the clarity of the
picture that policy-makers use to identify key issues. Identiﬁed
reviews may only partially address the review question of inter-
est; theremay be both substantial overlap of reviews and gaps in
the evidence. Examination of eligibility criteria, study character-
istics and pertinent outcomes will indicate comparability across
reviews.
Importance/selection of relevant data: RoRs usually encompass
more populations, interventions, settings and outcomes than
standard systematic reviews. Breadth of coverage is an ad-
vantage of RORs, but it may be impractical to include all data
reported across all included reviews. Subject experts selecting
the most important outcomes could mitigate this, but omission
of key outcomes would lead to decreased utility of the RoR; the
selection process could be prone to interpretive and conceptual
biases of previous reviewers.
Applicability (ability to apply to a particular situation) and gener-
alizability (ability to transfer across populations/settings): In order
to meet these requirements, the included systematic reviews
need to be up-to-date, and data available for all relevant inter-
ventions. The time lapse between research being conducted and
included ina systematic review, is compoundedby theconductof
aRoR. This is particularly important in areaswith rapidly evolving
technology/treatments.
Costs and cost-effectiveness: The use of cost-consequence analy-
ses was encouraged, to provide policy-makers and commission-
ers with information on necessary resources, and help estimate
budgets; these are more readily reported within systematic re-
views than cost-effectiveness data.
Conclusions: RoRs are a useful means of mediating policy-
relevant evidence of broad topic areas at speed, although their
applicability andgeneralizability is reduced if important informa-
tion is missed by limiting data extraction to systematic reviews.
Commentary
Prepared by: Sue Brennan
Correspondence to: sue.brennan@monash.edu
Australasian Cochrane Centre, Monash University, Australia
Reviews of reviews (overviews) have garnered attention for their
potential to accelerate research synthesis. Such expediency is
important for evidence-informed policy where the broad scope
of reviews and tight timeframes often prohibit detailed review of
primary studies. Caird and colleagues explore different method-
ological approaches for overviews in relation to their potential to
generate ‘useful’ evidence. The authors consider the trade-offs
and value of different approaches in terms of the efﬁciency of
overviewproduction, the validity of ﬁndings (bias), and the utility
of the overview. Many of the issues discussed are not unique to
overviews (e.g. dealingwith sparseandheterogeneousdata). Nor
do the issues apply equally to all overviews. For example, dealing
with reviews that use different methods for assessing risk of bias
is rarely an issue in an overview of Cochrane Reviews, but arises
when including reviews from other sources. Challenges faced by
most overview authors include how to deal with overlapping re-
viewswithout losing information (whenselectingonereviewfrom
many) or over-emphasising individual studies (when including all
reviews), and whether to delve into primary studies (if so, when
is it feasible and beneﬁcial to do so?). The myriad of approaches
used to address these, other challenges are often geared tomax-
imise efﬁciency, but their effect on the utility, and validity of an
overview needs evaluation. Indirectly, the paper demonstrates
that we need to delineate methods unique to overviews in or-
der to evaluate the performance of different methods, and thus
provide better evidence fromwhich to understand their impact.
Critical appraisal and data extraction
for systematic reviews of prediction
modelling studies: the CHARMS
checklist
Moons K, de Groot J, Bouwmeester W, Vergouwe Y, Mallett
S, Altman DG, et al. PLOS Medicine 2014;11(10):e1001744
Background: Diagnostic and prognostic prediction studies are
becoming increasingly common in the medical literature. There
is no formal checklist for guidance on deﬁning a review ques-
tion, extracting data or critically appraising primary studies that
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develop or validate diagnostic or prognostic prediction models.
Reviews of prediction model studies have created their own
checklists with variable inclusion of key details.
Objective: To design a CHecklist for the critical Appraisal and
data extraction for systematic Reviews of prediction Modelling
Studies (CHARMS).
Design: Existing risk of bias tools, critical appraisal checklists for
systematic reviews of randomized trials and diagnostic test accu-
racy studies, methodological recommendations for the conduct
and reporting of prediction model research, and data extraction
sheets used in published reviews of predictionmodelling studies,
were examined to identify seven items important for framing the
reviewquestion, and11domains toextract andcritically appraise
the primary included studies.
Main results: The CHARMS checklist contains two parts.
1. Key items to guide the framing of the review aim, search
strategy, and study inclusion and exclusion criteria. The
key items includeprognosticversusdiagnosticprediction
model, intended scope of the review, type of prediction
modelling studies, the target population, outcome to be
predicted, time span of the prediction, and intendedmo-
ment of using the model. A focused review question that
deﬁnes these key points enables researchers to develop
a tailored search strategy and to deﬁne the inclusion
and exclusion criteria (thus the applicability) of primary
studies to be included in the review.
2. Overall domains and speciﬁc items within each domain
to be extracted from the reports of primary prediction
modelling studies to answer the review question, and
evaluate risk of bias and applicability. The key items to
be extracted from each primary study were grouped into
11 domains (source of data, participants, outcomes to
be predicted, candidate predictors, sample size, missing
data, model development, model performance, model
evaluation, results, interpretation and discussion). Each
domain was discussed in detail.
Conclusions: Published reporting guidelines, quality assessment
tools, and key methodological publications were combined to
produce the CHARMS checklist. The checklist is intended to
help frame the review question, design the review, and ex-
tract the relevant items from the reports of the primary pre-
diction modelling studies and to guide assessment of the risk
of bias and the applicability of the reviewed prediction models.
The checklist will require further evaluation, adjustment and
improvement.
Commentary
Prepared by Rob Scholten
Correspondence to: r.j.p.scholten@umcutrecht.nl
DutchCochraneCentre and Julius Center for Health Sciences and
Primary Care, University Medical Center Utrecht, Utrecht, The
Netherlands
Variouschecklistsandtoolshavebeenpublishedregardingthere-
porting of results ofmedical scientiﬁc studies (see www.equator-
network.org/) or risk of bias assessment. Recently, a novel
checklist has been added to these tools: the ‘CHecklist for crit-
ical Appraisal and Data Extraction for Systematic Reviews of
Prediction Modelling Studies (CHARMS)’.
Prediction models are used for calculating the probability of a
certain condition (e.g. a diagnosis of deep vein thrombosis) or a
certain disease outcome (e.g. the probability of being dependent
after one year in patients with multiple sclerosis).
CHARMS discriminates itself from other instruments, because its
objective is to help authors of systematic reviews of prediction
models (both diagnostic and prognostic) to frame the review
question, write the protocol for the review, extract the relevant
items from the original studies, and to guide assessment of
the risk of bias and the applicability of the reviewed prediction
models. The authors state explicitly that the checklist is not
intended for assessing the risk of bias of primary studies of prog-
nostic factors, for which they refer to the Quality in Prognostic
Studies (QUIPS) tool,1 nor for prediction model impact studies,
for which the intervention framework is used and methods for
addressing randomized controlled trials (RCTs) can be applied.
They also refer to the Preferred Reporting Items for Systematic
Reviews andMeta-Analyses (PRISMA) statement for the reporting
of systematic reviews of prediction models.2
The authors developed the checklist in a pragmatic way. They
looked at published risk of bias tools, existing critical appraisal
checklists forsystematic reviewsofRCTsanddiagnostic testaccu-
racy studies, methodological recommendations for the conduct
and reporting of prediction model research, and data extraction
sheets used in published reviews of predictionmodelling studies.
In addition, key methodological literature regarding prediction
models was scrutinised. They also used their experiences with
pilot versions of the checklist that were tested and discussed
at annual Colloquia, and the feedback that they received from
the workshop participants. Finally, they applied the checklist to
various systematic reviews of prediction models and modiﬁed
the checklist according to their experience.
The resulting checklist consists of two broad domains. Domain 1
consists of key items to guide the framing of the review aim,
search strategy, and study inclusion and exclusion criteria. Do-
main 2 covers relevant items to extract from individual studies
(for enabling assessment of risk of bias and applicability of the
ﬁndings).
Currently, systematic reviews of prognosis or prediction mod-
elling studies are not yet part of the scope of Cochrane. How-
ever, there are plans for piloting such reviews in Cochrane (see
pages 7–8) and CHARMS can serve as a very useful tool to as-
sist the authors of those pilot reviews. Applying CHARMS will
inevitably lead to more insight into what information is missing
in the reports of primary studies and will guide researchers of
future predictionmodelling studies to frame their study question
better and consequently their study designs.
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Ethics and equity in research
priority-setting: stakeholder
engagement and the needs of
disadvantaged groups
Bhaumik S, Rana S, Karimkhani C, Welch V, Armstrong R,
Pottie K, et al. Indian Journal of Medical Ethics
2015;12(2):110-3.
Background: Decision-makers and funders of health research
are increasingly engaging patient representatives andhealthcare
consumers to make research more relevant. Although this is
welcomed, there is a concern that the needs of disadvantaged
groups may go unrepresented.
Objective: To develop recommendations on the engagement of
different stakeholdersanddisadvantagedpopulations inpriority-
setting exercises.
Design: Aworkshopwas conducted at the 2014HyderabadCollo-
quium. Attendeesweredivided into focus groups, each taking the
perspective of a policy-maker, clinician or member of the public.
The groups discussed Ebola prevention or the implementation of
‘sin taxes’ on sugarybeverages. Focusgroupoutputsandkeynote
presentations were used to develop recommendations for future
priority-setting exercises.
Main results: Several challenges for developing and implement-
ingstructuredpriority-settingmethodswere identiﬁed, including:
difﬁculty identifying a representative sample of experts; reaching
individuals not aligned with organizations; narrowing down and
reaching consensus on the list of priorities; converting topics to
research questions; the scarcity of epidemiological and baseline
health data; and the limitations of data-driven methods in low-
and middle-income countries. Planned and coordinated action
was considered necessary to ensure security, healthcare and
health equity; methods of prioritization had to be ﬂexible and
diverse to allow application in different research areas; step-wise
approaches were suggested.
Itwassuggestedthatstakeholderengagementwasmoreeffective
when priority-setting began at the micro level, before expanding
nationally or globally. Communication strategies that had been
developed over timewere recommended in order towin the trust
of the relevant populations, build their capacity to participate,
take into account their concerns, and provide feedback on the
results. The need to learn from other similar situations, identify
funding and develop strategies to win trust, were highlighted.
Conclusions: Research priority-setting exercises need to meet
organizational objectives and be aligned with the values of the
stakeholders. The following ﬁve strategies to develop an ethical
and equity-oriented framework for setting research priorities for
the disadvantaged were recommended:
1. Involve diverse stakeholders in a transparent priority-
setting processwhile systematically collecting, analyzing
and reporting the conﬂicting interests of all participants.
2. Create strategies to engage stakeholders from different
socioeconomic groups to examine research values, ex-
pectations and context.
3. Synthesize research agenda-setting publications from
different regions of the world in a publicly available
database.
4. Cross-link groups working on priority-setting in similar
domains to empower low- and middle-income nations
with limited research capacity.
5. Identify common themes across research agendas.
Commentary
Prepared by: Jennifer Petkovic
Correspondence to: jennifer.petkovic@uottawa.ca
Bruye`reResearch Institute, University ofOttawa,Ottawa, Canada
The use of priority-setting methods within Cochrane has been
increasing in recent years, resulting in the establishment of
the Cochrane Agenda and Priority Setting Methods Group
(CAPSMG) in 2011 (see pages 59–60). Priority-setting is a key part
of Cochrane’s Strategy to 2020 and in 2014 a list of 200 priority
reviews was published on the Cochrane website.1,2
In this paper, Bhaumik and colleagues present recommenda-
tions for engaging disadvantaged populations in priority-setting
exercises. These recommendations are based on previous work
identifyingpriority-settingapproachesusedbyCochranegroups3
and discussions held during a workshop at the 2014 Hyderabad
Colloquium (21-25 September). This work builds on the equity
lens for priority-setting within Cochrane groups.4 The authors
describe presentations and discussions from the workshop and
how these contributed to the development of a research agenda
for CAPSMG and recommendations for equity-focused priority
setting for the disadvantaged.
The recommendations described in this paper have importance
beyond identifying the priorities for conducting and updating
reviews. With eleven systematic reviews published each day,5
thiswork canalsobeusedbygroupsproducing systematic review
derivative products (e.g. Evidence Aid, Health Systems Evidence,
Communicate to vaccinate (COMMVAC), SUPPORT Summaries
(i.e. structured summaries of systematic reviews)) to determine
which reviews are most important for policy-making, especially
within resource-constrained settings. The Equity Methods Group
is currently conducting a priority-setting exercise with ﬁve pan-
els of international stakeholders to identify reviews important
for health equity for a special collection of systematic review
summaries, called Evidence for Equity.
For the broader Cochrane community, these recommendations
can ensure that the values and needs of disadvantaged groups
are considered with those of policymakers, practitioners, and
researchers when determining priority reviews and derivative
products.
These recommendations are a good start to increased engage-
ment with disadvantaged groups in priority-setting. Future
research should assess whether these recommendations result
in priorities that can improve health equity.
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Development and evaluation of
’brieﬁng notes’ as a novel knowledge
translation tool to aid the
implementation of sex/gender analysis
in systematic reviews: a pilot study
Doull M, Welch V, Puil L, Runnels V, Coen SE, Shea B, et al.
PLOS ONE 2014;9(11):e110786.
Background: Sex (genetic) and gender (cultural/societal) analy-
sis is a framework used to guide researchers in assessingwhether
interventions have meaningful differential effects for males and
females. Men and women often exhibit different vulnerabilities,
symptoms and responses to treatments. The lack of report-
ing and analysis of sex/gender evidence in primary studies and
systematic reviews raise scientiﬁc and ethical concerns.
Objective: To describe the development, pilot testing and evalu-
ationof sexandgenderbrieﬁngnotes to translate evidenceabout
how to consider sex and gender in systematic reviews.
Design: An interactive process was used to translate knowledge
about sex and gender into brieﬁng notes, a concise communi-
cation tool used by policy and decision makers, in collaboration
with three Cochrane Review Groups (HIV/AIDS, Hypertension,
Musculoskeletal).
Data collection and analysis: Brieﬁng note development was
informed by existing systematic review checklists, literature on
sex and gender, in-person and virtualmeetings, and consultation
with topic experts. Reviewswere chosenby: seekingnominations
from Review Group collaborators; searching for sex and gender
in the Cochrane Database of Systematic Reviews; and using the
Montori search ﬁlter and keywords ‘sex’ and ‘gender’ in PubMed.
No exemplar reviews that could serve as a model for integrating
sex and gender analysis were identiﬁed. After a period of feed-
back and revision from the three collaborating Review Groups,
the brieﬁng notes were evaluated during a workshop at the 2012
Canadian Cochrane Symposium.
Main results:Nineteenworkshop participantswith backgrounds
in research, clinical practice, community health, education and
health policy evaluated the brieﬁng notes. Systematic review
experience ranged from none to 10 years, and most were ‘some-
what’ or ‘a little’ knowledgeable about the concepts of sex and
gender. Participants rated the readability and content of the
brieﬁng notes highly, indicated that the issue of sex and gender
analysis was highlighted clearly, the concepts of sex and gender,
and sex and gender analysis were well deﬁned, and that the
brieﬁng notes provided clear methodological guidance to ad-
dress sex and gender in reviews. Most participants (89%) agreed
that the application of the sex and gender guidance would add
value to a Cochrane Review. However, 79% thought there were
potential barriers to incorporating sex/gender into systematic
reviews, arising from the lack of reporting in primary studies and
the subjectivity and cultural aspect of gender.
Conclusions: Sex and gender brieﬁng notes are a promising
knowledge translation tool. By encouraging sex and gender anal-
ysis and equity considerations in systematic reviews, brieﬁng
notes can assist systematic reviewers in ensuring the applica-
bility of research evidence, with the goal of improved health
outcomes for diverse populations.
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Background: Sex and gender considerations in medicine are
easy to endorse but much more difﬁcult to assess in clinical
research and apply in practice. Systematic reviews are meant to
inform evidence-based practice, but reviewers rarely pre-specify
sex and gender-based analysis (SGBA) in their protocol nor is
sex-disaggregated data presented in the ﬁnal review. Doull and
colleagues describe a qualitative pilot study. They met with au-
thors fromthreeCochraneReviewGroups coveringhypertension,
HIV/AIDS, and musculoskeletal conditions to explore if brieﬁng
notes would be useful for making decisions about whether and
what SGBAanalyses to include in systematic reviewprotocols.1−3
This paper describes researchers’ input on the brieﬁng note for-
mat and the information that was helpful in the brieﬁng notes
to promote the use of SGBA in systematic reviews. These brief-
ing notes are available at the Cochrane Equity Methods Group
website: www.cochrane.equity.org.
What did the authors say? Themajority of researchers endorsed
the brieﬁng note format (see example here: journals.plos.org/
plosone/article?id=10.1371/journal.pone.0110786#pone.01107
86.s001). They appreciated information on how to distinguish
sex and gender issues for the topic under study. One concern
was the limited amount of sex-disaggregated data available from
clinical trial publications, which serves as a deterrent to estimat-
ing the magnitude of effect for men and women separately in
meta-analysis. Instead of the usual textbook or instruction book
approach, the authors used the brieﬁng note4 format, most com-
monly used by policymakers. The key element of this format is
a concise description of the issue along with pertinent evidence,
options and recommended actions in a user friendly layout.
The process of generating the brieﬁng notes is detailed in the
paper. The notes were evaluated by authors and users of reviews
who participated in a workshop at the 2012 Canadian Cochrane
Symposium. SGBA is a new approach for most Cochrane Review
authors, and the guidance was welcomed.
Importanceof the research forpractice: Thebrieﬁngnotespro-
vide a concise background on the reasons for conducting SGBA
in systematic reviews, along with methodological guidance on
the analyses to include. The notes were welcomed by systematic
review authors.
The Cochrane and Campbell Equity Methods group will be mon-
itoring the uptake of SGBA in Cochrane Reviews and promoting
the dissemination of these brieﬁng notes.
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Engaging stakeholders to identify
evidence synthesis priorities for
National Health Insurance Schemes:
lessons learned from Uganda
Obuku EA, Nabudere H, Semakula D, Sewankambo NK.
Abstracts of the 22nd Cochrane Colloquium; 21-26
September 2014; Hyderabad, India. Cochrane Database of
Systematic Reviews, Supplement 2014: Art. No. CD201200.
doi:10.1002/14651858.CD201200.
Background: Uganda is in the process of embracing a National
Health Insurance Scheme (NHIS). Stakeholder engagement in
identifying key policy concerns provides a crucial opportunity to
use research evidence to address the implementation considera-
tions about this NHIS.
Objectives: To identify priority health systems questions for
evidence synthesis for the proposed Uganda National Health
Insurance Scheme.
Methods: We invited 54 stakeholders by email, telephone calls
and letters at least 21 days prior to the priority-setting meet-
ing. We purposively selected decision makers and researchers
(n = 27) from workers unions, professional associations, health
service providers, health-related government departments, con-
sumer advocacy groups, health insurance companies and non-
governmental organizations. We presented participants with a
set of documents constituting: 1) a draft NHIS Bill 2012; 2) a back-
ground document outlining the context of the National Health
Insurance Schemes in low- and middle-income countries. We
completed three iterations of a mini–Delphi survey technique.
Results: The response rate was 100% for the ﬁrst two rounds
(27/27). We collected responses from 14 out of 27 respondents
for the third round. There were 32 initial policy concerns, which
were narrowed to 15 key areas. In this interim analysis, the key
concerns were about the: 1) range of beneﬁts in the package; 2)
additional taxation to the formal sector employees at 8% salary;
3)paymentmechanismsandrates toproviders, particularly those
in government facilities; 4) governance of the funds and account-
ability to the public (corruption) and; 5) accreditation to facilitate
quality services across participating providers.
Conclusions: Our ﬁndings suggest that the key policy concerns
in implementing the Uganda NHIS are about mechanisms of ﬁ-
nancing, remuneration and payment mechanisms of providers,
governance of the fund and quality of care. In our next steps,
we intend to synthesize relevant research evidence to inform
implementation considerations of these policy concerns.
Commentary
Prepared by: Mona Nasser
Correspondence to: mona.nasser@plymouth.ac.uk
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Background: Increasingly, governmental and public health care
organizations are adopting a more transparent and evidence-
informed decision-making process to make decisions on health
coverage policies. This usually requires assessing the adequacy
of the research literature and often conducting research to meet
the needs of the policy makers in those organizations. Differ-
ent organisations adopt a variety of approaches to engage with
policy makers in their setting to achieve this goal. This study
reports a project conducted to initiate a new National Health
Insurance Scheme in Uganda. There is another report available
in Cochrane Methods (pages 33–35) on the process used to set
and implement research priorities by states for an established
insurance programme for low-income and disabled Americans.
What did the authors say? There was a need to identify priority
topics for evidence synthesis that can inform the key decisions
on allocating resources for coverage decisions in a proposed Na-
tional Health Insurance Scheme in Uganda. The authors decided
to use a combination of a priority-setting meeting with a survey
(as part of the meeting) to address this need.
The key topics for research and analysis that emerged from the
process were: 1) a range of beneﬁts in the package; 2) methods
for additional taxation to formal sector employees; 3) payment
mechanisms for providers, particularly those in government facil-
ities; 4) governance of the funds and accountability to the public,
especially to prevent corruption; and 5) accreditation of health-
care facilities and practices to assure and improve the quality of
services across participating providers.
Limitation of the study: Surveys can be a potentially useful tool
to collect information from participants. However, they often fail
to elicit evidence about the complexity of policy-making contexts
and processes. This limitation can be an additional challenge
in early conversations around major decisions like proposing a
national insurance scheme. Morewide-ranging conversationsare
required to demonstrate whether the identiﬁed topics reﬂect a
consensus across the key stakeholders. Such established organi-
zations like the Medicaid Evidence-Based Decision project in the
USA (described in Cochrane Methods (pages 33–35)) adopted an
iterative process to devise, revise and contextualize questions for
research and analysis. The results of this research and analysis
become the basis of evidence reviews, available in a variety of
formats that can informpolicyand its implementation. Moreover,
the small stakeholder groups (27 out of 54 invited) might exclude
critical players in the process who are not afﬁliated to the formal
entities listed by the authors.
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Importance of the research for practice:
Cochrane Review Groups (CRGs) and authors: CRGs and authors
should consider that policy makers in different decision-making
positions in different countries deal with different problems and
uncertainties. The need for, and questions about, health cover-
age, for instance, differbetweencountrieswithestablishedpublic
insurance schemes and those in the process of establishing new
schemes. These differences have implications for decisions on
priority questions for CochraneReviews aswell as for shaping the
questions,methods and recommendations of systematic reviews
and other types of reviews.
Cochrane Review users: The process of selection and prioritiza-
tion of topics for evidence synthesis is important to ensure an
evidence-informed decision-making framework for health cover-
age decisions. A key step in this process is scoping the topic and
shaping it into an answerable question that can be appropriately
addressed in a systematic review.
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Recommendations for quantifying the
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intervention effect and estimating the
between-study heterogeneity variance
in random-effects meta-analysis
Areti Angeliki Veroniki, Dan Jackson, Wolfgang Viechtbauer,
Ralf Bender, Guido Knapp, Oliver Kuss, Dean Langan
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Introduction: The interpretation of the results from random-
effects meta-analyses depends on the extent of the between-
study heterogeneity in the included studies’ results. In the
presence of substantial clinical and/or methodological hetero-
geneity (e.g. notable differences in patient characteristics and
study-designs between studies), it may not be advisable to com-
bine the results into a single pooled estimate. However, small-to-
moderate heterogeneity in the study-speciﬁc intervention effects
beyond what is expected by sampling error can be incorporated
intothepooledeffectusingarandom-effectsmodel. Theselection
of the ‘best’methods to computea conﬁdence interval (CI) for the
summary intervention effect, and estimate the between-study
variance among various suggested procedures, is an important
issue in meta-analysis that may affect the interpretation.
Objective: The objective of this article is to present recommen-
dations for calculating the CI for the summary intervention effect,
estimating the between-study heterogeneity variance, and com-
puting the corresponding CI, based on a review of simulation and
empirical studies.
Main content: Different methods for calculating the summary
effect’s CI or estimating the heterogeneity variance and com-
puting its CI may provide different or conﬂicting results, and
their performance might vary with respect to the meta-analysis
characteristics.1–8
Inference for the summary intervention effect
Several methods have been proposed to calculate the CI for the
summary intervention effect, including the popular Wald-type
(Wt) method9 that is the default approach in RevMan10 Simula-
tion studies suggest that the Wt method yields lower coverage
compared to the proﬁle likelihood (PL) method11 when the num-
ber of studies is small (< 8).12,13 For a moderate-to-large number
of studies (8 to 16), basing the interval on a t-distribution (t)14 im-
proves coverage compared with the Wt and PL methods.6,16–18 It
hasalsobeensuggestedthat thequantile-approximation12, t, and
Knapp and Hartung17,19 (HKSJ for heterogeneity > 0) methods
have coverage closer to the nominal level than the Wt method.12
An advantage of the HKSJ method is that it is insensitive to the
magnitude and estimator of heterogeneity, as well the number
of studies included in a meta-analysis.8
A prediction interval of the possible intervention effect in an
individual setting can also be calculated, to facilitate the inter-
pretation of the meta-analysis result.20–22
Inference for the between-study heterogeneity variance
The heterogeneity variance can be estimated using various ap-
proaches, including the method proposed by DerSimonian and
Laird (DL)9 that is the most commonly implemented approach.
However, its use has often been criticized because DL may un-
derestimate the true heterogeneity variance, especially for large
heterogeneity in dichotomous outcomes,23 thereby producing
overly narrow CIs for the summary intervention effect.19 Simu-
lation studies suggest that DL performs well for small or close
to zero heterogeneity and for a large number of studies.3,23–27
It has been shown that estimating the heterogeneity variance
in meta-analyses including only a few studies is particularly
inaccurate.2,3,28 Several options exist to quantify the uncer-
tainty in the heterogeneity variance.4,29,30 For a comprehensive
overview of these methods, see Veroniki and colleagues.5A CI for
the heterogeneity variance when using the DL estimator can be
calculated using Jackson’s method.4
The restrictedmaximum likelihood (REML)31 estimator has often
been encountered in the literature, and studies suggest that
REML outperforms DL.3,27,28 However, a limitation of REML is
that it requires numerical maximization (e.g. Newton-Raphson).
The uncertainty in the heterogeneity variance when using the
REML estimator can be estimated using the PL method.30 An-
other alternative is thePaule andMandel estimator (PM),32 which
may reduce bias when compared with DL and REML.3,7,23,24 The
PM method overestimates the heterogeneity variance when it is
small among few studies, and underestimates the heterogeneity
variance when it is large among many studies;3 but generally
appears to be less biased than the alternatives. The PM method
can be combined with the Q-Proﬁle method to estimate the
uncertainty in the heterogeneity variance.29
Several statistical measures have been suggested for quanti-
fying the between-study heterogeneity.33–35 The most popular
measure of this type is the ’generalized I2-statistic’, which most
meta-analysis software computes based on the DL estimator
(I2DL).
9 Simulation studies indicate that the I2DL statistic should be
interpreted with caution when the number and size of studies is
small (< 10 studies,< 100participants).35–37 This is because, for a
ﬁxed heterogeneity variance, I2DL increases with increasing study
Copyright c 2015 The Cochrane Collaboration. Cochrane Methods. Cochrane DB Syst Rev 2015 Suppl 1: 1–72
Published by John Wiley & Sons, Ltd. 25
size36,37 and has low precision when few studies are included in
a meta-analysis.35,38 Empirical evidence suggests caution is also
needed with the interpretation of I2DL when a meta-analysis in-
cludes fewer than 500 events.39 The I2 statistic can be calculated
based on other heterogeneity estimators (e.g. PM, I2PM). To high-
light the inherent uncertainty of the I2 statistic, CIs can also be
calculated.24,33,38,40 It has been suggested that coverage is close
to the nominal level when using the Q-Proﬁlemethod in contrast
to the I2DL and the corresponding CI based on the variance of the
square root of the Hˆ2measurei.24,38,
Conclusions and recommendations: Overall, in the presence
of heterogeneity, we suggest the HKSJ method17,19 to calculate
the uncertainty around the summary intervention effect, as it
outperforms the alternatives and is the only method with cov-
erage insensitive to the heterogeneity magnitude and estimator.
Although theHKSJmethodperformswell inmost random-effects
meta-analysis scenarios, caution is needed when heterogeneity
equals zero as the KHCImay be narrower than the corresponding
Wt CI in some cases.8 For the estimation of the heterogeneity
variance, the REML31 and PM32 methods are better alternatives,
and we recommend the Q-proﬁle method29 and the approaches
based on ’generalized Cochran heterogeneity statistics’ to calcu-
late the corresponding CI.4,41 The Q-Proﬁle approach29 is simple
to compute, but themethod suggested by Jackson4 with weights
equal to the reciprocal of the within-study standard errors out-
performs the Q-Proﬁle method for small heterogeneity. For
the measurement of the uncertainty around the I2 statistic, we
suggest using the I2PM and the Q-Proﬁle approach. These are ten-
tative recommendations, and a sensitivity analysis using several
approaches might be needed before interpreting meta-analysis
results, particularly when few studies are included in a meta-
analysis.
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Introduction:MostCochraneReviewsof randomizedcontrolled
trials (RCTs) summarize results based on an intention-to-treat
(ITT)analysis. The ITTanalysis isunbiased for thecausal effectof
treatment assignment. However, if adherence is less than 100%
in either treatment arm, the ITT analysis does not answer the
question that most patients ask their clinician: ‘‘How effective
is the treatment if I take it as you recommend?’’
To determine the causal effect of receiving treatment in an RCT
with less than 100% adherence, the RCT is now essentially an
observational study. Thismeans that onemustmake additional
unveriﬁable assumptions. The ﬁeld of causal inference has
made great strides in outlining these necessary assumptions
and has developed analytical tools over the last 20 years.1−3 If
the assumptions hold true, the estimated association can be in-
terpreted as an effect. Often, sensitivity analyses are conducted
to determine the robustness of the assumptions.
Generally, the causal inference ﬁeld has focused on single
studies. Although Pearl and Bareinboim have produced some
work onmeta-analyses,4 the methods are still being tested and
debated. The purpose of this article is brieﬂy to review the
foundations of the approaches used to determine the effect of
treatment fromanRCT, and to outline the additional challenges
when the results across many studies are summarized in a
systematic review or meta-analysis.
Although these methods all have signiﬁcant limitations, one
must remember that the patient in the clinic needs an answer
to his question. Our choices are: 1) allow clinicians and patients
to do the work in their heads without guidance; 2) use the ITT
analysis that we know does not address the right question; or
3) address the question using tools that require untestable, but
transparent, assumptions.
Deﬁning thecausal effect of interest:Whencombining studies
in a systematic review or meta-analysis, authors must identify
the target population as part of the research question. If
one were interested in the effects of treatment assignment
on adults, one would not normally combine data from chil-
dren unless it was clear the effects were the same in the two
populations. When assessing effects of treatment, what are
generally considered the target populations (e.g. adults versus
children)mustbe sub-classiﬁed. Researchquestions that canbe
answered are:
• What is the average causal effect in the entire population if
everyone was forced, or decided, to receive treatment?
• What is the average causal effect in the population? Who
would receive the treatment if recommended, and not
receive the treatment if not recommended? (Complier
average causal effect)
• What is the average causal effect in those that actually took
the treatment? (Effect of treatment on the treated)
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All of the above deﬁnitions of causal effects require speciﬁc
assumptions. For instance, ﬁve assumptions are required to
estimate the complier average causal effect from an RCT.
1. Randomization: Randomization creates comparison
groups with equal prognosis.
2. Non-interference: The treatment (and adherence) of one
participant does not cause a change in the outcome of
a different participant under ﬁxed treatment (and adher-
ence).
3. Consistency: The treatments appliedwithin each treatment
group are similar enough that there is no differential effect
on the outcome.
4. Exclusion restriction: Assigning treatment does not affect
the outcome independent of receiving the treatment.
5. Monotonicity: A participant would never act in a manner
that is exactly opposite to group assignment (i.e. take
treatment when assigned control and take control when
assigned treatment).
These assumptions have received a lot of attention in the litera-
ture with regard towhen theymight hold true, or not, andwhen
they can or cannot be relaxed.2,6,7
In an RCT, four subpopulations are deﬁned, based on the con-
cept that particular participant characteristics will cause the
participant to fall into one of four groups: those participants
who will:
1. take treatment whether they are recommended it or not
(always takers);
2. never take treatment whether they are recommended it or
not (never takers);
3. taketreatment if recommendedtreatmentandtakecontrol
if recommended control (baseline compliers); and
4. always do the opposite of what is recommended (deﬁers).
Although it is often reasonable to assume deﬁers do not exist,
the assumption should be re-evaluated for every study.8 For an
individual study, we cannot completely categorize individuals.
However, causal inference tools allow us to calculate the av-
erage outcome across some of the sub-populations, and then
use sensitivity analyses to determine a plausible range for the
causal effect for eachof the above researchquestions. Note that
the Per Protocol and As Treated analyses are generally biased
if there are differences in the causal effects between the four
sub-populations.5
Sinceameta-analysis is aweightedaverageof study results, one
might think it is appropriate to apply the same statistical meth-
ods to answer each of the three research questions. However,
there are speciﬁc challenges and we illustrate this for the Com-
plier Average Causal Effect. If incentives to adhere to treatment
assignment differ across studies, then the study methods and
contextwould likely affect how individualswouldbe subcatego-
rized. If the outcome in participants who change subcategories
with context is different from those who do not change sub-
categories with context, one must adjust for the characteristics
causing these differences.9 Although we recently summarized
methods to obtain estimates in the sub-populations based on
summary data that might be available in a published paper
for a meta-analysis,7 we have not yet evaluated adequately
the effects of adjusting for baseline imbalances on summary
estimates. Recent work suggests that effect estimates based
on summary scores of baseline imbalances (e.g. propensity
scores in observational studies) are sometimes biased toward
the null for non-linear models.10 We believe that adjusting for
covariates using individual patient data might be one solution,
but these data are often not available. Finally, we are currently
evaluating how causal inference tools reveal important under-
recognized assumptions of networkmeta-analysis for the effect
of treatment assignment. For the causal effect of treatment,
these assumptions are in addition to those described above for
regular meta-analysis.
Conclusion: In summary, there are contexts where the causal
effectof treatmentassignment is important, andcontextswhere
the causal effect of treatment itself is important. Estimating
these latter causal effects requires assumptions and deﬁnitions
beyond those of traditional analyses. The current available
choices for a clinician are to provide estimates based on: 1)
the wrong question or, 2) a summary estimate based on the
clinician’s idiosyncratic method. We believe the future lies in
using the best available mathematical methods for the right
question, even if these methods have their own limitations.
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Background: This article summarizes the ﬁndings of an audit of
two cohorts of published Cochrane Reviews. The full report is
available from the Cochrane Editorial Unit (CEU) website. Goal
1 of Cochrane’s Strategy to 2020 reafﬁrms Cochrane’s mission
to produce high-quality systematic reviews, and speciﬁcally, to
develop comprehensive quality assurance processes.1 The target
set for 2014 directly supports this aim by using a subset of the
Methodological Expectations of Cochrane Intervention Reviews
(MECIR) standards as the basis for an audit of Cochrane Reviews.
Since September 2013, the CEU has been screening pre-
publication drafts of new intervention reviews. Based on
preparatory work in April 2013 we have been using a set of
key standards to check review quality during the screening
process.
Thefocusof theauditcomparedtwocohortsofpublishedreviews:
the ﬁrst cohort comprised new intervention reviews published in
August 2013, and the second cohort comprised new intervention
reviews published in August 2014.
Objective: To assess changes in the quality of new Cochrane In-
tervention Reviews following implementation of pre-publication
review screening in the CEU.
Methods:
Standards
The subset of the MECIR standards that were used as the basis
of the audit was based on the CEU review screening criteria
at the time of the audit. The standards are subdivided ac-
cording to three discrete components of the review: implemen-
tation of protocol methods, interpretation, and inconsistency
(Table 1).
Table 1 MECIR audit standards5.
Standard title MECIR item The Standard
Implementation of protocol methods
Searching trials registers C27 Search trials registers and repositories of results, where relevant to the topic through
ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) portal
and other sources as appropriate.
Searching for studies C37 Rerun or update searches for all relevant databases within 12 months before publication
of the review or review update, and screen the results for potentially eligible studies.
Selecting studies into the
review
C40 Include studies in the review irrespective of whether measured outcome data are
reported in a ‘usable’ way.
Comparing subgroups C68 If subgroup analyses are to be compared, and there are judged to be sufﬁcient studies to
do this meaningfully, use a formal statistical test to compare them.
Differences between
protocol and review
R106 Explain and justify any changes from the protocol (including any post hoc decisions about
eligibility criteria or the addition of subgroup analyses).
Interpretation
‘Summary of ﬁndings’ table R97 Present a ‘Summary of ﬁndings’ table according to recommendations described in
Chapter 11 of the Cochrane Handbook for Systematic Reviews of Interventions (version 5
or later). Speciﬁcally:
• include results for one clearly deﬁned population group (with few exceptions);
• indicate the intervention and the comparison intervention;
• include seven or fewer patient-important outcomes; describe the outcomes (e.g.
scale, scores, follow-up);
• indicate the number of participants and studies for each outcome;
• present at least one baseline risk for each dichotomous outcome (e.g. study
population or median/medium risk) and baseline scores for continuous outcomes
(if appropriate);
• summarize the intervention effect (if appropriate); and include a measure of the
quality of the body of evidence for each outcome.
Summarizing the ﬁndings C76 Use the ﬁve GRADE considerations (study limitations, consistency of effect, imprecision,
indirectness and publication bias) to assess the quality of the body of evidence for each
outcome, and to draw conclusions about the quality of evidence within the text of the
review.
Reaching conclusions C78 Base conclusions only on ﬁndings from the synthesis (quantitative or narrative) of studies
included in the review.
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Table 1 Continued.
Standard title MECIR item The Standard
Authors’ conclusions R101 Provide a general interpretation of the evidence so that it can inform healthcare or policy
decisions. Avoid making recommendations for practice.
Completeness of reporting in the abstract and internal consistency
Abstract, Main results: bias
assessment
R11 Provide a comment on the ﬁndings of the bias assessment.
Abstract, Main results:
ﬁndings
R12 Report ﬁndings for all primary outcomes, irrespective of the strength and direction of the
result, and of the availability of data.
Abstract, Main results:
adverse effects
R13 Ensure that any ﬁndings related to adverse effects are reported. If adverse effects data
were sought, but availability of data was limited, this should be reported.
Consistency of summary
versions of the review
R18 Ensure that reporting of objectives, important outcomes, results, caveats and conclusions
is consistent across the text, the Abstract, the Plain language summary and the
‘Summary of ﬁndings’ table (if included).
Consistency of results R86 Ensure that all statistical results presented in themain review text are consistent between
the text and the ‘Data and analysis’ tables.
Analysis
We decided that members of the CEU review screening team
would lack objectivity in auditing reviews post-screening. An ed-
itor (NO) who had not previously been involved in the screening
programme undertook assessments of the reviews in order to
maintain independence.
We created an audit tool in Excel addressing 14 MECIR standards
outlined in Table 1. Judgements were made as ‘Yes’ (e.g. all
changes from protocol declared), ‘Partially met’ (e.g. reported
changes fromprotocol are incomplete), ‘Unclear’ (inadequate in-
formationpresentedtodeterminewhether thestandardhasbeen
met) and ‘No’ (standard not met). We compared the proportion
of reviews meeting each of the 14 MECIR standards across the
two cohorts.
Summary of main results: Fifty-six reviews were included in the
audit. The characteristics of the two cohorts are summarized
in Table 2. Overall, a higher proportion of MECIR standards
were met by the reviews in 2014 compared with 2013 (86.0%,
265 of 308 items versus 71.2%, 339 of 476 items). When ex-
pressed as the proportion of compliant reviews (i.e. those
reviews judged as having each standard fully or partially met)
a greater proportion of reviews were compliant from the 2014
cohort (65%, 13 of 22 reviews) than from 2013 (18%, 6 of 34
reviews).
Table 2 Characteristics of included reviews.
Characteristic 2013 2014 Total
Reviews (N) 34 22 56
Review groups (N) 22 18 32
Number of included studies (median, range) 9 (0 to 77) 7 (0 to 129) 8 (0 to 129)
Weeks between search date & publication (median, range) 26 (2 to 107) 28 (3 to 195) 27 (2 to 195)
Weeks between protocol & publication (median, range) 130 (13 to 449) 139 (41 to 342) 130 (13 to 449)
Number with ‘Summary of ﬁndings’ tables (%) 21 (62) 16 (73) 37 (66)
Findings on the subset of MECIR standards relevant to imple-
mentation of protocol methods are shown in Figure 1. There
were improvements in three standards: searching trials registries
and repositories for ongoing studies – although the proportion of
reviews meeting this criterion remained below 50% in 2014; cur-
rency of the searches; and reporting and justiﬁcation of changes
to protocol. Exclusion of studies based on outcome reporting
was relatively low in both cohorts of reviews. No changes were
apparent for appropriate conduct of subgroup analyses.
Findings on the subset of MECIR standards relevant to inter-
pretation are shown in Figure 2. Substantial improvement was
observed in two criteria: appropriate presentation of ‘Summary
of ﬁndings’ (SoF) tables and implementation of GRADE (Grading
of Recommendations Assessment, Development and Evaluation)
in the body of reviews. Appropriate formulation of implica-
tions for practice and drawing of conclusions (without making
recommendations for practice) remained high in both cohorts.
Findings on the subset of MECIR standards relevant to complete-
ness of reporting in the abstract and internal consistency are
shown in Figure 3. Improvements were observed in the reporting
of ﬁndings of bias assessment, adverse effects and consistency
of key ﬁndings across summary and full-text versions of the re-
views. Complete reporting of ﬁndings for primary outcomes and
consistency of results across the review remained high in both
cohorts.
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Figure 1. Implementation of protocol methods.
Figure 2. Interpretation.
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Figure 3. Completeness in reporting in the Abstract and internal consistency.
Discussion: The audit provides some evidence that a substantial
proportion of key quality standards are met for many recent
Cochrane Reviews. Improved adherence is probably attributable
to a range of efforts, and not simply a function of pre-publication
screening (e.g. training, increasing awareness of Cochrane stan-
dards by review authors and editorial teams).
Whilst it is encouraging to see the growing proportion of reviews
meeting key standards, there remain areas where improvement
is needed. Although most reviews do not exclude studies based
on the availability of outcome data, careful attention is re-
quired to ensure authors explicitly address this standard and
do not introduce a bias that they have taken steps to avoid
with an extensive search strategy.2 Where subgroup analysis
is considered useful, careful attention to its implementation
and interpretation is warranted to avoid potentially misleading
inferences.3
Focused attention to improve clarity and completeness of out-
come reporting is still needed, including description of pre-
speciﬁedoutcomesnotmeasured.3 In addition, concerted efforts
to integrate GRADE ratings beyond SoF tables into the text of
reviews are warranted, drawing on guidance for incorporating
GRADE into the text of the review6.
The audit has limitations. We focused on a limited set of stan-
dards to assess review quality. We may therefore have neglected
aspects of searching, analysis of data or implementation of the
‘Risk of bias’, tool by review teams that would provide more
extensive insights into review quality. Although we would be
interested to explore the impact of adopting GRADE on review
quality, our sample was too small to assess this reliably.
Recommendation for furtherwork: Further research is required
into subgroup analysis, impact of eligibility decisions based on
utility or reporting of outcome data, and approaches to support
better integration of GRADE in the review process. The 2015
target for the Strategy to 2020 will assess the use of GRADE and
SoF tables, and we will develop an audit tool to evaluate this
feature of reviews.
Acknowledgement: We would like to thank Orla Ni Ogain for
helpwith the review screening andDavid Tovey for comments on
the manuscript.
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Introduction and objective: To explore the methods used
by the Medicaid Evidence-based Decisions (MED) project
(www.ohsu.edu/med) to select and prioritize research topics
and study designs for using evidence to inform policy related
to ﬁnancing prescription drugs, medical devices, and other
healthcare interventions. In doing so, this paper intends to
provide information to understand better how the processes
to inform decisions on topics for Cochrane Reviews can be
shaped to meet the needs of policymakers. It is an early prod-
uct of a larger Cochrane project comparing priority setting for
systematic reviews and other research in several countries.
Background: Medicaid is a federal and state government part-
nership to ﬁnance health care for low-income Americans. In
aggregate, it is the largest health insurance program in the USA
both in terms of lives covered and in expenditure. While federal
policy establishes an overall framework for the program, states
have considerable policy latitude related to coverage of speciﬁc
interventions.
The MED project is a collaborative of 17 USA state Medicaid
programs and other agencies. Its primary purpose is to im-
prove decision-making in Medicaid (and other state health
programs) by:
• producing independent and objective evaluations of clin-
ical evidence related to topics identiﬁed as important by
policymakers;
• supporting state efforts to increase transparency and
evidence-informed decision making in Medicaid coverage
policies.
Participating states fund the collaborative by paying mem-
bership dues of approximately USD 150,000 per year. The
collaborative is governed by the participating states through a
facilitated, self-governing process in which each state has an
equalsay in thedecisions taken. Leadershiproles inanExecutive
Committee and a Budget Committee rotate among states. Deci-
sions are most often reached by consensus, but if a formal vote
is required, each state has one vote. The governance process is
conducted through twice-monthly telephone conferences and
two in-personmeetingsper year. TheCenter for Evidence-based
Policy (CEbP) (www.ohsu.edu/policycenter) staffs the MED gov-
ernance process, performs MED’s administrative duties, and
conducts most of its research.
Approximately 75% of MED’s discretionary budget is spent on
research. This research consists of a variety of report types
listed below. In 2014, CEbP produced 47 research products for
MED participants.
• Full Systematic Review: use methods strongly inﬂuenced
by Cochrane and the Agency for Healthcare Research and
Quality (AHRQ) approaches. While this has always been an
option for the state participants, they have yet to commis-
siona full systematic review. Rather, theyhave successfully
nominated topics for full systematic reviews conducted by
AHRQ and often make use of Cochrane Reviews.
• Rapid Review (12 in 2014): is an evidence report that sum-
marizes existing best evidence and often builds upon exist-
ing good quality systematic reviews or technology assess-
ments drawn from trusted sources (e.g. Cochrane, AHRQ,
National Institute for Health and Clinical Excellence (NICE),
US Preventive Services Task Force (USPSTF)) with scan-
ning for and appraisal of new research relevant to the
key questions. These reports include a formal critical ap-
praisal of evidence and generally include an assessment
and summary of guidelines and coverage policies. Recent
RapidReviewreports included: ‘Non-invasive tests for stag-
ing liver ﬁbrosis in chronic hepatitis C infection’; ‘Insulin
pumps for type 1 and type 2 diabetes’; and ‘Deep sedation
and general anesthesia for dental procedures’.
• Participant Request (35 in 2014): are reports that brieﬂy
describe evidence or policies on a focused question in re-
sponse toadhoc inquiries. States can request these reports
individually without the vote of other participants. Meth-
ods are customized tomeet the needs of the requester. The
topics tend to have a shorter turn-around times and to be
more focused than Rapid Reviews. A Participant Request
may result in a brief summary of:
– existing systematic reviews, technology assessments
or guidelines;
– expert librarian search with annotated bibliography,
an update of existing systematic reviews or tech-
nology assessments, or a primary summary of the
evidence if these types of syntheses are not avail-
able;
– review of select payer policies or national policy
summaries;
– review of the evidence behind manufacturer or ven-
dor marketing claims, professional society or advo-
cacy group guidelines, or existing policies.
Recent requests included: ‘Extended hormonal therapy for
breast cancer survivors’; ‘Wearable cardioverter-deﬁbrillators’;
and ‘Cranial molding helmets for plagiocephaly’.
• Policy Reports (four in 2014): are completed as either
stand-alone reports or in conjunction with an evidence
report. Policy Reports address state policy development
and implementation issues, such as: cross-agency inte-
gration strategies, ﬁnancial and economic considerations,
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state or privatepayermodels andbest practices, data anal-
ysis, policy implementation tool development, stakeholder
considerations, and other key policy issues. These reports
analyze existing policies of other public and private US
and international payers and agencies. Four such reports
were completed in 2014, two of which were companion
pieces to evidence reports. Subjects included: ‘Buprenor-
phine for treatment of opioid use disorder in primary care’;
‘Effectiveness of patient ﬁnancial incentives’; ‘Treatment
for opioid dependence during pregnancy’; and ‘Medicaid
policies and programs to increase the use of long-acting
reversible contraception’.
Topic selection and priority setting process: Topic selection
and prioritization is an integral part of the MED governance
process. Due to the collegial nature of the collaborative, it
is intense, iterative, and grounded in earned mutual trust. It
is driven entirely by the policymakers who participate in the
project and is supported by a rolling conversation between the
policymakers and the research staff throughout. Information for
this paper, for example, was collected through interviews with
CEbP staff and senior policymakers frommultiple participating
states.
The research work plan is set every six months. A face-to-face
governancemeeting isheldeachsixmonthperiod. Participating
states nominate topics approximately twomonths before these
in-person governance meetings.
Nominated topics enter a scanning and reﬁnement stage during
which policymakers and staff act in close partnership. The
CEbP staff meets with nominators via phone to learn about the
actual policy needand to reﬁne thequestions. Researchers then
scan a set of select sources to gauge the quality and volume
of the evidence available for the each nominated topic and to
further reﬁne the PICO (participants, intervention, comparison,
outcomes), draft key questions, and the proposed research ap-
proach for the nomination. This process is iterative, and may
require multiple rounds to get to a ﬁnal nomination.
Documentsgeneratedforallnominationsarethendistributedto
the participating states. A governance teleconference is held in
which the CEbP staff and the nominating state summarize each
nomination, its policy context and intended use. This provides
an opportunity for clarifying questions, friendly amendments,
and deep discussion among the state policymakers with the
purpose and utility of studying each topic. The states then
complete an online survey prioritizing the nominated topics.
The CEbP staff analyzes the results of the survey and constructs
a draft researchwork plan for the next six-monthperiod. Project
staffworktoensurethatthegroup’sprioritiesaremet, estimated
research timelines, resource and staff limits are accounted for,
the appropriate research approach is selected, and that each
state gets a sufﬁcient number of reports on topics it feels are
important. The work plan, with all of its assumptions, is then
presented at the next face-to-face governance meeting where
it is discussed in depth, revised as needed, and ﬁnalized by the
participating states.
Important characteristics of process emphasized by par-
ticipants: Topic nomination, research design, and research
priorities are driven by participating states’ political and policy
needs. The process allows policymakers to account for the nu-
merous stakeholder interactions they encounter ranging from
legislative bodies, to advisory councils, to multi-stakeholder
collaborations, to managed care and other contractors and
vendors, and to ad hoc conversations that occur as part of
the normal governance of the state agencies. Participants em-
phasize that budget constraints, rapidly evolving health tech-
nologies, health systems and delivery reform, and the desire
to obtain maximum value for health expenditures are driving
factors incorporated into their decisions.
The blend of staff support and policymaker autonomy is viewed
ashitting the ‘sweet spot’ of suchanendeavour. The rolling con-
versation among policymakers themselves and with research
staff is seen as critically important to ensuring that questions
are optimally focused and properly prioritized. Participants
note that their initial ideas for research are vastly improved
by the vetting process and, as a result, their top priority sur-
vey votes often go to topics nominated by other states. They
also recognize the need for all participants to receive adequate
value for their investment in Cochrane and thus regularly back
researching subjects that are not particularly useful to their own
state in order to support their colleagues investment.
Tensions between participants are minimal. Policymakers cite
the conversational nature of the topic selection and prioriti-
zation process as key. Members regard each other as peers,
and view the resource allocation process as requiring a com-
munity perspective in order to be done properly. While votes
are taken in the ﬁnal work plan ratiﬁcation process, they are
seldom contested and serve as a validating measure. Finally,
participants note that ‘Participant Request’ reports serve as an
important pressure relief valve when priorities among states
differ. They offer a way for a state to obtain some actionable
information, if not the full study they desired with their formal
topic nomination bid.
Conclusions: Selecting and prioritizing the right topics and
study designs for research using shared resources to inform
Medicaid policy is a labour-intensive process. Structured con-
versations characterized by respect and deep inquiry among
policymakers themselves and research staff are required. While
the logic of systematic review methods is compelling and the
evolution of these methods continues to shape the conﬁdence
policymakers have in using research (e.g. detecting systematic
bias of various types, especially in industry-sponsored primary
research) they may avoid commissioning new systematic re-
views for a number of reasons.
• Commissioning systematic reviews is expensive:
USD 250,000 to USD 500,000 per study is generally pro-
hibitive in the state policy context.
• Systematic reviews take considerable time to complete
even when funding is available. Political realities often
drive the need for decisions to be made more quickly than
can be accomplished if policymakers must wait for a full
new systematic review.
• Often existing systematic reviews provide useful informa-
tion and updating original searches and appraising new
evidencealonecangivepolicymakers sufﬁcient conﬁdence
to act.
• The existing evidence base may be so poor, effect sizes
so small, or industry sponsorship or lack of transparency
so replete that conducting a systematic review would add
little value to policy deliberations.
Recommendations: Cochrane Review Groups should routinely
includepolicymakers in the selectionandprioritizationof topics
for Cochrane Reviews. This can help correct some of the short-
comings foundwhenapplyingCochraneReview results topolicy
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(e.g. insufﬁcient attentionpaid toharms, cost, and relevant sub-
populations). Cochrane should increase its understanding of
how factors such as funding, topic, and questions inﬂuence
the time and cost required for systematic reviews to be com-
pleted. In addition, Cochrane should intensify its current efforts
to develop internationally vetted methods for reports that are
quicker and less expensive than full systematic reviews, but
still adhere to the fundamentals of detecting and accounting
for bias in primary research. These steps will increase the use
of Cochrane Reviews to inform policy and, correspondingly,
increase the inﬂuence of Cochrane work on improving health
service delivery and patient care.
Dissemination: The project is part of a larger project exploring
engagement with policymakers to inform priority setting deci-
sions in Cochrane. The reports from different countries will be
presented in ameeting at the 2015 Vienna Colloquiumand used
to raise a discussion with other Cochrane Contributors.
Author’s note: Special thanks to Mona Nasser for her interest
in theMEDprocess and her encouragement to proceedwith this
paper.
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Objective: To identify a list of research recommendations and
guideline topics fromarangeoforganizationsacross six countries
and tomatch these toCochraneReviewGroups (CRGs) and topics
in the Cochrane Library browse list.
Background: The creation of a Cochrane priority review list,
which best meets the needs of clinicians, healthcare policy mak-
ers and consumers, is a target in Cochrane’s Strategy to 2020. In
support of this target, the Cochrane Editorial Unit encouraged
CRGs to engage with stakeholders to create a priority topic list,
but also undertook work to identify a list of external research
priorities from a range of organizations in six countries.
Methods:
External organizations
The research priorities and guideline topics were identiﬁed by
scanning the websites and, in some cases, making contact with
members of the following organizations:
Australia AusAID, National Health and Medical Research Council (NHMRC) and Pharmaceutical Beneﬁts Scheme (PBS)
Canada Canadian Institutes of Health Research (CIHR)
Spain Instituto de Salud Carlos III (ISCII); Biomedical Research Networking Centre In Bioengineering, Biomaterials &
Nanomedicine (CIBER-BBN); Network Biomedical Research Centre in Diabetes and Associated Metabolic
Disorders (CIBERDEM); Network Biomedical Research Centre in Hepatic & Digestive Diseases (CIBEREHD);
Network Biomedical Research Centre in Rare Diseases (CIBERER); Network Biomedical Research Centre in
Respiratory Diseases (CIBERES); Network Biomedical Research Centre in Epidemiology & Public Health
(CIBERESP); Network Biomedical Research Centre Obesity & Nutrition (CIBEROBN); Network Biomedical
Research Centre in Mental Health (CIBERSAM); Centro Superior de Investigaciones Cient ı´ ﬁcas The Spanish
National Research Council (CSIC); GuiaSalud (Guidelines); Health Technology Agencies
Switzerland World Health Organization (WHO) Essential Medicine List, World Heart Federation
UK Evidence Aid, James Lind Alliance, Medical Research Council (MRC), National Institute for Health and Clinical
Excellence (NICE) Guidelines, NICE Research Recommendations Database, Scottish Intercollegiate
Guideline Network (SIGN), Wellcome Trust
United States Agency for Health Research Quality (AHRQ), Patient-Centered Outcomes Research (PCORI), United States
Agency for International Development (USAID)
The research recommendations had to be prospective and
the guidelines had to be upcoming or in the early stages of
development.
Data extraction
The following data were extracted by Ruth Foxlee into an Ex-
cel spreadsheet: country, organisation name, broad health care
topic area, speciﬁc topic or question, the topic in the Cochrane
Library browse list to which the research priority related and
the CRGs that would cover the topic. Some topics fell into the
scope of more than one group, in which case they were as-
signed to all relevant groups. The assignment of topics to CRGs
and to the Cochrane Library browse list entries were checked
by Sera Tort.
Feedback to Cochrane Groups
Individualized lists were sent to each CRG, including all the top-
ics that matched their scope and particularly highlighting the
focused questions or guidelines for which a Cochrane Review
might be relevant.
Summary of main results: Research recommendations and
guideline topics were identiﬁed from 28 organizations in six
countries. The precise number of speciﬁc topics was difﬁcult to
ascertain because in some cases the research priority was com-
prised of a set of goals that related to a range of health conditions
or states.
The identiﬁed external research priorities mapped to 49/53 CRGs
(92%). The number of topics mapped per group ranged from 1 to
33. The top ten CRGs are shown in Figure 1, with more than half
(70/132) of the research priorities mapping to three groups - the
PublicHealth,Heart, andEffectivePractice&OrganisationofCare
Groups. Whentheexternal researchprioritiesweremappedto the
topic in the Cochrane Library browse list, the picture was similar
but with some important differences. The top 13 browse topics
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are shown in Figure 2, with 30% (57/189) of the research priorities
mapping to the Public Health and Heart Groups, however Cancer
and Mental Health gain prominence when the research topics
are mapped in this way. Thirteen rather than ten browse topics
were chosen because the bottom four all had the same number
of topics. The inclusion of the research priorities identiﬁed by
Evidence Aid contributed signiﬁcantly to the number of topics
that mapped to the Public Health Group (22/33); however, even
with the Evidence Aid topics taken out, the Public Health Group
remains in the top ten.
Discussion: Cochrane editorial teams often have strong links
to clinical and policy stakeholders, so at the CRG-level there is
usually a good understanding of the research needs within a
particular ﬁeld; however wewanted to see overall how Cochrane
output maps to external research and guideline priorities at a
national and international level. The focus on Public Health was
clear when mapping the external topics to both CRGs and the
browse list, although this was due in part to our choice of organ-
isations. The role of Cochrane’s cancer-focused groups became
much clearer when we mapped according to the browse list.
Cancer treatment as a topic is spread across several Cochrane
Groups, which meant that at a CRG level none had a sufﬁciently
large number of topics to make the top ten list. However, when
grouped together under the browse topic ‘Cancer’, they repre-
sented a signiﬁcant proportion of all topics. This was similar
for the Mental Health CRGs, which points to the value and im-
portance of creating alliances within Cochrane to help deliver
answers to the research questions that are of greatest impor-
tance to clinicians, healthcare policymakers and consumers. For
this project, however, the total number of research questions
was less important than their relationship to Cochrane evidence
output. These broader topics were not necessarily helpful to
CRGs as they created their priority lists, but they contributed to
the wider view of where Cochrane’s overall research portfolio
intersects with national and international research priorities.
Dissemination of ﬁndings: Findings have been disseminated
in an oral presentation at the 2014 Hyderabad Colloquium and
there are plans to publish these results as an editorial in the
Cochrane Library.
Figure 1. External research priorities mapped to Cochrane Review Groups.
Figure 2. External research priorities mapped to browse topics in the Cochrane Library.
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Background: It is currently challenging to identify eligible stud-
ies for inclusion in systematic reviews in a timely and reliable
way. A signiﬁcant proportion of a review’s budget or human
resource is spent developing and implementing search strate-
gies and then sifting through thousands of search results –most
of which are irrelevant. Moreover, Cochrane is producing an
increasing number of complex reviews where a broad range
of search terms and information sources may be required,
often leading to many weeks of screening to identify the eli-
gible studies. New developments in information technologies
and crowdsourcing approaches promise to transform the way
studies are identiﬁed, reducing the time and resource spent
screening the results of database searches.
Part of the recently funded Cochrane ‘game changer’ project,
called ‘Project Transform’, aims to address the above screening
workload challenges through a combination of human effort
through crowdsourcing (CS), aided by text mining (TM). While
TM and CS have received a great deal of individual attention
over recent years, the way in which they can operate synergisti-
cally to achieve a common objective is also signiﬁcant, and has
methodological interest.
We will introduce the individual methodologies of TM and CS
brieﬂy beforemoving to discuss howmore canbe accomplished
when the two approaches are employed together.
Text mining (TM):When being used to identify eligible studies
in systematic reviews, TM operates by examining examples of
relevant and irrelevant citations, and building a model that is
able to distinguish between them (strictly speaking, this is a
combination of TM and ‘machine learning’ but we will use the
shorthand ‘text mining’ (TM) here)ii. The method thus depends
on having good examples fromwhich to learn, and usually can-
notgeteverydecisioncorrect. Anemergingstandardapplication
ofTM in reviewsusesan iterativeprocess called ‘active learning’,
whereby the more data a machine has to work with, the better
it gets, progressively, at identifying eligible studies.10,11
In this method, there is interplay between the machine and
the reviewer, with the machine suggesting what it consid-
ers to be relevant studies to the reviewer, and the re-
viewer stating whether or not they are eligible for the review
at hand.
Completed evaluations have demonstrated that TM technolo-
gies are mature enough for real efﬁciencies to be gained, and a
recent systematic review of methods for using TM for screening
found that most situations reported a reduction in workload
of 30% with some methods reducing workload by more than
90%7. Wallace and colleagues report extremely high perfor-
mance metrics in genetics –saving more than 90% of screening
effort with 99% to 100% recall9. Performance is not guaranteed
across all contexts however, and TM is more effective in some
reviews than others, with reviews in social and psychological
areas possibly requiring more sophisticated technology than
those in clinical areas 2
Despite the promise of TM, it is used in few systematic reviews.
This is partly because the technology is new, andmore research
is needed to understand how it might best be utilised; and be-
cause there are few deployed systematic review software tools
that incorporate TM functionality 8. A major concern regarding
the use of TM in reviews is that the technology does not guar-
antee 100% recall, and there is always the possibility that, if TM
is used to automate the screening process, relevant studies will
be missed.
Crowdsourcing (CS): It is likely there will always be classiﬁ-
cation-type tasks where humans outperformmachines. CS, the
use of large online communities in performing key tasks or ser-
vices, offers a way to process large data sets, such as thousands
of citations identiﬁed from a sensitive search, accurately and
efﬁciently. CS classiﬁcation-type tasks (sometimes referred to
as ‘human intelligence tasking’, or ‘microtasking’) in this way is
not new and successful platforms exist that ‘‘use the efforts and
ability of volunteers to help scientists and researchers deal with
the ﬂood of data that confronts them’’12. However, research
on the effectiveness of CS is disparate and exists in disciplinary
silos, making it hard to access and evaluate1. Within the
review production process, CS remains relatively unexplored,
and certainly rarely utilised, as a method. However, a few
methodological studies focusing on CS for citation screening
have indicated the potential beneﬁts of this method; namely
high levels of crowd accuracy, time efﬁciencies over traditional
methods, and the feasibility to recruit a ‘crowd’ to perform
this task3,4.
Cochrane’s Embase Project represents the organization’s ﬁrst
formal step in the use of this method to identify reports of ran-
domized trials (RCTs) eligible for Cochrane’s Central Database
of Controlled Trials (CENTRAL) from the major bibliographic
biomedical database, Embase5,6. Here the crowd classiﬁes cita-
tions either as describing an RCT or not, with an ‘unsure’ option
also available. To date, a crowd of over 1000 contributors has
collectively classiﬁed more than 140,000 citations. Two evalua-
tions of crowd performance have shown crowd sensitivity and
crowd speciﬁcity at over 99%. In each, the performance of the
crowdwas compared to an information specialist and a system-
atic reviewer acting as reference standards; further evaluations
are on-going.
The high accuracy can be attributed to two key features, both
of which are vital in a crowd model. First, the ‘crowd algo-
rithm’: how many times does a citation need to be classiﬁed
and what is the pattern of decision-making needed to ensure
that the citation ends up in the right place? The algorithm
currently in place for the Embase project has so far proved
robust. It requires three consecutive matching classiﬁcations
for that citation to be either fed into CENTRAL or rejected.
The second key feature is about integrated support and train-
ing. This includes interactive practice records, and a function
in which key words and phrases are highlighted to help di-
rect screeners to the relevant parts of a citation. This latter
function has not only signiﬁcantly reduced the time taken to
screen a citation, but has also improved individual screener
accuracy5. In terms of crowd recruitment, success relies on a
iicommunity.cochrane.org/transform
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number of factors, but a key feature is concerned with making
it very easy for people to contribute to a task that needs to be
completed.
ThepotentialofCS,bothwithinthe‘EmbaseProject’speciﬁcally,
and within the wider context of systematic review production
and evidence synthesis is great. Within the project speciﬁcally,
as the crowd swells, the time needed to screen amonth’s worth
of citations is decreasing. This enables us to explore bring-
ing other databases into the mix and involving the crowd in
screening those results – all of which contributes signiﬁcantly
towards making CENTRAL a truly comprehensive repository of
randomized trials. This brings efﬁciencies in trial discovery for
individual reviews and other evidence products or services. So
far, this successful test case has focussed on citation screening
for studydesign, butwork is underwaywithin Project Transform
to explore where else a crowdmight be used successfully in evi-
dence production, particularly in aiding trial discovery through
additional PICO (patient, intervention, comparison, outcome)
annotation.
Combining TM and CS for citation screening: The method-
ological and procedural innovation that we propose in Project
Transform is to combine the strengths of the two approaches
to achieve a speciﬁc goal: the creation of an up-to-date tri-
als register, which contains all relevant trials for the majority
of Cochrane Reviews. Clearly, with such a trials register in
existence, the identiﬁcation of eligible studies for inclusion in
reviews becomes simply a task of looking in one database.
Methodologically, there are many similarities and synergies be-
tween utilising TM and CS for citation screeningiii both aim to
make the process more efﬁcient for reviewers, but they differ
in their strengths and weaknesses. TM (and machine learning)
is potentially an efﬁcient way of identifying relevant studies, as
human input is minimized and the potential for saving human
time is notable. However, TM cannot guarantee 100% recall -
and for the creation of a comprehensive trials register this is
unlikely tobeanacceptable trade-off (thoughweneed tobear in
mind that human screeners canmakemistakes too!). CS, on the
other hand, is extremely demanding in terms of human labour,
requiring at least three people to examine each citation before
a decision is reached about its eligibility (using the algorithm
outlined above).
There are three main ways in which the strengths of the two
approaches can be combined that minimize their weaknesses:
1) utilising the crowd to identify the ‘features’ of studies that
are used in machine learning; 2) using the machine to prioritise
the order in which citations are examined; and 3) having the
machine ‘join the crowd’. We will address each option in turn.
1. Crowdsourced ‘feature selection’
A critical issue in using TM for machine learning is ‘feature se-
lection’; that is, the identiﬁcation of which terms to use when
training the machine. Before a computer can ‘learn’ to dis-
tinguish an RCT from a non-RCT, the text of a citation’s title,
abstract and MeSH terms (and other controlled vocabularies,
where available) need to be reconstructed in a way that a com-
puter can analyse. This usually involves building an index of
every word that is used in the set of citations, and then con-
structing a table, which tells the computer which words were
used in which citation. An example is given in Table 1 below,
showing how the following two titles (which are not real) might
be indexed, where the presence of a term is indicated by a 1
and its absence by a 0. Table 2 then shows what is given to the
computer for modelling.
Title 1: ‘‘reducing childhood obesity: a randomized controlled
trial’; Title 2: ‘‘increasing childhood wellbeing: a controlled
clinical trial’.
Table 1 Example of indexing words in a title.
Childhood Obesity Wellbeing Randomize Control Clinical Trial Reduce Increase
Title 1 1 1 0 1 1 0 1 1 0
Title 2 1 0 1 0 1 1 1 0 1
Table 2 Example of what the computer sees.
1: 1 1 0 1 1 0 1 1 0
2: 1 0 1 0 1 1 1 0 1
This is called a ‘bag of words’, as the computer does not have
any conception of how the words are related to one another;
they are all jumbled up in a ‘bag’; and when indexed across
thousands of citations, the ‘bag’ can contain tens of thousands
of words. Despite the apparent loss of sense when we compare
Table 2 with the two titles, this is a highly effective technique
and is used in manymachine learning situations.
However, it is clear that somemeaning is lost, and the machine
therefore cannot always model subtle distinctions between
citations, which, for example, use the same words, but in the
opposite sense tooneanother. Ahumanpicks thesedistinctions
upquickly, but it is not always possible to know in advancewhat
these distinctions might be. This is where CS can come in to
iiiWe are not the ﬁrst to have thought of this: see, for example, a workshop at the International Conference on Machine Learning in Atlanta, 2013,
entitled ‘‘Machine Learning Meets Crowdsourcing’’ at: http://www.ics.uci.edu/∼qliu1/MLcrowd ICML workshop/
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makethemachinemoresensitivetothe importanceofparticular
words –and combinations of words. As mentioned above, term
highlighting can be very useful in helping reviewers to see the
relevant terms in a given citation quickly; and as reviewers
see more citations, they are able to specify which terms are
particularly important in helping them to distinguish between
relevant, and irrelevant, citations.
Figure 1 depicts a screenshot of the Embase screening tool in
action, showing how terms thatmight describe an RCT (‘double
blind’ and ‘placebo controlled’) are highlighted in yellow; and
those that are unlikely to be present in the report of an RCT
(‘systematic review’, ‘meta-analysis’) are highlighted in red. As
well as being a quick visual indication that this title and abstract
is not describing an RCT, the highlighted words can be used as
additional information for themachine learning; and, as review-
ers see more citations, they become familiar with the words
indicative of relevance and irrelevance and can add them to the
list (e.g. using the ‘highlight’ button shown in Figure 1). This
information is extremely valuable inamachine learningcontext,
because it identiﬁes speciﬁc features (words and combinations
of words) that are especially important in terms of their ability
to distinguish between relevant and irrelevant citations, and
the machine learning can be ﬁne-tuned to take account of this
new information.
Figure 1. Term highlighting in the Embase screening tool.
2. Machine-prioritized screening
As well as being trained to distinguish between relevant and
irrelevant citations, a machine can quantify the extent to which
its assessment is likely to be accurate. When applied to a large
number of citations, this quantiﬁcation can be used to generate
a ranked list,with thecitations thataremost likely tobe relevant
(in our example, to be RCTs) at the top. It can be very effective
at doing this, with the relevant citations clustered towards the
top of the list, but cannot guarantee that every relevant citation
will be identiﬁed. Figure 2 depicts just such a ranked list, with
the machine being asked to distinguish between 21 relevant
citations and 200,000 irrelevant: the cumulative number of rele-
vant citations is given in the y-axis, and the number that would
need to be screened manually is in the x-axis. This example
is from a real review, and is a genuine ‘needle in a haystack’
challenge for the machine learning, as only about 1 in 10,000
citations was relevant. Despite this, the ﬁgure shows that 19 of
the 21 citationswould be identiﬁed after screening less than 5%
of the citations. The example also shows the possible pitfalls
of machine learning: two citations (which were of less central
concern to the review) appear further down the list; and one
not until near the end. Thus, the machine can be used to rank
citations for manual screening, with those at the beginning of
the list highly likely to be the ones for which the reviewers
are looking. In a CS situation, the efforts of the crowd can be
focused on themost likely relevant citations, leaving the harder
to identify citations for later.
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Figure 2. Creating a ranked list of citations for crowd screening.
3. Inviting the machine to ‘join the crowd’
Finally, given theabove levels of performance, and theenhance-
ments possible when ‘features’ are also identiﬁed by the crowd,
having themachine ‘join the crowd’ is likely tobeaviablepropo-
sition. In this scenario, a citationmight be considered ‘included’
if it is highly ranked by the machine, and has been classiﬁed
as relevant by two consecutive human screeners. At a stroke,
this would improve the crowd’s efﬁciency by a third compared
with the current rule (where a citation needs to be considered
relevant by three consecutive screeners), greatly increasing the
speed with which the crowd is able to work through its list of
citations.
Discussion and conclusions: We have discussed potential ap-
plications of TM and CS in the context of identifying studies for
inclusion in Cochrane Reviews. Considerable efﬁciencies are
likely to be possible, though the precise conﬁguration of meth-
ods and technologies will be determined by practical testing.
There is of course nothing preventing us from utilising all three
of the approaches mentioned in the previous section simulta-
neously; and we expect to ﬁnd that the greatest efﬁciencies will
be obtained when this becomes our standard practice.
Using these methods in Project Transform: These methods will
be utilised, adapted and evaluated as part of the Cochrane
‘Transform’ Project. Working with a pilot of a new ‘Centralised
Search Service’, this project aims to combine the power of ma-
chine learning and the crowd to help the Cochrane Register of
Studies Database become the most comprehensive and up to
date database of trials in theworld. Over time, the aim is for this
central trials database to be the only source that needs to be
searched for many reviews. New citations from large databases
(e.g. MEDLINE, Embase and CINAHL) will be identiﬁed regularly
andentera ‘pipeline’,whichwill automatically identify thestudy
type (RCT, diagnostic test, etc.) and themost relevant Cochrane
Review Group(s). It will then be possible to utilise the methods
described above (‘Combining TM and CS for citation screening’)
to focus effort from the crowd in the most effective way. The
project aims to have implemented some of these approaches in
time for the 2015 Vienna Colloquium in October. In the mean-
time, further information can be found on the project’s website,
at: community.cochrane.org/transform. The task of creating a
database of every known trial may be daunting, but if it is ever
to be achieved, these technologies and approaches are likely to
play an important part.
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Background: Embase is a key database to search when under-
taking systematic reviews. It contains unique content, but there
is a perception that it can suffer from high levels of indexing that
result in the retrieval of large numbers of irrelevant records. A
suggestion to use the option to focus (major) the Emtree subject
headings may help to improve the efﬁciency of searching.
Objectives: The objectives of this project were to assess whether
using focused Emtree terms would reduce the volume of records
to assess for relevance without losing relevant studies. We set
out to identify the proportion of relevant records retrieved by
searches using some or all major Emtree subject headings in a
search, rather than all (i.e. non-major) subject headings.
Methods: The relative recall approachwas used to select reviews
produced since 2010 by a range of agencies including Cochrane.
We reran the search strategies reported in those reviews, varying
the use of major Emtree headings, to identify the impact of the
changes on the retrieval of the known relevant records (included
studies) in the SRs. The terms were majored in the intervention
concept, the population concept and both concepts. The total
number of records retrieved, and the number of included studies
retrieved was recorded and the sensitivity and precision of each
strategy was calculated, along with the percentage decrease in
sensitivity and precision from the original strategy for each of
the amended strategies. We calculated the mean, median and
ranges for the groups of strategies available for each test.
Results: We collected 463 SRs and randomly selected 50 that
addressed a variety of topics. Focusing the intervention (39 SRs)
concept resulted in a reduction ofmean sensitivity from 71.6% to
68.8%andan improvementofprecision frommeanof1%to1.1%.
Focusing the population concept (39 SRs) resulted in a reduction
of mean sensitivity from 74.3% to 67.4% and an improvement of
precision from mean of 0.9% to 1.3%. Focusing both concepts
(34 SRs) resulted in a reduction of mean sensitivity from 72.8%
to 63.9% and an improvement of precision frommean of 0.8% to
1.5%.
Conclusions: This analysis of 50 SRs of widely varying topics
found that focusing the Emtree terms for the intervention, pop-
ulation or both, could achieve small improvements in precision,
but at the risk of losing relevant studies in already suboptimal
strategies.
1. Glanville J, Kaunelis D, Mensinkai S, Picheca L. Prun-
ing Emtree: does focusing Embase subject headings impact
search strategy precision and sensitivity? [Internet]. Ot-
tawa: CADTH; 2015 Apr. [cited 2015-04-29]. Available from:
https://www.cadth.ca/pruning-emtreeembase.
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Date of study: From August 2012 to April 2014
Objective: To determinewhether a ‘Summary of ﬁndings’ table
(SoF) format isnot inferiorcomparedto thecurrentstandard for-
mat. Inferioritywasassessedfortheoutcomesofunderstanding,
perceived accessibility, satisfaction and preference by health
care professionals, guideline developers, and researchers that
either use or develop systematic reviews, or both.
Location: Study conducted by McMaster University, Depart-
ment of Clinical Epidemiology and Biostatistics, Hamilton, On-
tario, Canada with collaborators internationally.
Background: Cochrane has been implementing SoF tables in
its reviews since 2004. While these tables are recognized as
an effective knowledge translation strategy,1 a limitation to the
routine implementation of SoF tables by all review groups is
the restricted options currently offered for displaying review
results. The inclusion of empirically tested alternative pre-
sentations of risks and other items in SoF tables would allow
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authors to choose from a variety of formats, and it would in-
troduce more ﬂexibility to the GRADE summary tables. The
ultimate goal of this work was to increase the acceptance of
SoF tables and potentiate their implementation. A detailed de-
scription of the items included in both formats is summarized in
Table 1.
Table 1 Comparison between items included in the current and new SoF table formats.
Current format New format
1 Inclusion of the N◦ of participants and studies column Exclusion of the N◦ of participants and studies column.
Information presented in the outcomes column
2 Quality of evidence presented with symbols and
labeled as High, Moderate, Low, or Very low.
Reasons for downgrading presented in the footnotes
Quality of evidence presented along with main
reasons for downgrading in the same column (e.g.
MODERATE due to imprecision)
3 ‘‘Footnotes’’ label ‘‘Explanations’’ label
4 Baseline risk and corresponding risk expressed as
natural frequencies
Baseline risk and corresponding risk expressed as
percentages
5 No column presenting absolute risk reduction (risk
difference) or mean difference
Inclusion of a column presenting absolute risk
reduction (risk difference) or mean difference
6 Comments column included Comments column deleted
7 No ‘‘what happens’’ column* ‘‘What happens’’ column included*
8 Description of the GRADEWorking Group grades of
evidence deﬁnitions below the table
No description of the GRADE Working Group grades of
evidence deﬁnitions
*The ‘‘What happens’’ column aims to summarize both the treatment effect and the quality of the evidence in one short narrative
statement.
Methods:Weconductedaparallel-arm,non-inferiority random-
ized trial comparing a new alternative format with the current
format of SoF tables. We contacted systematic review users
by email, including health professionals, guideline developers
and researchers, and asked them to complete an online ques-
tionnaire. Collected data included questions about baseline
information (demographic characteristics, background, famil-
iarity with systematic reviews and the GRADE approach, native
language, among others). Initially, 390 subjects expressed their
intention to participate. Of those, 290 accessed our online
platform and were willing to be randomly allocated, using a
randomization scheme that was concealed from the investiga-
tors, to view either a new alternative format of the SoF table
(table 2), or the current format. The randomization process
was stratiﬁed according to theparticipants’ background (health
professional, guideline developer, or researcher). The primary
outcome represented different aspects of understanding (each
measured using a multiple choice question). The proportion of
questions answered correctly for each aspect of understanding,
was compared between groups. The secondary outcome acces-
sibility of information was measured using three items (1) how
easy it was to ﬁnd critical information in the table, 2) how easy
it was to understand the information, and 3) whether or not the
information was presented in a way that is helpful for decision-
making; all measured using a 7-point Likert scale with higher
scores indicating greater accessibility). Another secondary out-
comewas the participant’s format preference. We disclosed the
alternate table to which the participant was initially assigned,
and asked participants to rate their preference using a 7-point
Likert scale (where 1 = strongly prefer new alternative format
and 7= strongly prefer current format). The data analyst was
blinded to group allocation. Further description of the study
methods and analysis plan has been published elsewhere.2
Summary of main results: In total, 290 participants were ran-
domized, of whom 122 were allocated to the alternative format
and 168 to the current format. In this study, we tested whether
seven new items included in the alternative format of the SoF
table could perform at least as effectively as the current for the
primary outcome understanding. Features of the new format
include the 1) exclusion of the N◦ of participants and studies
column, 2) presentation of certainty in the evidence along with
the reasons for downgrading in the same column, 3) use of
the label ‘‘explanations’’ heading for the footnotes, 4) presen-
tation of baseline risk and corresponding risk expressed as a
percentage, 5) exclusion of the comments column, 6) inclusion
of a column showing the risk difference or the mean difference
and its 95% conﬁdence interval, and 7) the inclusion of a new
column describing the results and the quality of the evidence
using a narrative statement (‘‘what happens’’ column). Inclu-
sion of the risk difference and the ‘‘what happens’’ column
improved understanding, while the remaining ﬁve items were
non-inferior compared to the current format by anon-inferiority
margin of 10% (Table 2). Participants considered that in using
the new alternative format it was easier to ﬁnd critical informa-
tion (Mean Difference (MD)= 0.4, 95%CI (0.06 to 0.74), p= 0.04),
the information presented was easier to understand (MD= 0.5,
95%CI (0.16 to 0.84), p= 0.017), and the way the information
was presented would help them to make decisions (MD= 0.5,
95%CI (0.17 to0.83), p= 0.011), compared to thecurrent format.
Irrespective of the order in which the tables were shown, re-
spondents consistently preferred the new format to the current
version (mean= 2.8, 95%CI (2.6 to 3.0)).
Conclusions: Compared to the standard SoF table, the new
format of SoF tables incorporating seven alternative items
improved understanding of risk differences and facilitated
participants’ interpretation of summary estimates and the
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certainty of evidence. The remaining ﬁve items proved to
be non-inferior compared to the items included in the cur-
rent SoF table. In addition, the review users preferred the
new format and found it more accessible. The results of
this study also provide additional evidence of the poten-
tial effectiveness of the use of standardized narrative de-
scriptions of review results within the table (‘‘what happens
column’’).
Table 2 Percentage of participants that answered each of the understanding questions correctly.
Concept Question asked
New format
(N= 122)
Current
format
(N= 168)
Risk
Difference
(95% CI%) P value
Ability to interpret footnotes For the outcome adverse events, why
is the quality of evidence rated as
low?
89% 82% 7% (-2 to 15) 0.18
Ability to interpret risk Will fewer children< 5 years old have
diarrhea if they take the probiotics?
96% 96% 0% (-5.3 to 5.4) 0.99
Ability to determine risk
difference
Howmany fewer children< 5 years
will have diarrhea if they have
probiotics than if they do not?
98% 35% 63% (54.6 to 71) < 0.001
Understanding of quality of
evidence and treatment
effect
Which of the following statements
best represents the results
informing the outcome adverse
events?
88% 26% 62% (52 to 71) < 0.001
Understanding of quality of
evidence
In children< 5 years old, what result
is most certain?
97% 90% 7% (0.1 to 12.4) 0.06
Ability to relate N◦ of
participant/ studies and
outcomes
Howmany participants and studies
are informing the outcome adverse
events?
95% 98% -3% (-7.5 to 1.7) 1.00
Ability to quantify risk In children> 5 years old, howmany
fewer or more children will have
diarrhea if they took probiotics as an
adjunct to antibiotics compared to
those who did not take probiotics?
94% 88% 6% (0.1 to 13.3) 0.06
Recommendations: We suggest that Cochrane includes the
new format as a viable alternative to the current standard
format (strong recommendation, moderate quality evidence).
Dissemination of ﬁndings: We have initiated dissemination of
thestudy results in the followingway: 1)Presentationofﬁndings
at the 2014 Hyderabad Colloquium (15 minute oral presenta-
tion), the GRADE working group session, and the 2015 Dave
Sackett Symposium, Hamilton, Canada (oral presentation). In
addition to conference andmeeting presentations, the protocol
of the trial was accepted for publication in the Trials Journal.
We have also submitted an article with the main ﬁndings for
publication to the Journal of Clinical Epidemiology. Further
dissemination will occur via implementation of the ﬁndings in
the GRADEpro software (www.gradepro.org) and update of the
content of the chapter related to preparation of SoF tables in
the Cochrane Handbook for Systematic Reviews of Interventions.
Acknowledgements: The Cochrane Methods Innovation Fund
(MIF) and McMaster University funded this study. Neither of
these institutions played any role on the planning, conducting
or publishing of the study ﬁndings. Authors of this research
article (HJS, GG, PT) are convenors of a Cochrane Methods
Group. The views expressed in this article are those of the
authors and not necessarily those of Cochrane or its regis-
tered entities, committees or working groups. The SoF MIF
authors group appreciate the valuable help provided by the
Cochrane Applicability and Recommendations Methods Group,
theOMERACT (OutcomeMeasures in Rheumatology) Group, the
Cochrane Effective Practice and Organisation of Care Group,
the Cochrane Consumers and Communication Review Group,
the Cochrane Public Health Group, the Cochrane Haemato-
logical Malignancies Group, the Cochrane Colorectal Cancer
Group, the Cochrane Airways Group, the Norwegian Branch
of the Nordic Cochrane Centre, the Cochrane Gynaecological
cancer Group, the Cochrane Bias Methods Group, the Cochrane
Oral Health Group, the Cochrane Wounds Group, the Cochrane
Pain, Palliative & Supportive Care Review Group, the Cochrane
Patient ReportedOutcomesMethods Group, the CochraneMus-
culoskeletalGroup, theCochraneScreeningandDiagnostic Test
Methods Group, the CochraneDepression, Anxiety andNeurosis
Review Group, and the Campbell and Cochrane Equity Methods
Group.
Copyright c 2015 The Cochrane Collaboration. Cochrane Methods. Cochrane DB Syst Rev 2015 Suppl 1: 1–72
Published by John Wiley & Sons, Ltd. 43
References
1. Rosenbaum SE, Glenton C, Oxman AD. Summary-of-ﬁndings
tables in Cochrane reviews improved understanding and
rapid retrieval of key information. Journal of Clinical Epidemi-
olgy. 2010;63(6):620-626.
2. Carrasco-Labra A, Brignardello-Petersen R, Santesso N, et
al. Comparison between the standard and a new alternative
format of the Summary-of-Findings tables in Cochrane re-
view users: study protocol for a randomized controlled trial.
Trials. 2015;16(1):164.
This is an abridged version of a paper currently under review
with the Journal of Clinical Epidemiology.
Author afﬁliations
1. Department of Clinical Epidemiology & Biostatistics, Mc-
Master University, Hamilton, Canada
2. Department of Oral and Maxillofacial Surgery, Faculty of
Dentistry, Universidad de Chile, Santiago, Chile
3. Evidence-Based Dentistry Unit, Faculty of Dentistry, Uni-
versidad de Chile, Santiago, Chile
4. Institute of Health Policy, Management and Evaluation,
University of Toronto, Toronto, Canada
5. Pontiﬁcia Universidad Cato´lica de Chile, Santiago, Chile
6. Departments of Medicine/Nephrology and Biomedical &
Health Informatics, University of Missouri-Kansas City, Mis-
souri, United States
7. Biostatistics Unit, Father Sean O’Sullivan Research Centre,
St Joseph’s Healthcare, Hamilton, ON, Canada.
8. Hofstra North Shore LIJ School of Medicine, Department of
Medicine, Manhasset, NY
9. Iberoamerican Cochrane Centre, Biomedical Research In-
stitute Sant Pau-CIBER of Epidemiology and Public Health
(CIBERESP- IIB Sant Pau), Barcelona, Spain.
10. German Cochrane Centre, Medical Center –University of
Freiburg, Freiburg, Germany.
Copyright c 2015 The Cochrane Collaboration. Cochrane Methods. Cochrane DB Syst Rev 2015 Suppl 1: 1–72
Published by John Wiley & Sons, Ltd. 44
11. Department ofMedicine, Innlandet Hospital Trust- Division
Gjøvik, Norway
12. NorwegianKnowledgeCentre for theHealth Services, Oslo,
Norway
13. Department of Medicine, McMaster University, Hamilton,
Canada.
14. Department of Internal Medicine, American University of
Beirut, Beirut, Lebanon
15. Department of Clinical Epidemiology, Biostatistics and
Bioinformatics, University of Amsterdam, Amsterdam, The
Netherlands
16. Centre for Academic Mental Health, School of Social
and Community Medicine, University of Bristol, Bristol,
UK
17. The Norwegian Branch of the Nordic Cochrane
Centre,
18. NorwegianKnowledgeCentre for theHealth Services, Oslo,
Norway
19. University of Ottawa, Department of Medicine, Faculty of
Medicine, K1H 8M5, Ottawa, Canada
20. Bruye`re Research Institute, University of Ottawa, Ottawa,
ON, Canada
21. Division of Cardiology, Department of Medicine, Veterans
AffairsMedicalCenter, Buffalo, NewYork; Departmentof In-
ternal Medicine, University at Buffalo, the State University
of New York, Buffalo
22. Evidence Synthesis for Global Health, Liverpool School of
Tropical Medicine, UK
23. Cochrane Applicability and Recommendations Methods
Group
24. McMaster GRADE center, McMaster University, Hamilton,
Ontario, Canada
Conﬁdence in the Evidence from
Reviews of Qualitative research
(CERQual): development and future
directions of a novel approach
Christopher J Colvin1 and MeganWainwright1
(on behalf of the GRADE-CERQual Project Core Group (Jane Noyes2,
Heather Munthe-Kaas3, Ruth Garside4, Benedicte Carlsen5, Arash
Rashidian6,7, AndrewBooth8,ClaireGlenton9,MeghanBohren10,11,
Simon Lewin9,12 and Ozge Tuncalp11) See end of article for afﬁlia-
tions.
Correspondence to: cj.colvin@uct.ac.za
School of Public Health and Family Medicine, University of Cape
Town, South Africa
Introduction: The primary purpose of the CERQual (Conﬁdence
in the Evidence fromReviews ofQualitative research) approach is
to provide amethod for assessing howmuch conﬁdence decision
makers and others can place in the individual review ﬁndings
from qualitative evidence syntheses, or ‘QES’ (sometimes called
reviews of qualitative research). The CERQual approach guides
review authors through a process of examining and appraising
the methodological limitations, coherence, relevance and ade-
quacy of the data contributing to a particular review ﬁnding, and
then using this information to develop an overall assessment of
conﬁdence in a review ﬁnding. The aim of this article is to trace
the development of CERQual and its link to the GRADE (Grading
of Recommendations Assessment, Development and Evaluation)
Working Group, to describe how the approach has been used in
reviews and guidelines, and highlight emergent methodological
questions.
Background:
Developing CERQual
As the demand for QES increases, so does the need to assess
how much conﬁdence to place in their ﬁndings.1 Guideline de-
velopment groups, and other users of evidence from systematic
reviews, are familiar with the GRADE system for assessing how
much certainty to place in ﬁndings from effectiveness reviews.
However, until very recently, no equivalent approach for qualita-
tive evidence synthesis has existed.
The CERQual approach ﬁrst emerged during the development
of the OptimizeMNH guidelines, the ﬁrst World Health Organiza-
tion (WHO) guideline to formally incorporate QES in its evidence
base.2 QES were included in the guideline development process
as a way of addressing questions of acceptability and feasibility
in relation to the task-shifting interventions that were the focus
of the guideline. The technical team needed a way to assess and
present how much conﬁdence they had in the individual review
ﬁndings systematically and transparently. The ﬁrst version of
the CERQual approach was based on the assessment of two key
components: methodological limitations and coherence of the
data.
Since then, we have continued to develop the CERQual approach
with input from researchers, methodologists and end-users with
a broad range of experience in qualitative research, the develop-
ment of GRADE, or guideline development, or both. The current
approachnow includes four components: methodological limita-
tions, coherence, relevance, and adequacy of data. We describe
each of these components and their operationalization in full
elsewhere.3 In addition, wewill be publishing separate papers on
each component of the approach in 2016.
In the development of CERQual, we have worked closely with the
GRADE Working Group, learning from their experience of devel-
oping approaches to assess how much conﬁdence to place in
review evidence. The CERQual team has also contributed to the
development of the DECIDE (Developing and Evaluating Commu-
nication Strategies to Support Informed Decisions and Practice
Based on Evidence) evidence-to-decision frameworks into which
qualitative evidence can be incorporated.4
Where CERQual has been used
The ﬁrst version of CERQual was used in three reviews that were
produced as part of the OptimizeMNH guideline.5,6,7 One of these
reviews6 was the ﬁrst qualitative evidence synthesis to be pub-
lished in the Cochrane Library. The ﬁrst iteration of the CERQual
approach was also used in a review developed for the Norwegian
government to support decisions regarding care in residential
childcare institutions8, in a review for WHO guidance on facility-
based deliveries9, and in a review of intervention effectiveness
for reducing unintended repeat pregnancies.10
Following these initial pilots of CERQual, there has been growing
interest in applying the approachacross a rangeof clinical, public
health and health system syntheses. The latest four-component
version of CERQual has been used in a recent review on the
mistreatment of women during childbirth11 and in two reviews
on taskshifting in medical abortion.12,13 A further review using
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the approach has focused on the use of mechanical ventilation
protocols.14 In addition, two reviews using CERQual are currently
being conducted to inform newWHO Antenatal Care guidelines.
Priorities for future work to develop CERQual
The application of CERQual across a range of QES has identiﬁed
a number of important methodological questions. Firstly, to
date, the CERQual approach has not considered whether differ-
ent weights should be assigned to each component, and further
research is needed on whether equal weighting is appropriate,
as well as on the extent to which there is overlap between com-
ponents. Secondly, work is needed to identify a minimum set
of ‘core domains’ for assessing the methodological limitations
of primary qualitative studies. Although checklists and tools
are available15−17 there is no agreement among qualitative re-
searchers about the best approach. Thirdly, we need to explore
whether it is feasible for researchers to apply the CERQual ap-
proach to ﬁndings from reviews other than their own and, if so,
what guidance is needed for this.
An Open Working Group
CERQual has developed from a pilot project to a well described
approach and continues to evolve through the process of ap-
plication, discussion and revision. To support the further de-
velopment of CERQual and facilitate the wide involvement of
methodologists, researchers, reviewers and other end users, a
subgroupof theGRADEWorkingGroup, calledtheCERQualProject
Group, has been established (see: www.gradeworkinggroup.
org/toolbox/index.htm). We encourage those with an interest in
how to assess conﬁdence in evidence from reviews of qualitative
research to join this open project group and contribute to the
ongoing development of the approach.
Conclusions: CERQual provides a systematic and transparent
method for assessing conﬁdence in the ﬁndings from QES. Like
the GRADE approach for evidence of effectiveness, CERQual may
facilitate the use of reviewﬁndings in guideline development and
other policy processes.
Dissemination and participation: To join the CERQual Project
Group and/or be added to our mailing list and receive our
newsletters, please contact megan@meganwainwright.ca.
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Background: Recent research investigating the methods used
in systematic reviews (SRs) has found that critical appraisal of
included studies is increasingly being performed. Critical ap-
praisal forms an important input into the synthesis process since
it allows reviewers to explore whether contradictory ﬁndings be-
tween studies reﬂect differences inmethodologies, different risks
of bias (RoB) or contextual factors. While some interventions (e.g.
health system or policy interventions) are not easily amenable
to randomized controlled trials (RCTs), there remains a lack of
agreement over the optimal approach to assessing quality for
other study designs.
Objectives: To examine if and how critical appraisals inform the
synthesis and interpretation of evidence in SRs.
Methods: All SRs published from March to May 2012 in 14 high-
rankedmedical journals and a sample from the Cochrane Library
were assessed systematically and independently by two review-
ers to determine if and how: critical appraisal was conducted;
level of bias was summarized at study, domain and review levels;
and study quality informed the synthesis process.
Results:Of 59 SRs studied, all except six (90%) conducted critical
appraisal of included studies, with most using or adapting a
standardized tool. Many reviews conducted critical appraisal in a
manner not allowing included studies to be ranked on the basis
of quality. Assessments of study quality were not incorporated
into the synthesis in one-third (20) of the reviews. Common
methods for incorporating quality into synthesis were sensitiv-
ity analysis, narrative assessment and exclusion of studies at
high RoB. Nearly half of reviews investigatingmultiple outcomes,
which summarized bias at the study-level, did not assess bias
in relation to speciﬁc outcomes. Incorporating critical appraisal
into synthesis occurred less often for reviews synthesizing studies
using non-RCTmethods.
Conclusions: The ﬁndings of SRs published inmajor journals are
frequently uninformed by quality appraisal of included studies,
even when critical appraisal has taken place. Further guidance is
needed, particularly for SRs with a primary focus on non-RCTs.
Thefullpaper isnowavailableat jech.bmj.com/content/69/2/189.
full.pdf+html
Reference
1. Katikireddi SV, Egan M, Petticrew M. How do system-
atic reviews incorporate risk of bias assessments into the
synthesis of evidence? A methodological study. Jour-
nal of Epidemiology and Community Health 2015;69:189-95.
jech.bmj.com/content/69/2/189.full.pdf+html
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Do Cochrane Reviewsmeasure enough of what patients want? A collaborative
study of Cochrane Reviews on HIV/AIDS
Ian J Saldanha, Kay Dickersin, Cesar Ugarte-Gil, Tianjing Li, George Rutherford and Jimmy Volmink
Correspondence to: isaldan1@jhmi.edu
Cystic Fibrosis and Genetic Disorders Group, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,
Baltimore, USA
Background: To minimize bias during systematic reviews (SRs),
outcomes should be completely pre-speciﬁed in the protocol,
including: domain (title), speciﬁc measurement (instrument),
speciﬁc metric (e.g. change from baseline), method of aggre-
gation (e.g. mean), and time-points. Also, SRs must include
patient-important outcomes (PIOs), as opposed to interim out-
comes only.
Objective: To evaluate the number of outcomes per SR, extent
of completeness of speciﬁcation of outcomes, and extent of
inclusion of PIOs in Cochrane SRs on HIV/AIDS.
Methods: The Cochrane Eyes & Vision Group, US Cochrane
Center, South African Cochrane Centre, and Cochrane HIV/AIDS
Review Group collaborated to assess all SRs published by the
Cochrane HIV/AIDS ReviewGroup by June 2013. For ongoing SRs,
we included the published protocol. From the Methods section
of each SR we extracted each outcome domain, the other four
elements for that domain, and whether that domain was a PIO.
Results:We identiﬁed 140 SRs, with a median of seven outcome
domains each (range 1 to 30). Overall, there were 294 unique
outcome domains, included a total of 1140 times (‘instances’).
Outcome domains were each included in median of two (range
1 to 68) SRs. We developed a classiﬁcation system for outcome
domains, with 14 categories. The largest categories were clini-
cal/biological (160/294 domains, 54.4%) and behavioural (51/294
domains, 17.4%; Table). Overall, a median of one element (range
1 to 4) was speciﬁed per outcome. Domain, speciﬁc measure-
ment, speciﬁc metric, method of aggregation, and time-points
were speciﬁed for 100%, 9.1%, 15.7%, 11.93%, and 2.5% of in-
stances respectively. We classiﬁed 747/1140 instances (65.5%)
as PIOs. Most SRs (136/140, 97.1%) included at least one PIO
(median= 5; range= 0 to 15 PIOs per SR).
Conclusions: Cochrane SRs on HIV/AIDS include a large number
of outcome domains, and outcome pre-speciﬁcation is incom-
plete. Almost two-thirds of outcomes are PIOs. The abundance of
outcomes could limit SR utility for decision-makers. The classiﬁ-
cation systemwedevelopedcouldprovideauseful framework for
developing core outcome sets for primary and synthesis research
in HIV/AIDS.
This is an updated abstract.
Table Summary of classiﬁcation system of outcome domains across Cochrane Systematic Reviews (SRs)
addressing HIV/AIDS.
Major (Level 1) category
Number of sub-
(level 2)
categories
(N= 32)
Number (%) of
unique outcome
domains
(N= 294) Examples of outcome domains
1 Clinical/biological outcome
domains
9 160 (54.4) Mortality, weight, body mass index (BMI), viral load, CD4
count, CD8 count, acquisition of sexually transmitted
infections (STIs), prevalence of STIs, opportunistic
cancers
2 Adverse outcome domains 1 5 (1.7) Adverse events (unspeciﬁed), allergic reaction to latex,
harm for false positives
3 Quality of life-related
outcome domains
1 1 (0.3) Quality of life
4 Prophylaxis/treatment-
related outcome
domains
3 10 (3.4) Pre-exposure prophylaxis, time to initiation of
antiretroviral treatment/HAART (Highly Active
Antiretroviral Therapy), switching of antiretroviral
treatment, resistance to antiretroviral treatment
5 Behavioral outcome
domains
3 51 (17.4) Needle sharing, needle changes, condom use –male
condoms, condom use –female condoms,
breastfeeding behaviors, number of sexual partners
6 Adherence-related outcome
domains
1 1 (0.3) Adherence
7 Economic outcome domains 1 3 (1.0) Cost/cost-effectiveness for patients,
cost/cost-effectiveness for providers
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Table Continued.
Major (Level 1) category
Number of sub-
(level 2)
categories
(N= 32)
Number (%) of
unique outcome
domains
(N= 294) Examples of outcome domains
8 Mental health/sociological
outcome domains
2 17 (5.8) Depression/depressive symptoms, anxiety/stress, suicide
9 Preference/satisfaction-
related outcome
domains
2 5 (1.7) Patient preference, patient satisfaction with intervention,
provider preference
10 Health services
access/uptake-related
outcome domains
3 9 (3.2) Barriers to services, utilization of health care,
ease/timeliness of access to services
11 Knowledge-related outcome
domains
1 8 (2.7) Knowledge about STIs, knowledge about HIV, knowledge
about condom use
12 Testing/counseling-related
outcome domains
3 8 (2.7) Referral for HIV testing, pre-test counseling, post-test
counseling
13 Attitude-related outcome
domains
1 5 (1.7) Attitudes about sexual risk behavior, attitudes about
condom use
14 Other outcome domains 1 11 (3.7) Marital conﬂict, breach of conﬁdentiality, domestic
violence/intimate partner violence
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Cochrane Methodology
Review Group
Mike Clarke
Correspondence to: m.clarke@qub.ac.uk
All-IrelandHub forTrialsMethodologyResearch, Centre forPublic
Health, Queen’s University Belfast, Northern Ireland, UK
The editorial base for the CochraneMethodologyReviewGroup is
based in theNorthern IrelandNetwork for TrialsMethodologyRe-
search in Queen’s University of Belfast, Northern Ireland. We are
one of the smaller Cochrane Review Groups, with no dedicated
funding. The Group is responsible for Cochrane Methodology
Reviews, which are among themost highly cited of any Cochrane
Reviews. Mike Clarke continues as Co-ordinating Editor, and
also covers the roles of Managing Editor and acting Trial Search
Co-ordinator (although theGroup is not able to conduct searches
for the authors of the Cochrane Methodology Reviews). He is
supported by a team of editors including Paul Glasziou, Sally
Hopewell, Asbjørn Hro´bjartsson, Philippa Middleton, Andy Ox-
manandKarenRobinson; with Sally andAsbjorn joining the team
during the year. In 2014, Peter Gøtzsche stood down as an editor,
and we are very grateful for the contributions he hasmade to the
work of the group and the quality of our reviews.
During 2014, twoCochraneMethodologyReviewswerepublished
in full for the ﬁrst time,1,2 bringing the number of completed re-
views to 26. The full collection was accessed more than 13,000
times in the Cochrane Library over the year, with an average per
review of just over 500. The most popular was the review of
methods to increase response to postal and electronic question-
naires, which was accessed nearly 2300 times.3 This is also the
second largest Cochrane Review on the basis of included studies,
having 514. Our second most accessed review brings together
the evidence on strategies to improve recruitment to randomized
trials,4 and identiﬁes many uncertainties that can be addressed
by research into research such as the SWAT (StudyWithin A Trial)
programme, which is also co-ordinated by the Northern Ireland
Network.5
The ﬁrst of our new reviews from 2014 looks at the similarities
and differences when healthcare outcomes are assessed with
observational study designs compared with randomized trials.1
Fifteen earlier reviewsmet the inclusion criteria. These contained
a total of 1583 meta-analyses, covering 228 different medical
conditions. The primary quantitative analysis used data from 14
reviews, and found a pooled ratio of odds ratios of 1.08 (95%
conﬁdence interval (CI) 0.96 to 1.22) comparing effects from
randomized trials with effects from observational studies. In
summarizing the implications of this Methodology Review, the
authors note that, on average, there is little evidence for signif-
icant effect estimate differences between observational studies
and randomized trials. They highlight the need for a better un-
derstanding of how various factors in the design and conduct of
both types of study might inﬂuence study effects and, therefore,
might help to ensure that the estimates from these studies are
reﬂective of true effectiveness.
Our other new review from 2014 brought together information
from seven studies of the selective inclusion and reporting of out-
comes and analyses in systematic reviews of randomized trials of
healthcare interventions.2 None of the studies had investigated
selective inclusion of results in systematic reviews, or discrepan-
cies inoutcomesandanalysesbetweensystematic reviewregistry
entries andpublished systematic reviews. Ameta-analysis of four
studies (including 485 Cochrane Reviews) found that 38% of
systematic reviews added, omitted, upgraded or downgraded
at least one outcome between the protocol and published sys-
tematic review. The authors concluded ‘‘discrepant outcome
reporting between the protocol and published systematic review
is fairly common, although the association between statistical
signiﬁcance and discrepant outcome reporting is uncertain’’.
If you are interested in contributing to the work of the Cochrane
Methodology Review Group, as an author, referee or in some
other way, please contact Mike Clarke (m.clarke@qub.ac.uk).
References
1. Anglemyer A, Horvath HT, Bero L. Healthcare outcomes as-
sessedwith observational study designs comparedwith those
assessed in randomized trials. Cochrane Database of System-
atic Reviews 2014, Issue 4. Art. No.: MR000034.
2. Page MJ, McKenzie JE, Kirkham J, Dwan K, Kramer S, Green S,
et al. Bias due to selective inclusion and reporting of outcomes
and analyses in systematic reviews of randomized trials of
healthcare interventions. Cochrane Database of Systematic
Reviews 2014, Issue 10. Art. No.: MR000035.
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Kwan I, et al. Methods to increase response to postal and
electronic questionnaires. Cochrane Database of Systematic
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Information from the
Methods Groups
Methods Groups have an important function in Cochrane. They
play a key role in the ongoing and evolving science of systematic
reviews to evaluate healthcare interventions, diagnostic tests
and potentially other related healthcare issues such as prog-
nosis. The Groups currently registered represent a breadth of
methodology, addressing, for example, bias assessment, inclu-
sion of non-randomized studies, qualitative research, economic
evaluations, patient reported outcomes, indirect comparisons of
multiple interventions and network meta-analysis, and agenda
and priority setting methods. There are 16 Methods Groups
and their contact details are on the inside front cover of this
issue of Cochrane Methods. Further information is provided here
on their activities over the last year. A core function of many
Methods Groups is to provide training. This is often done by
holding workshops at Cochrane Colloquia and regional meetings
of contributors to thework of Cochrane. Cochrane also organizes
an annual methods training event on a speciﬁc topic. Methods
Groups also develop methods, tools and guidance; please refer
to the CochraneHandbook for Systematic Reviews of Interventions
(handbook.cochrane.org).
Adverse Effects Methods Group
Su Golder, Andrew Herxheimer, Daniela Junqueira, Yoon
Loke, and Sunita Vohra
Highlights of 2013 to 2014: We are proud to welcome on board
Daniela Junqueira as co-convenor. Daniela is a Research Fellow
at the Universidade Federal de Minas Gerais, Brazil. She has
expertise in Epidemiology and Pharmacoepidemiology and is a
very enthusiastic member of our group.
Introduction/News: The Adverse Effects Methods Group contin-
ues todevelop themethods for producinghighquality systematic
reviews and to advise Cochrane on how the validity and precision
of systematic reviews can be improved. We currently have over
170 members from 26 countries and these numbers continue to
grow. The ﬁve co-convenors of the group are now:
Andrew Herxheimer, UK Cochrane Centre
a.herxheimer@ntlworld.com
Su Golder, Department of Health Sciences, University of York
su.golder@york.ac.uk
Yoon Loke, University of East Anglia
Y.Loke@uea.ac.uk
Sunita Vohra, University of Alberta
svohra@ualberta.ca
Daniela Junqueira, Universidade Federal de Minas Gerais, Brazil
danijunqueira@gmail.com
For more details on our group, our activities and how to get
involved please see our website at aem.cochrane.org
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PRISMA Harmsmeeting Banff, Canada.
Research and methodological development: The PRISMA
(Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) Harms is an extension of the PRISMA Statement with
the primary intention of improving reports of adverse events in
reviews. Development followed three main steps: 1) document
the need for a guideline (this document is published in BMJ Jan
2014 by Zorzela and colleagues-see publication list); 2) a Delphi
exercise; and 3) a face-to-face meeting. The meeting happened
in Banff, Canada in 2012 with 25 experts in systematic reviews
and guideline development (see photo). Final revisions to the
guideline are in progress prior to journal submission.
We have also undertaken preliminary research into the most ef-
fective search strategies and data sources for identifying adverse
effects of medical devices using a case example systematic re-
view (Golder and colleagues in 2014, see the publication list).
The identiﬁcation of evidence for the adverse effects of non-
pharmacological interventions is a very challenging area and
currently under-researched.
Training and support activities:We have undertaken a number
of presentations andworkshops onawide rangeof issues in iden-
tifying and incorporating adverse effects in systematic reviews.
These have been undertaken in different locations and countries.
We had a busy time at the Quebec Colloquiumwith the following
workshops; ‘Quality in reporting adverse events and the PRISMA
HarmsExtension’byLilianneZorzela, SuGolderandSunitaVohra,
‘Search strategies and data sources for adverse effects reviews’
by Su Golder and Lilianne Zorzela, and ‘Summarising evidence
for harms in systematic reviews’ by Andrew Herxheimer.
SuGolder has alsopresented results fromherPhD. Shepresented
on ‘The performance of adverse effects search ﬁlters in MEDLINE
and Embase’ at the Pharma-Bio-Med conference in Berlin in
November 2013 and at the InterTASC Information Specialists’
working group meeting at the National Institute for Health
and Care Excellence (NICE), Manchester in December 2013. In
addition, Su conducted a workshop at the Pharma-Bio-Med
conference on ‘The contribution of different information sources
for adverse effects data’.
In 2014 Su continued to disseminate her PhD work through
presentations andworkshops at the CochraneUKand IrelandAn-
nual Symposium in Manchester in April, at the Medical Librarian
Association (MLA) Conference in Chicago in May, at the Health
Libraries Group Conference, Oxford in July and the InterTASC
Information Specialists’ Sub-Group (ISSG) Workshop in Exeter in
July.
In addition to face-to-face workshops Su Golder gave an Embase
webinar in June 2014 entitled ‘Systematic reviews: Where and
how to search for information on adverse effects’.
In July 2014 Andrew Herxheimer was invited to introduce DIPEx
International’s (DI) ﬁrst proper conference in Kyoto. DI is a
network of groups in different countries that collects peoples’
experiences of illness using the same methods. The conference
was hosted by DIPEx Japan which was started by neurologist
Andrew Herxheimer DIPEx International, Japan
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Hiro Beppu. Andrew ﬁrst met Hiro in the 1970s when they were
both involved in the successful law suits that followed the terrible
subacute myelo-optic neuropathy (SMON) epidemic.
Medwatchers Japan (a campaigning group trying to keep tabs on
regulators and industry) also asked Andrew Herxheimer to give a
lecture in Tokyo the week after the DI conference. They had two
excellent interpreters and Andrew was well received.
Daniela Junqueira gave aworkshop at Sorocaba in Brazil in Octo-
ber 2014 on ‘Balanced clinical decisions: the evaluation of harms
effects in systematic reviews. International Workshop in rational
use of medicine: sharing experiences on how to use the best
evidence’.
Su’s next adventure is looking at socialmedia as a source of infor-
mation on adverse effects and in October 2014 she presented her
preliminarywork ‘Rising above thenoise: the beneﬁts andpitfalls
of searching social media for adverse effects’ at the Pharma-
Bio-Med & BioSciences Information Conference & Exposition in
Rome.
Yoon Loke has also been busy and has presented on ‘If nothing
happens, is everything all right? Distinguishing genuine reassur-
ance from a false sense of security.’ An overview and special
problems in measuring and reporting serious adverse events in
randomized controlled trials and in observational studies. This
presentation opened a programme of talks under the umbrella
‘Serious adverse events: challenges and new ideas’ at the Royal
Statistical Society (RSS) in March this year. An older version of
Yoon’s presentation can be found on YouTube.
What’s new: The group have been in discussions with staff
working at Elsevier. The most signiﬁcant development in the
area of adverse effects indexing in Embase during 2014 was the
introductionof anewsubheading: AdverseDeviceEffect. Todate,
over 4000devices havebeen indexedwith this subheading,which
is currently available on Embase.com and will become available
on other platforms in 2015. To support this indexing, Emtree’s
coverage of medical device terminology has continued to be
expanded: Emtree nowcounts 3466 device terms, with synonyms
that now include many device trade names. In addition, the use
of the subheading adverse drug reaction in reviews (records with
publication type ‘review’) isnowrestricted todrugs thataremajor
topics in the review, reducing the proportion of review records
indexed with adverse drug reaction by about 50% in 2014.
Looking ahead: Su Golder has just started her NIHR fellowship
entitled, ‘Using unpublished data, text mining and social media
to maximise the efﬁciency and effectiveness of the retrieval of
adverse effects data’.
Daniela Junqueira is designing a research project to improve
strategies on risk of bias assessment with regard to harm effects,
possibly integrating a postdoctoral research post supervised by
Sunita Vohra.
We have submitted four workshops for consideration at the 2015
Vienna Colloquium and have our ﬁngers crossed that we will be
well represented this year.
We also intend to provide some web-based training, in the form
of a series of short presentations on aspects such as formulating
the question, searching, quality assessment and standards for
reporting. We also intend to continue to undertake workshops
on an ad hoc basis.
Key publications for 2014 to 2015:
Golder S, Wright K, RodgersM. Failure or success of search strate-
gies to identify adverse effects of medical devices: a feasibility
study using a systematic review. Systematic Reviews 2014;3:113.
Golder S, Wright K, Rodgers M. The contribution of different
information sources to identify adverse effects of a medical de-
vice: a case study using a systematic review of spinal fusion.
International Journal of Health Technology Assessment in Health
Care 2014;30:4,1-7.
Loke YK, Mattishent K. If nothing happens, is everything all right?
Distinguishing genuine reassurance from a false sense of secu-
rity. Canadian Medical Association Journal 2015;187(1):15-6. doi:
10.1503/cmaj.141344.
Saini P, Loke YK, Gamble C, Altman DG, Williamson PR, Kirkham
JJ.Selective reportingbiasofharmoutcomeswithinstudies: ﬁnd-
ings from a cohort of systematic reviews. BMJ 2014;349:g6501.
doi: 10.1136/bmj.g6501.
Zorzela L, Golder S, Liu Y, Pilkington K, Hartling L, Joffe A, et
al. Quality of reporting in systematic reviews of adverse events:
systematic review. BMJ 2014; 348:f7668.
Agenda and Priority Setting Methods
Group
Mona Nasser on behalf of the Agenda and Priority Setting
Methods Group (APSMG)
Highlights of 2014 to 2015:
• Soumyadeep Bhaumik joined the group as the Methods
Group Co-ordinator.
• Starting the project on engaging with policy makers in
setting priorities for topics of Cochrane Reviews in USA,
England, Italy and South Africa.
• Further development of the Global Burden of Disease
Project to inform future priorities for Cochrane Reviews.
Introduction: The Agenda and Priority Setting Methods Group
aims to inform Cochrane Groups about the empirical evidence
available for methods to set research agendas or priorities, in
particular (but not limited to) systematic reviews.
Research andmethodological development:
• Engaging with policy makers in setting priorities for topics
of Cochrane Reviews: The Cochrane Editorial Unit provided
support to start a pilot project. Teams in the USA, Eng-
land, Canada, South Africa and Italy have been formed. A
development of a sampling frame and data collection has
started in four of these countries. The results intend to
inform future priority setting processes within Cochrane. A
commentary in this issue of Cochrane Methods outlines the
intermediate results of the project’s USA partner (see page
21).
• Furtherdevelopmentof theGlobalBurdenofDiseaseProject:
Last year, we started a project that mapped cause-speciﬁc
disease burden (as determined by the Global Burden of
Disease Study) to systematic reviews and protocols of
clinical interventions, which target the same diseases in
the Cochrane Library. We conducted and published new
evaluations this year. Details of the ﬁnished and ongoing
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projects are available here: capsmg.cochrane.org/global-
burden-disease-gbd cochrane-project
Training and support activities:
• The Methods Group organized a training workshop at
the 2014 Hyderabad Colloquium on ‘Research priority
setting exercises: how to reach and address needs of
disadvantaged groups’, and facilitated a special session
on ‘Setting research agendas: balancing public health and
patient level priorities’. The notes and details of the work-
shop and special session are available on our website:
capsmg.cochrane.org/workshop-and-special-session-
hyderabad-cochrane-colloquium-2014
• Roberto D’Amico and Mona Nasser organized a workshop
on ‘Researchpriority setting’ at the ItalianCochraneCentre
in October 2014.
• The Methods Group has submitted applications to run
training workshops and special sessions at the 2015 Vi-
enna Colloquium, Austria, on research priority setting and
informing the development of future research. The lat-
ter is developed in collaboration with the Evidence Based
Research Network (www.ebrnetwork.org).
• Soumyadeep Bhaumik organized a panel session on ‘Iden-
tifying research priorities and setting research agenda in
clinical toxicology with a focus on snake envenomation’ in
the 4th Annual Conference of the Society Toxicology, India
& International Colloquium, 2014 (TSICon 2014) in Kolkata.
• The Methods Group has a twitter account @capsmg that is
used to disseminate our work on research priority setting
and engage with other stakeholders on this topic.
What’s new?
• The start of the project ‘Engaging with policy makers in
setting priorities for topics of Cochrane Reviews’, in the
USA, England, Italy and South Africa.
• Soumyaeep Bhaumik joining us as Methods Co-ordinator.
• Publishinga report on thediscussions in the special session
and workshop at the 2014 Hyderabad Colloquium.
Looking ahead:
• Progress ongoing projects.
• Organization of workshops at Cochrane Colloquia.
• Fundingwill be sought toconductmethodological research
to consolidate ﬁndings thus far. This includes a systematic
review of research priority setting exercises, which will in-
clude conducting a survey within Cochrane and evaluation
of the value of information analysis tool.
Key publications for 2014 to 2015:
BhaumikS,RanaS,KarimkhaniC,WelchV,ArmstrongR,PottieK,
et al. Ethics and equity in research priority-setting: stakeholder
engagement and the needs of disadvantaged groups. Indian
Journal of Medical Ethics 2015:12(2):110. Epub 2015 Mar16.
Dhakal P, Oliver S, Francis DK, Nasser M, Crowe S, Aksut B,
et al. Ethics and equity in research priority-setting: stakeholder
engagement and the needs of disadvantaged groups. Indian
Journal of Medical Ethics 2015;12(2):110-3. Epub 2015 Mar 16.
Boyers LN, Karimkhani C, Hilton J, Richheimer W, Dellavalle
RP. Global burden of eye and vision disease as reﬂected in the
Cochrane Database of Systematic Reviews. JAMA Ophthalmol-
ogy 2015;133(1):25-31.
Pederson H, Okland T, Boyers LN, Karimkhani C, Rosenfeld RM,
Nasser M, et al. Identifying otolaryngology systematic review
research gaps: comparingGlobal Burdenof Disease 2010 results
with Cochrane Database of Systematic Review content. JAMA
Otolaryngology - Head & Neck Surgery 2015;141(1):67-72.
Tong A, CroweS, ChandoS, Cass A, ChadbanSJ, Chapman JR, et
al. ResearchPriorities inCKD: reportofanationalworkshopcon-
ducted in Australia. American Journal of Kidney Diseases 2015
pii: S0272-6386(15)00593-4. doi: 10.1053/j.ajkd.2015.02.341.
[Epub ahead of print].
Tong A, Chando S, Crowe S, Manns B, Winkelmayer WC, Hem-
melgarn B, et al. Research priority setting in kidney disease:
a systematic review. American Journal of Kidney Diseases
2015;65(5):674-83.
Applicability and Recommendations
Methods Group
Holger Schu¨nemann and Gordon Guyatt
Please visit armg.cochrane.org for an update on this Group’s
activities, also for further information visit http://www.
gradeworkinggroup.org/. A change to the registered title of
this Group is under discussion.
Bias Methods Group
Doug Altman, Isabelle Boutron, Asbjørn Hro´bjartsson, David
Moher, and Alain Mayhew
Highlights of 2014 to 2015:
• Multiple training sessions using a variety of deliverymodes
(workshops, seminars, webinars).
• Providing input and guidance to new Cochrane develop-
ments.
• Publishing on a wide range of topics with direct relevance
to the Bias Methods Group (BMG).
Introduction: The BMG is based in Ottawa, Canada with con-
venors based in the UK, France and Denmark. Membership
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is open to any researcher interested in methods and develop-
ments of tools to assess risk of bias (RoB) in Cochrane Reviews.
Our activities include:
• undertaking empirical research to examinewhether, and in
whichcircumstances, variousbiasesmayhaveasubstantial
impact on systematic reviews, including the preparation of
Cochrane Methodology Reviews;
• undertaking methodological research on how to identify
and address potential biases in systematic reviews and
meta-analyses;
• helping to complete and co-ordinate Methods systematic
reviews pertinent to the Group’s remit;
• providing advice to Cochrane entities; and
• offering training to both Cochrane and non-
Cochrane systematic reviewers via formal and informal
opportunities.
Research and methodological developments: Convenors
of the BMG have been very involved in the develop-
ment of ‘A Cochrane Risk of Bias Assessment Tool: for
Non-Randomized Studies of Interventions’ (ACROBAT-NRSI;
www.riskofbias.info). We are also developing an updated ver-
sion of the RoB tool for randomized controlled trials. We are
supporting and providing guidance to the establishment and
development of a new Methods Group for Rapid Reviews.
We have been involved in a variety of research relevant to the
remit of BMG. This includes reporting guidelines, evaluation of
blinding, outcome reporting and newer topics such as reporting
to exaggerate trial results and waste in medical research (see
Key References list below).
Training and support activities: We have conducted training
in a variety ofmodes for Cochraneauthors and readers. Wehave
developed content and conducted four workshops, two small
group seminars and two webinars focusing solely on the RoB
components and how the RoB tool can be incorporated into
reviews. Target audiences have included federal government
groups and health technology agencies; we have also worked
with Cochrane Centres and Review Groups in providing two
author training workshops. Workshops have been presented in
both French and English.
We continue to work with authors of Cochrane and non-
Cochrane reviews, providing expertise and consultation. The
RoB tool remains amandatory component of CochraneReviews
and updates and is frequently used in non-Cochrane reviews as
well.
We have updated ourwebsitewith our 2014membership survey
results, and an updated list of key references for users. We have
participated in, andare in theprocessofwritingup the resultsof,
asurveyofCochraneReviewGroupsandhowtheyassessanduti-
lizetheselectiveoutcomereportingcomponentof the ‘RoB’tool.
In May 2014, in collaboration with Cochrane Canada, we pro-
vided a train-the-trainer workshop focusing speciﬁcally on RoB
training to help meet the need for trainers across Canada. Over
half of the attendees have offered training on RoB since the
workshop, providing a broader base of training expertise.
At the 2014 Hyderabad Colloquium, we supported four work-
shops, covering basic, intermediate and advanced topics. We
also invited scientiﬁc abstracts at our annual meeting in Hy-
derabad; three abstracts presented were well received. We
were invited to participate in a meeting addressing issues of
updating Cochrane Reviews, providing impact of how RoB as-
sessment could both impact and be affected by the updating
process.
Looking ahead: We will continue our involvement with the
development and implementation of RoB tools for both ran-
domized and non-randomized studies. We will work with other
groups to ensure the appropriate incorporation of the RoB tools
with other components of Cochrane Reviews such as ‘Summary
of ﬁndings’ tables. We continue to offer workshops at national
and international Cochrane and non-Cochrane meetings, cov-
ering both basic and advancedmethods. The BMG is supporting
sixworkshopsat the 2015ViennaColloquiumandwill beputting
out a call for presentation abstracts for the BMGmeeting.
Keypublications for2014 to2015: IversN,TriccoAC,Trikalinos
TA, Dahabreh IJ, Danko KJ, Moher D, et al. Seeing the forests
and the trees--innovative approaches to exploring heterogene-
ity in systematic reviews of complex interventions to enhance
health system decision-making: a protocol. Systematic Reviews
2014;2(3):88.
Galipeau J, Moher D, Campbell C, Hendry P, Cameron DW,
Palepu A, et al. A systematic review highlights a knowledge gap
regarding the effectiveness of health-related training programs
in journalology. Journal of Clinical Epidemiology 2015;68(3):257-
65.
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petti-
crew M, et al. Preferred reporting items for systematic review
and meta-analysis protocols (PRISMA-P) 2015: elaboration and
explanation. BMJ 2015;349:g7647.
Fa¨ssler M, Meissner K, Kleijnen J, Hro´bjartsson A, Linde K. A
systematic review found no consistent difference in effect be-
tween more and less intensive placebo interventions. Journal
of Clinical Epidemiology 2015:68(4):442-51.
Moustgaard H, Bello S, Miller FG, Hro´bjartsson A. Subjective and
objective outcomes in randomized clinical trials: deﬁnitions dif-
fered in methods publications and were often absent from trial
reports. Journal of Clinical Epidemiology 2014;67(12):1327-34.
Bello S, Moustgaard H, Hro´bjartsson A. The risk of unblinding
was infrequently and incompletely reported in 300 random-
ized clinical trial publications. Journal of Clinical Epidemiology
2014;67(10):1059-69.
Bello S, Krogsbøll LT, Gruber J, Zhao ZJ, Fischer D, Hro´bjartsson
A. Lack of blinding of outcome assessors in animal model ex-
periments implies risk of observer bias. Journal of Clinical
Epidemiology 2014;67(9):973-83.
Hro´bjartsson A, Emanuelsson F, Skou Thomsen AS, Hilden J,
Brorson S. Bias due to lack of patient blinding in clinical trials.
A systematic review of trials randomizing patients to blind and
nonblind sub-studies. International Journal of Epidemiology
2014;43(4):1272-83.
Hro´bjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Ras-
mussen JV, Hilden J, et al. Observer bias in randomized clinical
trials with time-to-event outcomes: systematic review of trials
with both blinded and non-blinded outcome assessors. Interna-
tional Journal of Epidemiology 2014;43(3):937-48.
Hopewell S, Boutron I, Altman DG, Ravaud P. Deﬁciencies in the
publication and reporting of the results of systematic reviews
presented at scientiﬁc medical conferences. Journal of Clinical
Epidemiology 2015;pii: S0895-4356(15)00151-1.
Yordanov Y, Dechartres A, Porcher R, Boutron I, Altman DG,
Ravaud P. Avoidable waste of research related to inadequate
methods in clinical trials. BMJ 2015;350:h809.
Boutron I, Altman DG, Hopewell S, Vera-Badillo F, Tannock I,
Ravaud P. Impact of spin in the abstracts of articles reporting
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results of randomized controlled trials in the ﬁeld of cancer: the
SPIIN randomized controlled trial. Journal of Clinical Oncology
2014;32(36):4120-6.
Hansen JB, Juhl CB, Boutron I, Tugwell P, Ghogomu EA, Pardo
Pardo, et al. Assessing bias in osteoarthritis trials included in
Cochrane reviews: protocol for a meta-epidemiological study.
BMJ Open 2014;4(10):e005491.
Maruani A, Boutron I, Baron G, Ravaud P. Impact of sending
email reminders of the legal requirement for posting results
on ClinicalTrials.gov: cohort embedded pragmatic randomized
controlled trial. BMJ 2014;349:g5579.
Buffel du Vaure C, Boutron I, Perrodeau E, Ravaud P. Reporting
funding source or conﬂict of interest in abstracts of randomized
controlled trials, no evidence of a large impact on general prac-
titioners’ conﬁdence in conclusions, a three-arm randomized
controlled trial. BMCMedicine 2014;12:69.
Emdin C, Odutayo A, Hsiao A, Shakir M, Hopewell S, Rahimi
K, et al. Association of cardiovascular trial registration with
positive study ﬁndings: epidemiological study of randomized
trials (ESORT). JAMA Internal Medicine 2015;175:304-7.
Saini P, Loke YK, Gamble C, Altman DG, Williamson PR, Kirkham
JJ. Selective reporting bias of harm outcomes within stud-
ies: ﬁndings from a cohort of systematic reviews. BMJ
2014;349:g6501.
Dwan K, Altman DG, Clarke M, Gamble C, Higgins JP, Sterne
JA, et al. Evidence for the selective reporting of analyses and
discrepancies in clinical trials: a systematic review of cohort
studies of clinical trials. PLOS Medicine. 2014;11(6):e1001666.
FlemingPS,Koletsi D,DwanK,PandisN.Outcomediscrepancies
and selective reporting: impacting the leading journals? PLOS
ONE 2015;10:e0127495.
Frosi G, Riley RD,Williamson PR, Kirkham JJ. Multivariatemeta-
analysis helps examine the impact of outcome reporting bias
in Cochrane rheumatoid arthritis reviews. Journal of Clinical
Epidemiology 2015;68(5):542-50.
Twitter: @CochraneBMG
Comparing Multiple Interventions
Methods Group
Tianjing Li on behalf of the CMIMG convenors
Correspondence to: cmimg.cochrane.org
Introduction: The Comparing Multiple Interventions Methods
Group (CMIMG) focuses on methods for network meta-analysis
and for overviews of reviews. Network meta-analyses (other-
wise known as multiple treatments meta-analyses and mixed
treatment comparisons) combine results from studies making
different comparisons from among a set of treatments for the
same condition, exploiting indirect comparisons of treatments
via common comparator treatments.
The group’s activities, supported primarily by a three-year
Cochrane Methods Innovation Fund grant, have focused on:
1) developing methods and guidance in the form of a chapter in
the Cochrane Handbook for Systematic Reviews of Interventions;
2) providing training to interested individuals; 3) providing peer
review support to reviews that include network meta-analysis;
and 4) serving as a forum for discussion.
Research and methodological developments: We developed
and published an approach for extending the GRADE (Grading
of Recommendations Assessment, Development and Evaluation)
system into network meta-analysis, which was presented at the
2014HyderabadColloquiumandthe ISPOR17th AnnualEuropean
Congress in Amsterdam.
We have produced guidance on how to write a protocol for a
systematic reviewwithmultiple interventions. Cochrane authors
requesting feedback on their protocols and reviews received this
guidance. We also covered key elements of this guidance at
educational events at which the co-convenors participated.
We prepared a chapter for the Cochrane Handbook for Systematic
Reviews of Interventions describing the methodology for network
meta-analysis. Key elements of the chapter will be presented
in a one-day workshop that will be held at the 2015 Vienna
Colloquium.
We compiled the available software tools for conducting network
meta-analysis. A brief description of these tools is available on
our website.
We were involved in the committee for extending the PRISMA
(Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) statement into network meta-analysis, now accepted
for publication.
Training and support activities: CMIMG facilitated three work-
shops during the 2014 Hyderabad Colloquium, India: ‘Intro-
duction to indirect comparison and network meta-analysis’,
‘Advanced statistical methodology for network meta-analysis’,
and ‘Advancing methods for overviews of reviews’. Members of
CMIMG also gave podium and poster presentations on a range
of topics pertinent to network meta-analysis and overviews of
reviews.
For the 2015 Vienna Colloquium in, Austria, CMIMG has planned
a one-day pre-Collo quium workshop on ‘Indirect comparison
and network meta-analysis in Cochrane Reviews’ and a half-day
post-Colloquium workshop on ‘Overview of systematic reviews’.
More information about these workshops can be found at
colloquium.cochrane.org/pre-and-post-colloquium-symposia-
1-2-october-8-october
Group access: CMIMG currently has 103 members regis-
tered in Archie. Our newly established listserv has 52 mem-
bers, and others are invited to join by sending an email to
CMIMG@lists.cochrane.org. More than 6000 users have visited
our website during the past year, and we have over 1500 page
views per month. Most users begin with our Network Meta-
Analysis Toolkit page.
Looking ahead: In the year ahead we hope to see publication
of our paper on writing a protocol for a systematic review, and
also of all the remaining outputs of our Methods Innovation Fund
project. We will present a full day workshop on network meta-
analysis, and a half-day workshop on overviews of systematic
reviews.
Key publications: Salanti G, Del Giovane C, Chaimani A, Cald-
well DM, Higgins JPT .Evaluating the quality of evidence from a
network meta-analysis. PLOS ONE 2014;9(7):e99682.
Caldwell DM. An overview of conducted systematic reviews with
network meta-analysis. Systematic Reviews 2014;3(1):109.
Jackson D, Barrett JK, Rice S, White IR, Higgins JPT. A design-
by-treatment interaction model for network meta-analysis with
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randominconsistencyeffects. Statistics inMedicine2014;33:3639-
54
Nikolakopoulou A, Chaimani A, Veroniki AA, Vasiliadis HS, Schmid
CH, Salanti G. Characteristics of networks of interventions: a
description of a database of 186 published networks. PLOS ONE
2014;9(1):e86754.
Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH,
Cameron C, et al. The PRISMA extension statement for reporting
of systematic reviews incorporating network meta-analyses of
healthcare interventions: checklist and explanations. Annals of
Internal Medicine in press.
Hartling L, Vandermeer B, Fernandes RM. Systematic reviews,
overviews of reviews and comparative effectiveness reviews: a
discussion of approaches to knowledge synthesis. Evidence-
based Child Health 2014;9(2):486-94.
Campbell and Cochrane Economics
Methods Group
Luke Vale on behalf of the C-CEMG convenors
Introduction: The Economics methods group has had another
active year.
Research and methodological development: The Group con-
tinues to look for opportunities to collaborate with review
groups and teams seeking to include an economics perspective
within their reviews, either as formal review outcomes or as
brief economic commentaries. The need to develop and test
methods of integrating resource considerations into reviews is
all the more pressing as two resources for identifying economic
evidence have been withdrawn. No new records have been
added to the NHS Economic Evaluation Database since 31 De-
cember 2014, although at the time of writing (and along with
DARE) the database is still accessible. The Health Economic
Evaluation Database (previously published by Wiley) also has
been withdrawn recently. In response to these changes, the
Economics Group has developed an interim ﬁx to identify rele-
vant economic evaluations and cost of illness studies. We are
looking for opportunities toworkwith review groups on piloting
this approach.
Training and support activities: The group has continued to
be active in disseminating methods. Luke Vale and Erin Graybill
gave aworkshop on ‘Developing brief economic commentaries’
at the UK Contributors’ meeting in Manchester in April 2014
and at the 2014 Hyderabad Colloquium. At Hyderabad, Luke
Vale, Laura Ternent and Ian Shemilt also delivered a two-
session workshop on ‘Incorporating economics into Cochrane
InterventionReviewprotocols’. Thesewerewell received (work-
shop materials can be obtained from the Group’s workshop at
www.C-CEMG.org). The Group also gave a satellite workshop
to introduce attendees to the basics of health economics. We
were very grateful for the support of the organizing committee
at Hyderabad and to the Indian Institute for Public Health for
hosting theworkshop and formaking bothworkshop attendees
and ourselves so welcome.
A full day training workshop on brief economic commentaries
was also held in Bath, UK in October. This workshop, or-
ganized by the Gynaecological, Neuro-oncology and Orphan
Cancer Group (CGNOC), gave practical guidance on developing
brief economic commentaries and was attended by repre-
sentatives of several review groups. The Group would be
keen to explore similar events with other review groups in the
future. Interested groups are encouraged to contact Luke Vale
(luke.vale@newcastle.ac.uk), who will be delighted to discuss
proposals.
Workshop participants at the Indian Institute of Public Health.
Workshop leaders: Laura Ternent, Ian Shemilt and Luke Vale from
theEconomicsMethodsGroupandAndyBryant from theStatistical
Methods Group.
Also in2014,EdWilsonandcolleaguesfromtheUniversityofYork
and the Agenda and Priority Setting Methods group presented
workshopson‘Value-of-informationapproachestoprioritizeup-
dates of reviews’ at the UK Contributors’ meeting in April, at the
CampbellColloquiuminMay,atameetingtodiscussapproaches
to keepingCochraneReviewsup-to-date atMcMasterUniversity
in June, and at the October CGNOC meeting in Bath. Value-of-
information methods showmuch promise: the Group will focus
on further developments in this area over the next two years.
In other areas, the group contributed to the DECIDE
(www.decide-collaboration.eu/) conference in Edinburgh in
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June 2014. The conference theme was ‘Developing and evalu-
ating communication strategies to support informed decisions
and practice based on evidence’. The conference focused on
supporting better clinical guidelines and better healthcare de-
cisions. The Group’s contribution was to provide a workshop
on ‘Incorporating evidence of resource use in Evidence to Rec-
ommendation (EtR) frameworks’. A copy of this workshop (on
the Group’s website: www.c-cemg.org) is being developed into
a pilot as part of the World Health Organization guideline on
abortion.
What’s new? The group, alongwith the other CochraneGroups,
has been rebranded. Within Cochrane, it is now known simply
as Cochrane Methods: Economics. However, as the group is run
jointly with the Campbell Collaboration, the group also retains
its original name: Campbell and Cochrane Economic Methods
Group (C-CEMG for short). The Group’s website is also in the
process of being revamped and migrated onto the Cochrane
website, having previously been hosted by the Centre for Re-
views and Dissemination (CRD) at the University of York. In
the interim, website information can be accessed on www.c-
cemg.org. Wewould like to thank the CRD for their support over
the last few years.
Looking ahead: At the 2015 Vienna Colloquium, workshopswill
be held on both brief economic commentaries and incorpora-
tion of health economics into Cochrane Intervention Reviews.
Following the success of the satellite event held in Hyderabad,
a further two-day workshop on health economics will be held
on 3-4 October in Vienna. The session will be introductory
and assumes no prior knowledge of the subject. Details of
the session can be found at: colloquium.cochrane.org/pre-and-
post-colloquium-symposia-1-2-october-8-october; at the time
of writing we are exploring whether participation can be made
available at a nominal fee.
Key publications: The Group published an article in System-
atic Reviews entitled ‘Issues in the incorporation of economic
perspectives and evidence into Cochrane Reviews’ to coin-
cide with the 20th Anniversary of Cochrane in 2013. The
article can be obtained by visiting www.systematicreviews
journal.com/content/2/1/83
Campbell and Cochrane Equity
Methods Group
Jennifer Petkovic on behalf of the Campbell and Cochrane
Equity Methods Group
Highlights of 2013 to 2014:
• The PRISMA-Equity Explanation and Elaboration paper
(accompanies the PRISMA-E 2012 reporting guideline)
will be published later this year.
• We published a paper on the development and evalua-
tion of brieﬁng notes for systematic review authors with
guidance on sex and gender analysis.
• Over the next three years we will be developing an eq-
uity extension of the CONSORT reporting guideline for
randomized controlled trials (RCTs).
• We are working with the GRADE Working Group on a
series of papers for including equity in guidelines.
• Published a Cochrane Review on ‘Food supplementation
for improving the physical and psychosocial health of
socio-economically disadvantaged children aged three
months to ﬁve years’.
• Published a Cochrane Review on ‘Strategies to increase
the ownership and use of insecticide-treated bed nets to
prevent malaria’.
Introduction:TheCampbellandCochraneEquityMethodsGroup
is registeredwithboth theCampbell CollaborationandCochrane.
The Group aims to encourage authors of Campbell and Cochrane
Reviews to include explicit descriptions of the effect of the inter-
ventions upon the disadvantaged and/or their ability to reduce
socioeconomic inequalities in health, and to promote their use
to the wider community.
The Migrant Health subgroup of the Methods Group focuses on
evidence-based migrant health, guidelines and migrant-equity
(equity.cochrane.org/migrant-health).
The Sex/Gender Methods Group is afﬁliated as a subgroup of the
Equity Methods Group and works to promote and integrate sex
and gender analysis in primary research and systematic reviews
(equity.cochrane.org/sex-and-gender-analysis).
Research and methodological development: In 2014, the Eq-
uity Methods Group completed the PRISMA (Preferred Reporting
ItemsforSystematicReviewsandMeta-analyses)-EquityExplana-
tionandElaborationpaper. This accompanies thePRISMA-E2012
Statement published in PLOS Medicine in 2012. This reporting
guideline is intended to improve the completeness and trans-
parency of reporting of equity-focused systematic reviews. The
paper will be published in 2015 –check our website for updates.
Members of our team published a systematic review on ‘Strate-
gies to increase the ownership and use of insecticide-treated
bednets to prevent malaria’ with the Cochrane Effective Practice
& Organisation of Care (EPOC) Review Group.
Led by Elizabeth Kristjansson, members of our team pub-
lished a Cochrane Systematic Review on ‘Food supplemen-
tation for improving the physical and psychosocial health of
socio-economically disadvantaged children aged three months
to ﬁve years’ with the Cochrane Developmental, Psychosocial
and Learning Problems Review Group.
Members of the Equity Methods Group are working with the
GRADE (Gradingof Recommendations Assessment, Development
and Evaluation) Working Group to develop guidance for consid-
ering equity in guidelines and recommendations. The current
development of a series of papers will provide guidance for
including equity in guideline development, evidence synthesis
and grading, moving from evidence to recommendations, and
guideline implementation.
A series of methodological papers on the inclusion of sex/gender
considerations in systematic reviews is in development. The
Sex/Gender Methods Group is leading this work and aims to
publish the series in 2015. In addition, a paper discussing
the development and evaluation of three knowledge transla-
tion brieﬁng notes providing systematic review authors with
information and guidance on sex and gender analysis was pub-
lished in PLOS ONE. The brieﬁng notes are available on our
website.
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Training and support activities: In 2013, we provided work-
shops on equity methods at the 2013 Quebec Colloquium. We
also increased the number of presentations andworkshops given
to non-Cochrane organizations, such as the Public Health Agency
of Canada, the International Development Bank, Health Quality
Ontario, and the National Collaborating Centre for Methods
and Tools.
Looking ahead: In 2015 to 2016, the Equity Methods Group
will be working on the development of a reporting guideline for
equity-sensitive randomized controlled trials (RCTs). This work
will include a methodology review (registered with the Cochrane
Methodology Review Group) to assess the reporting of equity
in RCTs, a study to assess available guidelines for RCTs that
consider health equity, consultations with global experts from
different disciplines and stakeholder organizations on methods
to improve reporting of health equity in RCTs, the development
of draft extension items, and seeking consensus on the extension
items. This work has been funded by the Canadian Institutes for
Health Research.
Our project, Evidence for Equity (E4E) aims to create a spe-
cial collection of Cochrane Review summaries of interventions
that are effective and could reduce health inequities. In 2015,
we will conduct a priority setting exercise with international
stakeholders to identify the most important reviews to sum-
marize in ﬁve topic areas. We will then conduct user test-
ing of the summary formats and website before launching the
website in 2016.
Keypublications for 2014 to 2015: Augustincic Polec L, Petkovic
J, Welch V, Uefﬁng E, Tanjong Ghogomu E, Pardo Pardo J, et al.
Strategies to increase the ownership and use of insecticide-
treated bednets to prevent malaria. Cochrane Database of
Systematic Reviews 2015, Issue 3. Art. No.: CD009186. doi:
10.1002/14651858.CD009186.pub2.
Doull M, Welch V, Puil L, Runnels V, Coen SE, Shea B, et al. De-
velopment and evaluation of ’brieﬁng notes’ as a novel knowl-
edge translation tool to aid the implementation of sex/gender
analysis in systematic reviews: a pilot study. PLOS ONE
2014;9(11):e110786. doi: 10.1371/journal.pone.0110786.
Katikireddi SV, Egan M, Petticrew M. How do systematic reviews
incorporate risk of bias assessments into the synthesis of evi-
dence? A methodological study. Journal of Epidemiology and
Community Health 2014;69(2):189-95. doi: 10.1136/jech-2014-
204711. Epub 2014 Dec 6
Kristjansson E, Francis DK, Liberato S, Benkhalti Jandu M, Welch
V, et al. Food supplementation for improving the physical and
psychosocial health of socio-economically disadvantaged chil-
dren aged three months to ﬁve years. Cochrane Database of
Systematic Reviews 2015, Issue 3. Art. No.: CD009924. doi:
10.1002/14651858.CD009924.pub2.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew
M, et al. Preferred reporting items for systematic review and
meta-analysis protocols (PRISMA-P) 2015 statement. Systematic
Reviews 2015;4(1):1.
Petticrew M, Welch V, Tugwell P. ‘It is surely a great criticism
of our profession. . .’ The next 20 years of equity-focused sys-
tematic reviews. Journal of Epidemiology and Community Health
2014;68(4):291-2. doi: 10.1136/jech-2013-203400. Epub 2013 Nov
27.
Ramke J, Welch V, Blignault I, Gilbert C, Petkovic J, Blanchet K, et
al. Interventions to improve access to cataract surgical services
and their impact on equity in low- and middle-income countries
(Protocol). Cochrane Database of Systematic Reviews 2014, Issue
9. Art. No.: CD011307. doi: 10.1002/14651858.CD011307.
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew
M, et al, the PRISMA-P Group. Preferred reporting items for
systematic review andmeta-analysis protocols (PRISMA-P) 2015:
elaboration and explanation. BMJ 2015;349:g7647
ShiC,TianJ,WangQ,PetkovicJ,RenD, YangK,etal.Howequity is
addressed in clinical practice guidelines: a content analysis. BMJ
Open 2014;4:e005660.
Group access: equity.cochrane.org
Follow us on Twitter: @CochraneEquity
Individual Participant Data
Meta-analysis Methods Group
Larysa Rydzewska, Jayne Tierney, Lesley Stewart, Maroeska
Rovers and Mike Clarke
Introduction: Systematic reviews based on aggregate data can
oftenbe constrainedby the availability andquality of suchdata.
However, meta-analyses based on individual participant data
(IPD) involve the central collection and re-analysis of data from
all relevant studies, and can bring about substantial beneﬁts to
thequalityof thedataandanalyses, translating tomoredetailed
and reliable results. The IPD Meta-analysis Methods Group now
has more than 100 members from a range of healthcare areas,
including cancer, epilepsy, stroke, perinatal care, renal disease,
arthritis and malaria; who are working on IPD meta-analyses in
prevention, diagnosis, treatment, rehabilitation and prognosis,
as well as undertaking IPD-related methodological research.
Highlights of 2014 to 2015: Series of ‘state of the art’ pa-
pers relating to IPD: Increased use of the IPD approach for
meta-analyses has highlighted practical and methodological
challenges. Therefore, members of the Group have been col-
laborating to develop a ‘state of the art’ series of papers on
the impact, understanding and use of systematic reviews and
meta-analyses based on IPD. This is supported by funding from
the (UK) Medical Research Council (MRC) Network of Hubs for
Trials Methodology Research (HTMR). In a separate project that
included hosting an international workshop funded through a
National Institute for Health Research (NIHR) Senior Investi-
gator award, we have developed PRISMA-IPD, a stand-alone
extension to PRISMA (Preferred Reporting Items for Systematic
ReviewsandMeta-Analyses), covering the speciﬁc requirements
of the IPD approach. More details can be found in the related
news item (page 6). This collection of open access papers (refer-
ences below) will become a key information source for multiple
stakeholders.
Data sharing: The increasing access to IPD is also bringing
a number of challenges, not least, the need to preserve par-
ticipant privacy and ensure that different providers transfer
their data in a coherent way. Therefore, members of the
Group volunteered to take part in a project aimed at de-
veloping standards for the de-identiﬁcation of participant
level data, which combine data privacy with data utility
(www.phuse.eu/Data Transparency.aspx/). It is hoped that
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this may encourage data providers to use these common
standards thereby making it easier for researchers when
requesting IPD datasets. We were also involved in the prepa-
ration of the recent report for the Wellcome Trust on access
to data from clinical trials (www.wellcome.ac.uk/About-us/
Policy/Spotlight-issues/Data-sharing/Access-to-clinical-trial-
data/index.htm).
2014 Hyderabad Colloquium: Members of the Group facilitated
a workshop aimed at introducing the use of IPD meta-analysis
in risk prediction research and discussing the opportunities and
challenges of combining IPD frommultiple studies when devel-
opingand/orvalidatingariskpredictionmodel.1 Therewerealso
three presentations of methodological research/developments
relating to IPD at the 2014 Hyderabad Colloquium (see below).
Research/methodological development: Abstracts and slides
from the following presentations are available on the Methods
Group website (ipdmamg.cochrane.org).
1. Nolan S,MarsonA, Tudur Smith C. Data sharing: is it getting
easier to access individual participant data? Experiences
from the Cochrane Epilepsy Group. Oral Session 19; Abs
19.4. Abstracts of the 22nd Cochrane Colloquium, 21-26
September 2014; Hyderabad, India. Cochrane Database of
Systematic Reviews, Supplement 2014: Art. No. CD201200.
doi: 10.1002/14651858.CD201200.
2. Debray T, Jolani S, Kofﬁjberg H, van Buuren S, Moons K.
Multiple imputation of systematicallymissing predictors in
an individual participant datameta-analysis: a generalized
approach using MICE. Oral session 10; Abstract 10.3. Ab-
stracts of the 22nd Cochrane Colloquium; 21-26 September
2014; Hyderabad, India. Cochrane Database of System-
atic Reviews, Supplement 2014: Art. No. CD201200. doi:
10.1002/14651858.CD201200.
3. Moons K, Debray T, Rovers M, Riley R, Reitsma H. How to
appraise individual participant data (IPD) meta-analysis in
diagnostic and prognostic risk prediction research. Poster
Session 3; Abstract P90. Abstracts of the 22nd Cochrane
Colloquium; 21-26 September 2014; Hyderabad, India.
Cochrane Database of Systematic Reviews, Supplement
2014: Art. No. CD201200. doi: 10.1002/14651858.CD201200.
4. Debray T, Moons K, Reitsma J. Individual participant data
(IPD) meta-analysis of risk prediction studies. Workshop
Session 2; Abs W37. Abstracts of the 22nd Cochrane Collo-
quium; 21-26 September 2014; Hyderabad, India. Cochrane
Database of Systematic Reviews, Supplement 2014: Art. No.
CD201200. doi: 10.1002/14651858.CD201200.
Looking ahead:Wewill undertake amajor update of the IPD re-
views chapter in the Cochrane Handbook for Systematic Reviews
of Interventions.
Several IPD-related research andworkshopabstracts havebeen
submitted to the 2015 Vienna Colloquium, and the Methods
Group will meet there.
Training and support: In addition to running workshops at
Cochrane Colloquia, the Methods Group can also provide spe-
cialist advice on IPD reviews and peer review on IPD elements
of Cochrane Reviews. We encourage Cochrane authors needing
advice, or wishing to join the Methods Group, to contact us
via our website. The website also contains further information
about the activities of the Group, along with resources and
guidance for those planning or undertaking IPD reviews, and
information about IPD reviews and IPD-related methodological
research published by Group members. Please do come and
visit us!
Keypublications: ValeCL,RydzewskaLH,RoversMM,Emberson
JR,GueyfﬁerF, Stewart LA;Cochrane IPDMeta-analysisMethods
Group. Uptake of systematic reviews and meta-analyses based
on individual participant data in clinical practice guidelines:
descriptive study. BMJ 2015;350:h1088.
Tierney JF, Pignon JP, Gueffyier F, Clarke M, Askie L, Vale, CL,
et al, on behalf of the Cochrane IPD Meta-analysis Methods
Group. How individual participant data meta-analyses have
inﬂuenced trial design, conduct and analysis. Journal of Clinical
Epidemiology. 2015; Jun 3. pii: S0895-4356(15)00268-1 doi:
10.1016/j.jclinepi.2015.05.024
Tierney JF, Vale C, Riley R, Tudur Smith C, Stewart L, Clarke M,
et al. Individual participant data (IPD) meta-analyses of ran-
domized controlled trials: guidance on their use. PLOSMedicine.
2015;12(7):e1001855
Debray TPA, Riley RD, Rovers MM, Reitsma JB, Moons KG, on
behalf of the Cochrane IPD Meta-analysis Methods group. In-
dividual Participant Data (IPD) meta-analysis of diagnostic and
prognostic modeling studies: a practical introduction to their
rationale and conduct.PLOS Medicine. Under review.
Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart
G, et al. Preferred reporting items for a systematic review and
meta-analysis of individual participant data: The PRISMA-IPD
Statement. JAMA 2015;313(16):1657-65.
Jolani S,DebrayTP,KofﬁjbergH, vanBuurenS,MoonsKG. Impu-
tation of systematically missing predictors in an individual par-
ticipantdatameta-analysis: a generalizedapproachusingMICE.
Statistics in Medicine 2015;34(11):1841-63. Epub 2015 Feb 9.
Information Retrieval Methods Group
(IRMG)
Julie Glanville, Carol Lefebvre, Jessie McGowan, Alison
Weightman (Co-Convenors) and Bernadette Coles
(Co-ordinator)
Visit us at irmg.cochrane.org
Highlights of 2014 to 2015: Highlights for the past year, which
will have a major impact on many members of Information
Retrieval Methods Group (IRMG), includes progress within the
Embase project, funding to assess when to base Cochrane Re-
views on clinical study reports and decisions to adopt a ‘publish
when ready’ model for the Cochrane Handbook for Systematic
Reviews of Interventions. For further details, please see below.
Introduction: The IRMGwas formed in2004. Its remit is toprovide
advice to Cochrane on information retrieval policy and practice,
toprovidetrainingandsupport, toconductempirical research(in-
cluding systematic reviews) into information retrieval methods,
to help monitor the quality of searching techniques employed
in systematic reviews and to serve as a forum for discussion.
The Group currently has over 300 members on its discussion
list. Please contact Bernadette Coles, IRMG Co-ordinator, to join
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(Colesbm@cardiff.ac.uk), or sign up via our email discussion list.
Research and methodological development: Bibliographic
databases versus supplementary search methods in public health:
Alison Weightman is working on a project that will determine the
importance of a multi-database search in addition to the use of
supplementary methods for public health reviews. A preliminary
analysis of nine reviews was presented at the 2014 Hyderabad
Colloquium.
Clinical study reports (CSRs): Funding has been received in the
recent round of Cochrane Methods Innovation Funding (MIF) to
assess the circumstances in which CSRs should be used as the
evidence base for Cochrane Reviews. This follows on from the
updated Cochrane Review on Relenza which was based solely on
CSRs,notonpublishedreportsordataderivedfromothersources,
suchas trials registers or regulatory agencyweb sites. Theproject
is led by Tom Jefferson (Acute Respiratory Infections Group), to-
getherwith his co-authors on the Relenza review, IRMGand other
interested Cochrane Methods Groups. For further information on
this and other MIF-funded projects, please see pages 4–6.
Cochrane Handbook for Systematic Reviews of Interventions:
Agreement has been reached to adopt a ‘publish when ready’
model not only for the major revision of the Cochrane Handbook
for Systematic Reviews of Interventions (due for publication in
2016 to 2017) but also for the ‘minor update’, which has been
in process for some time. We hope, therefore, that the ‘minor
update’ to Chapter 6: Searching for studies (incorporating MECIR
standards) will now be published by the end of 2015.
Embase: Julie Glanville has been working with Anna Noel-Storr
(CochraneDementiaandCognitive ImprovementGroup (CDCIG)),
Gordon Dooley (Metaxis) and Ruth Foxlee (Cochrane Central Ex-
ecutiveTeam)on thedevelopmentof aCochraneHighlySensitive
Search Strategy for identifying randomized controlled trials in
Embase. Embase research continues within that team. The team
has recently won a CDCIG discretionary fund application for a
project entitled ‘Semi-automating citation screening: an assess-
ment of machine learning approaches using 18months’ worth of
human-generated data from the Embase crowdsourcing project’.
MECIR: During 2015 all IRMG members were consulted on the
document that will formMECIR standards on updating Cochrane
Reviews.
Peer Review of Electronic Search Strategies (PRESS): The PRESS
Checklist will be updated as a guideline by a team led by Jessie
McGowan, Carol Lefebvre and Margaret Sampson. We hope
that the update will be ﬁnalized by late 2015. All IRMG mem-
bers will be invited to contribute to this project by responding
to a survey planned for June/July 2015 (as they were for the
original PRESS Checklist; see www.cadth.ca/press-peer-review-
electronic-search-strategies-0).
Searching for adverse events: SuGolder and colleagues havebeen
surveying systematic reviews of adverse effects and looking at
the reporting of search strategies and sources used compared to
intervention reviews.
Training and support activities: The IRMG ran two workshops
at the 2014 Hyderabad Colloquium:
• Methodological requirements for searching for studies for
Cochrane Reviews: ensuring that new Cochrane Reviews
meet the MECIR standards. Facilitators: Carol Lefebvre,
Ruth Foxlee (CET) and Anna-Noel-Storr (CDCIG).
• Searching trials registers to identify studies for Cochrane
Reviews. Facilitators: Carol Lefebvre, Alison Weightman
and Mala Mann (IRMGmember).
What’s new and looking ahead:
Application foraCochraneRapidReviewsMethodsGroup:The IRMG
Co-Convenors have recently supported a proposal for the estab-
lishment of a RapidReviewsMethodsGroup. Given the additional
complexities around identifying studies for rapid reviews, IRMG
very much welcomes this development and looks forward to
working closely with this Group.
Cochrane Linked Data Project: IRMG will be supporting the
Cochrane Informatics & Knowledge Management Department
(IKMD) by helping to test the annotation tool that they have
built to annotate or tag PICO (patient, intervention, compari-
son, outcome) to support the Cochrane Linked Data Project (see
data.cochrane.org/linked-data-project/models-and-ontologies).
MECIR and search strategies audit: IRMG still plans to conduct a
survey, in line with its remit, examining search strategy quality
and compliance with MECIR standards, but has been unable to
obtain funding to date. This survey is likely to be based on the
original funding application for a survey that was submitted to
Cochrane in March 2010.
Search methods in Public Health: Following on from the public
health search methods poster presented at the 2014 Hyderabad
Colloquium, international collaborators have volunteered to
expand the number of public health reviews analyzed (from
Cochrane and elsewhere). The results of the study will be pre-
sented as a poster at the Evidence Based Library and Information
Practice (EBLIP) conference in 2015 and a journal publication is
in preparation.
Textmining: JulieGlanvilleandherteamatYorkHealthEconomics
Consortiumareexploring textmining for the identiﬁcationof eco-
nomic evaluations during 2015.
Key publications for 2014 to 2015: Glanville J, Kaunelis
D, Mensinkai S, Picheca L. Pruning Emtree: does focus-
ing Embase subject headings impact search strategy preci-
sion and sensitivity? [Internet]. Ottawa: CADTH; 2015
Apr. www.cadth.ca/sites/default/ﬁles/pdf/ATS0022 Pruning%20
Emtree Methods Project e.pdf (see page 41)
Golder S, Loke YK, Zorzela L. Comparison of search strategies in
systematic reviewsof adverse effects toother systematic reviews.
Health Information and Libraries Journal 2014;2(31): 92-105
Non-Randomised Studies Methods
Group
Barney Reeves on behalf of the NRSMG
Highlights of 2014 to 2015: The Non-Randomised Studies
Methods Group (NRSMG) has had another year focused around
theACROBAT-NRSI (A CochraneRisk of Bias Assessment Tool for
Non-Randomized Studies1). The tool was formally launched at
the 2014 Hyderabad Colloquium (two presentations and three
workshops). Representatives from review groups also had the
opportunity to work through the risk of bias domains with ex-
ample papers during a two-day workshop in Paris in December
(the 2014 Cochrane training event), led jointly by the NRSMG
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and the Bias Methods Group, with the help of the Applicability
and Recommendations Methods Group and facilitated by the
FrenchCochraneCentre. This allowedmanyexperienced review
authors within Cochrane to experience for the ﬁrst time the
dilemma facing the tool developers, i.e. how to reconcile the
complexity of the ways in which bias can arise with the need for
a practical tool. The workshop also presented a draft algorithm
to help review authors to decide whether they should include
non-randomized studies in a review of the effectiveness of an
intervention. Themethods groups are currently developing this
further.
Research and methodological development: Even though
with advanced piloting the Paris workshop showed that further
development is still required. In particular, the appropriate-
ness of the existing signalling questions for study designs and
analyses used to evaluate public health and health systems
interventions, e.g. including time series studies, before-after
studies, natural experiments, instrumental variable and regres-
sion discontinuity analyses, is uncertain. Wells, Waddington
and Reeves are also extending the taxonomy checklist2 to in-
clude these study designs and analyses. Fortunately, Higgins
and colleagues have recently been awarded funding from the
UK Medical Research Council to do this; this award also in-
cludes funding to study the relationship between assessments
made using the tool and effect estimates in various types of
non-randomized study, and to produce an online version that
integrates the structure, guidance and examples.
The AMSTAR (A MeaSurement Tool to Assess systematic Re-
views) team (Shea and colleagues) are continuing towork on an
extension of AMSTAR (with funding from a Canadian Institute
Health Research operating grant) to assess systematics reviews
that include non-randomized studies. The revised AMSTAR 2
was recently presented at the Canadian Cochrane Symposium
in Calgary and will be extensively piloted in June and July 2015
(www.amstar.ca).
Training and support activities: Training workshops were
held at the 2014 Hyderabad Colloquium, the 2015 UK and
Ireland Contributors’ symposium in Dublin and at the Canadian
Cochrane Symposium in Calgary (April 2015). These workshops
focused on two risk of bias domains that do not affect ran-
domized controlled trials, that is, bias due to confounding and
selection of participants. There was a commitment at the Paris
workshop to develop on-line training tools for the ACROBAT-
NRSI. This remains the intention, but, regrettably, it has not
progressed at the time of writing. The key to these materials
will be worked examples that contrast studies at varying risk of
bias in different domains.
What’s new? The NRSMG continues to collaborate with the
GRADE (Grading of Recommendations Assessment, Develop-
ment and Evaluation) working group to develop recommen-
dations for grading evidence based on systematic reviews of
non-randomized studies. Schu¨nemann and Santesso led one of
the sessions at the Paris workshop, showing how GRADE plans
to build on the new risk of bias tool in this process.
Lookingahead: TheNRSMGwill lead twoworkshopsat the2015
Vienna Colloquium. We are also investigating the possibility of
running another extendedworkshop, similar to the one in Paris,
somewhere in North America. This will depend on securing
funding to support the event.
Newrecruits: TheNRSMGwelcomesnewmembersofourmeth-
ods group. Please contact Bev Shea (bevshea@uottawa.ca) or
Barney Reeves (Barney.Reeves@bristol.ac.uk) if you would like
further information about the group and how you could partici-
pate in the future.
Key publications for 2014 to 2015: Sterne JAC, Higgins JPT,
Reeves BC on behalf of the development group for ACROBAT-
NRSI. A Cochrane Risk Of Bias Assessment Tool: for Non-
Randomized Studies of Interventions (ACROBAT-NRSI), Version
1.0.0, 24 September 2014. Available from www.riskofbias.info
[accessed 28 May 2015].
Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: In-
cluding non-randomized studies. In: Higgins JPT, Green S
(editors), Cochrane Handbook for Systematic Reviews of In-
terventions. Version 5.0.2 [updated September 2009]. The
Cochrane Collaboration, 2009.
Patient Reported Outcomes Methods
Group
Donald Patrick (Co-Convenor),Gordon Guyatt
(Co-Convenor), Tatiana Gauchon (Co-ordinator), and Julie
Mayoud
Highlights of 2014 to 2015:
• Several publications have appeared during this time and
are cited below.
• The patient reported outcome (PRO) reviews have been
updatedandput on thePROMethodsGroupwebsite. See
Documents section of our Group website
• Additional PRO reviews will be conducted and put on the
Cochrane website as available.
• Wearecurrently launchingastudyofMinimally Important
Differences in PROs funded by the Canadian Institutes of
HealthResearch tosummarizeandappraise theavailable
methods to estimate anchor-based MIDs. We will doc-
ument all anchor-based MIDs reported for adults and
pediatric populations and will develop a rating instru-
ment to assess the credibility of the reported MIDs. With
the information collected, we will create an inventory
of available anchor-based MIDs, including the context in
which they were assessed (condition/disease), and the
conﬁdence users can place in a particular MID.
• Two abstracts on theMID project have been accepted for
oral presentation at the 2015 Vienna Colloquium.
• The PRO Methods Group will be giving a workshop
at the 2015 Vienna Colloquium on ‘Making results of
patient-reported outcomes interpretable’.
Introduction/News: The focus of the PRO Methods Group
(PROMG), is on patient-important outcomes in treatment tri-
als. The goal is to see that PROs are included in all Cochrane
Reviews, where appropriate. A second goal is to assist review-
ers preparing Cochrane Reviews in evaluating the methods and
outcomes of PROs used in clinical trials included in systematic
reviewsandmeta-analyses. This year thePROMG is embarkingon
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a study of the minimally important differences (MIDs) associated
with PROs used in Cochrane Reviews.
Research and methodological development: As described
above we are working on a project to summarize all published
MIDs for PROs used in clinical trials including assessment of their
acceptability and ﬁt with established methodological criteria.
We will search MEDLINE, Embase, PsycINFO, and CINHAL (1989
to present) to identify studies addressing methods to estimate
anchor-based MIDs of PRO instruments or reporting empirical
ascertainment of anchor-based MIDs. Teams of two reviewers
will screen citations identiﬁed, and extract relevant data. We will
summarize the availablemethods and develop a new instrument
addressing the credibility of empirically ascertained MIDs. We
will evaluate the credibility of all studies reporting on anchor-
based MIDs estimates using our new credibility tool, and assess
inter-rater reliability.
Our synthesis will improve the interpretation of results of clinical
trials using PROs, informclinical practice guidelines that trade on
desirable and undesirable outcomes, and facilitate sample size
calculations for clinical trials using PROs as primary outcomes.
Key publications for 2014 to 2015: Ebrahim S, Johnston BC,
Akl EA, Mustafa RA, Sun X, Walter SD, et al. Addressing contin-
uous data measured with different instruments for participants
excluded from trial analysis: a guide for systematic reviewers.
Journal of Clinical Epidemiology 2014;67(5):560-70.
Regnault A, Hamel JF, Patrick DL. Pooling of cross-cultural PRO
data in multinational clinical trials: how much can poor mea-
surement affect statistical power? Quality of Life Research 2015
Feb;24(2):273-7. Epub 2014 Sep 5.
Vodicka E, Kim K, Devine EB, Gnanasakthy A, Scoggins JF, Patrick
DL. Inclusion of patient-reported outcome measures in regis-
tered clinical trials: Evidence from ClinicalTrials.gov (2007-2013).
Contempory Clinical Trials 2015; pii: S1551-7144(15)00075-0.
Prognosis Methods Group
Alexandra Hendry (Co-ordinator) on behalf of the Prognosis
Methods Group (PMG) Convenors
Background: The Prognosis Methods Group (PMG) was regis-
teredwith Cochrane in 2008 to develop thebestmethodological
standards for conducting systematic reviews of prognosis stud-
ies. The PMG works with other Cochrane Groups to ensure
the best use of evidence of prognosis when conducting and
reporting Cochrane Reviews.
The Convenors of the PMG are:
• Doug Altman (UK)
• Jill Hayden (Canada)
• Karel Moons (The Netherlands)
• Richard Riley (UK)
• Katrina Williams (Australia)
• Susan Woolfenden (Australia)
The PMG has an international membership with approximately
170 researchers listed on the Archie database.
News: The PMG Prognosis Exemplar Review initiative is pro-
gressing well and methodological work related to each of the
approved three exemplar reviews will be used to inform future
systematic reviews of prognostic studies. It is anticipated that
methodological development and reﬁnement for these three
reviewswill beused toassist authorsof futureprognosis system-
atic reviews. ShawnStevenson joined thePMG in2013, thanks to
agrant fromtheCochraneDiscretionary Fund. Hehasbeen liais-
ingwith theauthors, reviewgroups, PMGconvenorsand training
co-ordinators as the reviews develop, and has been collating
informationabout theprocesses involved that couldbe relevant
for training purposes and methodological development. The
Discretionary Fund activities will continue throughout 2015 and
anticipated objectives will be met by mid-2016.
The exemplar reviews to be published in the Cochrane Library
are each addressing an important type of prognosis research:
overall prognosis, prognostic factors, and prognostic models.
Overall Prognosis Exemplar Review: This review is an update
of an existing review and is focused on the topic of overall
prognosis of autism spectrum disorder (ASD), investigating the
proportion of individuals with ASD who are still diagnosed with
an ASDone ormore years later. The review is registeredwith the
Cochrane Developmental, Psychosocial and Learning Problems
ReviewGroupand theprotocol is beingﬁnalised for submission.
Prognostic Factor Exemplar Review: The protocol for this re-
view, titled ‘Individual recovery expectations and prognosis of
outcomes in non-speciﬁc low back pain’, registered with the
Cochrane Back Review Group, was published in Issue 9 of the
Cochrane Database of Systematic Reviews 2014. The Canadian
Institutes of Health Research funded this review.
PrognosticModel Exemplar Review: This review ‘Predictionmod-
els for the risk of postoperative nausea and vomiting’ was
registered in title form with the Cochrane Anaesthesia Review
Groupand theprotocol submitted for peer-review in September
2013, and published in September 2014.
Methodological tool development:
QUIPS: The Quality in Prognostic Studies (QUIPS) tool can be
used to assess risk of bias in prognostic factor studies and was
published in early 2013.
CHARMS: The CHecklist for critical Appraisal and data extrac-
tion for systematic Reviews of prediction Modelling Studies
(CHARMS) is a template and checklist for designing reviews, for
data extraction and for critical appraisal in systematic reviews
of prediction modelling studies, and was published in 2014.
TRIPOD:TheTransparentReportingofamultivariableprediction
model for IndividualPrognosisOrDiagnosis (TRIPOD) statement
is an evidence-based reporting guideline for studies develop-
ing, validating, and/or updating, or extending diagnostic or
prognostic prediction models. An international group of ex-
perts comprising statisticians, methodologists, clinicians and
medical journal editors developed the statement. In January
2015, the TRIPOD statement was published simultaneously in
11 coremedical journals, and one journal published the TRIPOD
Explanation and Elaboration paper. Numerous other journals
have addressed TRIPOD in an editorial or editor’s comment.
PROBAST: The Prediction study Risk Of Bias ASsessment Tool
(PROBAST) initiative is currently developing a formal risk of bias
tool for risk prediction modelling studies.
Search strategy: A validated search strategy for the retrieval
of primary studies for systematic reviews of risk prediction
modelling studies was published in 2012.
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PROGRESS: A series of ﬁve papers on the PROGnosis RESearch
Strategywas published in 2013 and 2014 on the essentials of the
different types of prognostic studies, and a recommendation for
the registration and sharing of protocols of prognostic studies.
GRADE: The GRADE (Grading of Recommendations Assessment,
Development and Evaluation) Working Group are developing
recommendations for prognostic evidence that will provide a
practical and useful approach to determining conﬁdence in
estimates of prognosis in broad populations.
Training activities: Four methodological workshops were held
at the 2014 Hyderabad Colloquium:
• ‘Systematic reviews of prediction modelling studies: de-
signing, critical appraisal and data collection’: this work-
shop introduced the methodology and challenges of con-
ducting systematic reviews of prognosis studies. It focused
on the importance of review question, how to search and
select thestudies to include, andhowtoperformthecritical
appraisal.
• ‘Systematic reviews of prognostic studies: a meta-
analytical approach’: during this workshop participants
were introduced to statistical methods for meta-analysis
of risk prediction models and the opportunities and chal-
lenges of combining previously published prediction mod-
els were discussed.
• ‘Individual participant data (IPD) meta-analysis of risk pre-
diction studies’: this workshop introduced the use of IPD
meta-analysis in risk prediction research and why it offers
unique opportunities to risk prediction research.
• ‘PROBAST: introduction to a new risk of bias tool for pre-
diction modelling studies’: this workshop introduced and
tested early phases of the PROBAST tool for formal ‘Risk of
bias’ assessments in systematic reviews of risk prediction
modelling studies.
Systematic reviewsofprognosis studieswerealsocovered in the
three-day PROGRESS training course, which was held at Keele
University in 2013 and 2014, and is being held again in July
2015. Furthermore, a four-day course on systematic reviews
andmeta-analysis of prognostic studies has been run at Utrecht
University in 2013 and 2014. The course leaders of both the
Keele and Utrecht University courses include members of the
Prognosis Methods Group.
The year ahead: Members of the PMG often contact the con-
venors for advice. When requested, we will continue to offer
advice to review authors who would like to incorporate prog-
nosis information into their therapeutic or diagnostic reviews.
Where possible, advice is based on empirical evidence from
the research conducted by either convenors or other members
of the PMG. We will continue to help with reviews and co-
ordinate direct contact between authors and methodologists
where appropriate.
The PMG will continue to progress the exemplar prognostic
systematic reviews for the Cochrane Library.
Five workshops will be prepared and presented at the 2015
Vienna Colloquium.
Key publications for 2014 to 2015: Collins GS, Reitsma JB,
Altman DG, Moons KGM. Transparent reporting of a multivari-
able prediction model for individual prognosis or diagnosis
(TRIPOD): the TRIPOD statement. Annals of Internal Medicine
2015;162:55-63.
Croft P, Altman DG, Deeks JJ, Dunn KM, Hay AD, Hemingway
H, et al. The science of clinical practice: disease diagnosis or
patient prognosis? Evidence about ”what is likely to happen”
should shape clinical practice. BMCMedicine 2015;13:20.
Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P,
Steyerberg EW, et al. Transparent reporting of a multivariable
prediction model for individual prognosis or diagnosis (TRI-
POD): explanation and elaboration. Annals of Internal Medicine
2015;162:W1-W73.
Iorio A, Spencer F, Falavigna M, Alba A, Lang E, Burnand B, et
al. Use of GRADE for assessment of evidence about prognosis:
rating conﬁdence in estimates of event rates inbroad categories
of patients. BMJ 2015;350:h870.
Altman DG. The time has come to register diagnostic and prog-
nostic research. Clinical Chemistry 2014:60:580-2.
Baker SG, Schuit E, Steyerberg EW, PencinaMJ, Vickers A,Moons
KG, et al. How to interpret a small increase in AUC with an addi-
tional risk prediction marker: decision analysis comes through.
Statistics in Medicine 2014;33(22):3946-59.
Debray TP, Vergouwe Y, Kofﬁberg H, Nieboer D, Steyerberg EW,
Moons KG. A new framework to enhance the interpretation of
external validation studiesof clinical predictionmodels. Journal
of Clinical Epidemiology 2014;68(3):279-89.
Hayden JA, Tougas ME, Riley R, Iles R, Pincus T. Individual re-
covery expectations and prognosis of outcomes in non-speciﬁc
low back pain: prognostic factor exemplar review. Cochrane
DatabaseofSystematicReviews2014, Issue9. Art. No.:CD011284.
Kengne AP, Beulens JW, Peelen LM, Moons KG, van der Schouw
YT, Schulze MB, et al. Non-invasive risk scores for predic-
tion of type 2 diabetes (EPIC-InterAct): a validation of existing
models. Lancet Diabetes & Endocrinology 2014;2(1):19-29. doi:
10.1016/S2213-8587(13)70103-7. Erratum in Lancet Diabetes
Endocrinology 2014;2(4):e11.
MoonsKGM, deGroot JAH, BouwmeesterW, VergouweY,Mallett
S, Altman DG, et al. Critical appraisal and data extraction for
systematic reviewsofpredictionmodelling studies: theCHARMS
checklist. PLos Medicine 2014;11(10):e1001744.
Moynihan R, Henry D, Moons KG. Using evidence to combat
overdiagnosis and overtreatment: evaluating treatments, tests,
and disease deﬁnitions in the time of too much. PLOS Medicine
2014;11(7):e1001655.
Peat G, Riley RD, Croft P, Morley KI, Kyzas PS, Moons KG, et al for
the PROGRESS Group. Improving the transparency of prognosis
research: the role of reporting, data sharing, registration and
protocols. PLOS Medicine 2014;11(7):e1001671.
Prospective Meta-Analysis Group
Davina Ghersi, Jesse Berlin and Lisa Askie
Introduction: The Prospective Meta-Analysis Methods Group
(PMAMG) is open to anyone who is conducting, has conducted,
or is interested in conducting a prospectivemeta-analysis (PMA),
regardless of the area of health care investigated.
Researchandmethodological development: Throughout 2014,
the PMAMG has been working together with the co-ordinators
of PROSPERO (International prospective register of systematic
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reviews) to potentially add a label to identify systematic reviews
as PMAs in a way that would allow speciﬁc searches for PMAs.
Training and support activities: The convenors provide advice
on request to members and also to others wanting to prepare
a prospective meta-analysis protocol, including the editors of
Cochrane Review Groups and the authors of these reviews. Ad-
vice is givenby email or telephone, or throughparticipation in the
advisory committees of several PMAs (for example, ongoingPMAs
of neonatal oxygen levels, and interventions for the prevention
of childhood obesity).
The co-convenors also frequently provide advice on prospective
meta-analysis as part of their regular jobs and via presentations
to internal and external organisations. Co-convenor Jesse Berlin,
as part of his role at Johnson & Johnson, has also been partici-
pating in developing company policies around transparency and
data sharing.
What’s new: Over the past year the PMAMG has expanded to
78 active members. Throughout the year, the co-convenors met
every three months by teleconference to discuss methodologi-
cal enquiries, research projects, website updates and relevant
Cochrane matters, for example, the revised Cochrane data shar-
ing policy andmonitoring forms.
Looking ahead: The PMAMethods Group is looking to expand its
remit to incorporate prospective trial registration.
Key publications: Berlin JA, Morris S, Rockhold F, Askie L, Ghersi
D,Waldstreicher J. Bumps andbridges on the road to responsible
sharing of clinical trial data. Clinical Trials 2014;11(1):7-12.
Berlin JA, Crowe BJ, Whalen E, Xia HA, Koro CE, Kuebler J.
Meta-analysis of clinical trial safety data in a drug development
program: answers to frequently asked questions. Clinical Trials
2013;10(1):20-31.
Cochrane Qualitative and
Implementation Methods Group
Karin Hannes on behalf of the QIMG convenors
Since the publication of the ﬁrst qualitative evidence synthe-
sis integrated with an intervention review in 2013 (Glenton
and colleageues –see publication list 2013), Qualitative and
Implementation Methods Group (QIMG) convenors have pro-
vided methodological support to several author teams. Proto-
cols are now published in the Cochrane Library that integrate a
qualitative evidence synthesis with an effect review, such as the
one by Hurley and colleagues (see publication list) and others
are in the pipeline. We look forward to seeing additional exem-
plar qualitative reviews published in the library in the coming
months.
TheQIMGorganized twocoursesonqualitativeevidencesynthe-
sis in2014 to support reviewauthors; one inUtrecht, ledbyKarin
Hannes and Hennie Boeije and, the ESQUIRE course in Shefﬁeld
organized by Andrew Booth. Convenors of QIMG contributed to
the talks and workshop modules offered to participants. The
courses reached approximately 80 people. The Methodolog-
ical Investigation of Cochrane Complex Intervention Reviews
(MICCI) Methods Innovation Fund (MIF) project was completed
in 2015. During the project CERQual (an approach for assessing
the conﬁdence in qualitative synthesised ﬁndings) and iCAT SR
(a tool for categorising and describing complex interventions)
was developed. Work was also undertaken on the relative
contribution of sibling (related to included RCTs) and unrelated
qualitative studies to understanding a phenomenon of interest,
and a survey of the use of theory in complex intervention re-
views was completed, from which guidance was produced on
the use of theory in Cochrane Reviews. A newMIF project led by
Claire Glenton to undertake additional development work with
CERQual was awarded in 2015.
In response to the ‘Implementation’ component thatwas added
to thegroup’smission, co-convenersof theMethodsGroupcom-
pleted a pilot study on the extent to which systematic reviews
incorporate process and implementation aspects. The CH-imp
(Checklist on IMPlementation) that resulted from their research
activity will be introduced at the 2015 Vienna Colloquium. Mem-
bers of the QIMG also contributed to ‘Complex interventions
in health’, an overview of research methods that places com-
plex interventions within a coherent system of research inquiry.
The book is intended to help researchers understand the re-
search processes involved at each stage of developing, testing,
evaluating and implementing complex interventions, and assist
them to integrate methodological activities to produce secure,
evidence-based healthcare interventions. We are currently
exploring options to publish our supplemental guidance on
qualitative evidence synthesis.
Key publications for 2014 to 2015: Booth A, Hannes K, Harden
A, Harris J, Lockwood C, Noyes J. Reporting criteria for quali-
tative research. In: D Moher editor(s). Standards for reporting
research. UK: Wiley-Blackwell, 2014.
Carroll C, Booth A. Quality assessment of qualitative evidence
for systematic review and synthesis: Is it meaningful, and if
so, how should it be performed? Research Synthesis Methods
2015;6(2):149-54. doi: 10.1002/jrsm.1128. Epub 2014 Oct 2.
Glenton C, Colvin CJ, Carlsen B, Swartz A, Lewin S, Noyes J,
Rashidian A. Barriers and facilitators to the implementation of
lay health worker programmes to improve access to maternal
and child health: qualitative evidence synthesis. Cochrane
Database of Systematic Reviews 2013, Issue 10. Art. No.:
CD010414. DOI: 10.1002/14651858.CD010414.pub2.
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Screening and Diagnostic Test Methods
Group
Yemisi Takwoingi, Mariska Leeﬂang, Petra Macaskill, Jon
Deeks and Clare Davenport
Highlights of 2014 to 2015:
• Record number of published reviews.
• One-day workshop prior to the 2014 Hyderabad Collo-
quium (22 September 2014).
• Publication of online training materials for diagnostic
test accuracy (DTA) reviews.
Introduction: Members of our methods group provide sub-
stantial support for the DTA editorial process through their
roles as editors and also as reviewers. As of April 2015, 44
Cochrane DTA reviews have been published in the Cochrane
Library, compared with 19 in April 2014 and 12 in April 2013.
A total of 85 protocols have also been published (source:
www.thecochranelibrary.com). We now have over 1000 contrib-
utors to Cochrane DTA Reviews from across the globe (Norway to
New Zealand, and from Colombia to the Philippines). Cochrane
DTA Reviews are now being produced by 34 different CRGs, and
some have now been cited in World Health Organization (WHO)
guidance.
Research and methodological developments: Members of the
Screening and Diagnosis Methods Group (SDMG) successfully ob-
tained funding from the Methods Innovation Fund for further
development of Plain language summaries for Cochrane DTA
Reviews. The 18-month project is being undertaken in collabora-
tion with Sense about Science and will commence in June 2015.
The project will draw on the experience and views of the public,
clinicians, policy makers, the media, methodologists and those
involved in the production of Cochrane DTA Reviews.
2014 Hyderabad Colloquium one-day Workshop
Training and support activities:
Methods for Cochrane DTA Reviews, One-day workshop prior to
the 2014 Hyderabad Colloquium
The one-day workshop combined our series of workshops usu-
ally run throughout the Colloquium into a one-day programme,
and was delivered through a mixture of interactive presenta-
tions, discussions and small group exercises. Participants were
introduced to the process of question formulation for a DTA re-
view; the methodology for quality assessment; the principles of
meta-analysis and recommended statistical methods; potential
sources of heterogeneity andmethods for assessing heterogene-
ity; comparisonsof testaccuracy; andpresentingand interpreting
results. The workshop was facilitated by 10 of our members and
was attended by 110 delegates. The feedback we received was
very positive.
Editing of DTA reviews: The DTA editorial process continues to
be a major commitment with all members of the editorial team
also being members of SDMG. Our training of DTA editors nom-
inated by their review groups is still ongoing, and those already
trained continue to participate in one of the two DTA editorial
team meetings that take place each month. The DTA editors
from review groups typicallymanage DTA reviews from their own
review groups.
Support for DTA review production: The members of our meth-
ods group provide methodological leadership and support for
diagnostic reviews, diagnostic review training and advice about
diagnostic issues throughout Cochrane. The seven years of fund-
ing from the NIHR to support the creation and introduction of
DTA reviews ﬁnished in September 2014 (this funded positions
in the UK Support Unit for Cochrane DTA Reviews based at the
University of Birmingham) but the Birmingham team continues
to make strong contributions to SDMG. Co-ordination of the DTA
editorial process is still managed bymembers of the Birmingham
team.
What’s new? The Cochrane DTA Working Group was dissolved
following our business meeting in Hyderabad last year. It was
decided that the working group had fulﬁlled its role and it was
time for SDMG to take on the remaining functions of the working
group. This seemed logical since all members of the working
group are also members of SDMG. Responsibility for the DTA
editorial process now sits within the Cochrane Editorial Unit.
Members of our group are publishing online training mate-
rials for authors planning to produce a Cochrane DTA Re-
view to ensure that training resources are available around
the world. Ten of the modules are now available on-
line (see training.cochrane.org/authors/dta-reviews/distance-
learning for links and a complete list) and more modules should
be published in themonths to come. Cochrane Handbook for DTA
Reviews chapters are available at srdta.cochrane.org.
Looking ahead: A pre-Colloquium workshop on methods for
developing Cochrane DTA Reviews, similar to the one held in
Hyderabad, will take place in Vienna on 3 October 2015. In addi-
tion, two workshops are planned –one on searching, which will
be facilitated by members of the Information Retrieval Methods
Group, and the other on advancedmethods for meta-analysis.
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Statistical Methods Group
Joanne McKenzie, Joseph Beyene, Georgia Salanti, and
Catrin Tudur-Smith (Convenors of the Statistical Methods
Group)
Highlights of 2014 to 2015:
• The appointment of Kerry Dwan as a Statistical Editor to
theCentral ExecutiveUnit. Part of Kerry’s role involves sup-
porting activities of the Statistical Methods Group (SMG),
including monitoring the literature for contemporary ex-
pectations of statistical methods in evidence synthesis,
and evaluation of how differentmethods formeta-analysis
impact on Cochrane Reviews.
• Settingupof theStatisticalMethodsNetwork. Thisnetwork
aims to provide a closer link between Cochrane Review
Groups, the SMG, and statistical editors; allow for commu-
nication between statistical editors; and, dissemination of
new statistical methods.
Introduction: TheSMGprovidesa forumwherestatistical issues
related to Cochrane can be discussed, provides policy advice
on statistical issues, and organizes training activities. The SMG
currently has 267 members from 30 countries, primarily based
in theUK (36%), Europe (24%), USA (11%), Australia andCanada
(8% each).
There have been some changes to the SMG Convenor and Co-
ordinator roles over the past year. Gerta Ru¨cker stepped down
as a Convenor of the SMG this year. Gerta has been a Convenor
since 2013, and we are very grateful for her contribution to
the SMG. Orestis Efthimiou made an invaluable contribution in
the inaugural role as Co-ordinator of the SMG (from October
2013 to 2014); this role has now been handed to his colleague
Adriani Nikolakopoulou. Adriani is a doctoral candidate at the
Department of Hygiene and Epidemiology at the University of
Ioannina, School of Medicine. Her doctorate research is focused
on planning of new randomized trials to address evidence gaps.
Research and methodological developments: Mark Sim-
monds (Centre for Reviews and Dissemination, University of
York, UK) was successful in leading a Methods Innovation Fund
applicationonbehalf of theSMGto investigate ‘Statisticalmeth-
ods for updating meta-analyses’ (see pages 5–6). Results from
this research will allow the SMG to provide advice on whether
adjustment of results is necessary when undertaking updates
in Cochrane Reviews, and if so, what statistical methods to
recommend.
Training and support activities: Five core SMG workshops
on introductory meta-analysis topics were offered at the 2014
Hyderabad Colloquium. These ﬁve workshops will be pre-
sented again at the 2015 Vienna Colloquium (covering: basic
ideas of meta-analysis, meta-analysis of binary and continu-
ous outcomes, dealing with heterogeneity, meta-analysis of
time-to-event data, and including non-standard studies and
non-standard data). In addition, other statistics-related work-
shops at Vienna include ‘Accounting for missing outcome data
in meta-analysis’, ‘Bayesian meta-analysis: hands-on in Win-
BUGS’, ‘Patient-relevant causal effects versus intention to treat:
a guide to understanding complex analyses’, and ‘Use R! An
Introduction to meta-analysis with R’. As well as the workshops
presented at Colloquia, SMG members continue to present
workshops on statistical issues in systematic reviews at regional
Cochrane events and events external to Cochrane.
Looking ahead: In early 2016, the SMG will run a two-day
training course for Cochrane statistical editors in Liverpool, UK.
Key publications: The SMG website includes a list of
publications which its members have contributed (avail-
able at smg.cochrane.org/publications). Members can sub-
mit their publications at any time through a form on the web-
site (smg.cochrane.org/suggestions-further-smg-publications),
or alternatively, email them to Catrin Tudur-Smith (Cat1@-
liverpool.ac.uk).
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Future Meetings
Cochrane Colloquium 2016: 21–25
October 2016
www.community.cochrane.org/news/tags/authors/cochrane-
colloquium-2016-seoul-south-korea-21-25-october-2016
Cochrane are pleased to announce that the 2016 Cochrane
Colloquiumwill be held in Seoul, South Korea on 21-25 October.
The event will be organized and hosted by the Korean Branch
of the Australasian Cochrane Centre and will be the third Collo-
quium in Asia after Singapore in 2009 and Hyderabad in 2014,
and the ﬁrst one in East Asia. This afﬁrms Cochrane’s ambition
and willingness to enhance capacity in this part of the world and
address local and regional issues.
7th International Conference for EBHC
Teachers and Developers
Evidence for Sustainability of Health Care: Increasing Value,
reducing waste.
Taormina (Italy), 28-31 October 2015
http://www.ebhc.org/index.php
The Conference aims to promote an evidence-based approach to
sustainabilityofhealth services,whereevidenceshould informall
health care decisions at every level (patients, health care profes-
sionals and policy-makers) and cuts-based programs to contain
costs should be replaced by an evidence-informed strategy to
reduce waste and increase value of health care.
Building on the success of six previous meetings the Conference
is an excellent opportunity to network with worldwide EBHC
teachers and developers in thewonderful frame of Taormina, the
pearl of theMediterranean Sea. It is an opportunity tomeet EBHC
colleagues from around the world in a program which includes
renowned keynote speakers, oral abstract presentations, poster
displays, surveys with televoter, and productive small group
sessions to encourage discussion and the development of new
ideas.
Guidelines-International-Network
http://www.g-i-n.net/document-store/g-i-n-conferences/
philadelphia-2016
The 2016 GIN event will take place in Philadelphia, USA. This
annual event usually takes place in August. G-I-N supports
collaboration in guideline development, adaptation and imple-
mentation. G-I-N facilitates networking and promoting good
practice to develop high quality clinical practice guidelines that
foster safe and effective patient care.
Evidence Live 2016: 22-24 June 2016
http://evidencelive.org/
Evidence Live is a partnership between The BMJ and the Centre
for Evidence-BasedMedicine in theUniversity ofOxford’sNufﬁeld
Department of Primary Care Health Sciences. We seek answers
to the question: how can we transform healthcare for the bet-
ter? This conference combines debate on the latest issues with
education and practical skills development.
Evidence Live Global Forum; a community coming together over
three days for a conference and evidence-based courses where
international thinkers share ideas to improve healthcare
Peer Review Congress 2017
Chicago, USA, 10–12 September
http://www.peerreviewcongress.org
This conference aims to improve the quality and credibility of
biomedical peer review and publication.
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Availability Of Cochrane Methods
Additional copies of Cochrane Methods may be obtained free of
charge fromMaria Burgess mburgess@cochrane.org
Cochrane Methods is also available electronically via the
Cochrane Library website http://www.cochranelibrary.com/
cochrane-database-of-systematic-reviews/cochrane-methods.html
More Information
The Cochrane Library
The Cochrane Library (www.cochranelibrary.com) contains the
Cochrane Database of Systematic Reviews (CDSR), which includes
Cochrane Reviews and Protocols as well as editorials and sup-
plements, and ﬁve other databases: the Database of Abstracts of
ReviewsofEffects(DARE)(uptoMarch2015), theCochraneCentral
Register of Controlled Trials (CENTRAL), the Cochrane Method-
ology Register (CMR) (up to July 2012), the Health Technology
Assessment (HTA) Database and the NHS Economic Evaluation
Database (EED) (up to March 2015). In addition, the Cochrane
Library contains information about Cochrane, complete contact
details for all Cochrane groups, and links to the Cochrane Hand-
book for Systematic Reviews of Interventions and a glossary of
Cochrane and methodological terminology. More information is
available from:
Jennifer Coates
Cochrane Library Customer Services Advisor
John Wiley & Sons Ltd
1 Oldlands Way
Bognor Regis
West Sussex, PO22 9SA
UK
Tel:+44 1243 843367
cs-cochrane@wiley.com
www.thecochranelibrary.com/view/0/HowtoOrder.html
Cochrane Internet Site
A wide range of information about Cochrane is available from
www.cochrane.org, including the abstracts fromall theCochrane
Reviews in the current issue of the Cochrane Library, details
of Cochrane email lists, opportunities to download Cochrane
software (including RevMan 5), contact details for all Cochrane
entities, copies of this publication, Cochrane Methods Groups
andmuchmore.
International Cochrane Newsletters
An excellent means of keeping informed about the activities and
policies of Cochrane is via Cochrane Connect. The newsletter is
used for announcements and discussion of matters relevant to
Cochrane as a whole. To subscribe go to the following webpage:
www.cochrane.org/news/newsletters
Cochrane Centre Internet Sites
There are 14 Cochrane Centres round the world; to speak to
someone about Cochrane please contact your local Centre.
Australasian Cochrane Centre
acc.cochrane.org
Brazilian Cochrane Centre
www.centrocochranedobrasil.org
Canadian Cochrane Centre
ccnc.cochrane.org
Chinese Cochrane Center
www.ebm.org.cn/
Dutch Cochrane Centre
www.cochrane.nl
French Cochrane Centre
fr.cochrane.org
German Cochrane Centre
www.cochrane.de
Iberoamerican Cochrane Centre
www.cochrane.es
Italian Cochrane Centre
www.cochrane.it
Nordic Cochrane Centre
www.cochrane.dk
South African Cochrane Centre
www.mrc.ac.za/cochrane
South Asian Centre
www.cochrane-sacn.org
UK Cochrane Centre
www.cochrane.ac.uk
US Cochrane Center
www.cochrane.us
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If you want to make sure that you receive the next issue of
Cochrane Methods please return this form to us. Comments are
welcome. Let us know what you liked and what you did not like
and any suggestions you have for the next issue.
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57–59 Haymarket
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UK
Tel:+44 203 372 6730
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